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Heart failure - origin
Heart failure is the term used to describe an abnormality of cardiac structure or 
function leading to failure of the heart to deliver oxygen at a rate commensurate 
with the requirements of the metabolizing tissue.1 Clinically, heart failure is a 
syndrome in which patients have typical symptoms (e.g. breathlessness and 
fatigue) and signs (e.g. oedema, rales, elevated jugular venous pressure) 
caused by abnormal cardiac structure or function.1 It is a progressive disorder 
that develops after a cardiovascular event either damages the heart muscle, 
resulting in loss of functioning cardiac myocytes, or disrupts the contractility of 
the myocardium.2 This event may be acute (e.g. myocardial infarction); it may 
have a gradual onset (e.g. hemodynamic pressure of volume overloading); or 
it may have a hereditary cause (e.g. genetic cardiomyopathies).2 Regardless 
of its nature, what all of these events have in common is that they result in a 
decline in the heart’s pumping capacity. The subsequent decrease in cardiac 
output eventually activates a series of compensatory mechanisms intended 
to maintain cardiovascular homeostasis. The patient’s cardiac function is thus 
preserved or only minimally depressed.2 Past studies have shown us that 
the combination of compensatory mechanisms include early activation of the 
adrenergic nervous system and a salt and water-retaining system in order to 
preserve cardiac output.3-5 Additionally, multiple vasodilatory molecules are 
released, including natriuretic peptides, nitric oxide and prostaglandins, to 
counteract the excessive vasoconstriction resulting from activation of 
aforementioned adrenergic and renin-angiotensin systems.2, 6, 7 Therefore, 
patients with depressed cardiac function can remain asymptomatic or minimally 
symptomatic for years. However, a critical ‘point of no return’ is reached when 
patients become overtly symptomatic, with a resultant striking increase in 
morbidity and mortality. This progression to symptomatic heart failure is 
characterized by further activation of adverse pathways, involving neuro
hormones and cytokines, as well as several adaptive changes 
within the myocardium.2, 8 This process is referred to as left ventricular 
remodeling. In this phase, the patient resides in a stateof chronic 
activation of compensatory mechanisms for heart failure, which include 
structural alterations in the heart muscle, such as concentric left 
ventricular hypertrophy (following long-standing hypertension and 
aortic stenosis) or eccentric left ventricular hypertrophy (following chronic 
mitral or aortic regurgitation). Another type of compensatory left 
ventricular remodeling occurs in patients who have suffered myocardial 
infarction, in whom disproportionate dilatation of the left ventricle 
(i.e. infarct area) occurs, resulting in decreased systolic function.1, 2
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Heart failure - manifestation
Approximately 2% of the adult population in developed countries has heart 
failure, although it mainly afflicts the elderly, affecting 6-10% of people over 
the age of 65 years.9 The prevalence of heart failure in the United States is 
expected to increase to 20% of the population by 2040 (Figure 1). Heart failure is 
currently the single most common cause of hospitalization in persons 
65 years of age or older, resulting in enormous costs to society and 
representing a major public health problem.10 The prognosis of heart failure has 
improved over time, although it remains poor. Before 1990, the majority of 
patients died within five years of diagnosis and admission to hospital with 
progression of heart failure was frequent and recurrent, leading to an 
epidemic of heart failure hospitalization in many countries.11-13 Effective 
treatment has improved outcome, with a relative reduction in 
hospitalizations of up to 30-50% in recent years, and a smaller 
but still significant decrease in mortality. Nevertheless, once acute heart 
failure ensues, 30% of patients die within one year, and the mortality 
rate after hospitalization exceeds that of most cancers.12, 13
The terminology used to describe heart failure is largely historical and based 
on measurement of left ventricular ejection fraction (LVEF). Mathematically, 
LVEF is the stroke volume (the end-diastolic volume minus the end-systolic 
Figure 1 The expected prevalence of heart failure in the United States. Reprinted 
from Owan TE et al., Epidemiology of Diastolic Heart Failure, 47(5), 320-32, Copyright 
(2005), with permission from Elsevier
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volume) divided by the end-diastolic volume. In patients with reduced con-
traction and emptying of the left ventricle, stroke volume is maintained 
through an increase in end-diastolic volume, because of left ventricular 
dilatation. In other words, the heart ejects a smaller fraction of a larger volume. 
The more severe the systolic dysfunction, the more the LVEF is reduced from 
normal and, generally, the larger the end-diastolic and end-systolic volumes.1
The LVEF is considered important in heart failure, and two syndromes 
are currently acknowledged: heart failure with reduced LVEF (HFrEF) and 
heart failure with preserved LVEF (HFpEF), see Table 1. In the past, HFrEF 
was referred to as ‘systolic’ heart failure, as opposed to ‘diastolic’ heart
failure, which corresponded with HFpEF. Because diastolic dysfunction was 
observed in both HFrEF and HFpEF, the terms diastolic and systolic heart 
failure were discarded.14, 15 It has been speculated that HFrEF and HFpEF 
either represent distinct forms of heart failure, or exist as part of one heart 
failure spectrum.16 Recent structural, functional and molecular biological 
arguments support the theory that they are two discrete disease processes.17-20
In addition to differences in terminology, HFrEF and HFpEF differ with regard to 
pathophysiology, clinical characteristics and treatment.16, 21, 22 HFrEF is far better 
understood in terms of pathophysiology and treatment. Coronary artery disease 
Table 1 : Diagnosis of heart failure  
  
The diagnosis of HFrEF requires three conditions to be satisﬁed: 
1. Symptoms typical of HF  
2. Signs typical of HF  
3. Reduced LVEF  
 
The diagnosis of HFpEF requires four conditions to be satisﬁed: 
1. Symptoms typical of HF  
2. Signs typical of HF  
3. Preserved LVEF 
4. Relevant structural heart disease (LV hypertrophy / LA enlargement) 
    and / or diastolic dysfunction 
 
HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HFpEF = heart 
failure with preserved ejection fraction; LA = left atrial; LV = left ventricular; LVEF = left 
ventricular ejection fraction.
Table 1 Diagnosis of heart failure
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is responsible for approximately 60% HFrEF cases.1, 23, 24 Other contributing 
factors include hypertension, alcohol abuse, chemotherapy, or ‘idiopathic’ 
dilated cardiomyopathy.9, 25 Patients with HFpEF, on the other hand, are more 
likely to have hypertension, diabetes mellitus and atrial fibrillation. These 
patients are also older and more often female than those with HFrEF.22 In 
the past two decades, many clinical trials successfully reduced mortality 
and morbidity rates in patients with HFrEF. Three neurohumoral 
antagonists – angiotensin converting enzyme inhibitors (or angiotensin receptor 
blockers), beta-blockers, and mineralocorticoid receptor antagonists – have 
been shown to substantially modify the course of HFrEF and reduce mortality, 
and should at least be considered in every patient.1 Diuretics are 
commonly used to relieve the symptoms and signs of congestion. In contrast, no 
treatment to date has convincingly been shown to reduce mortality or morbidity 
in patients with HFpEF. Treatment of underlying co-morbidities, such as 
hypertension or atrial fibrillation, is considered important, but remains 
empirical. The use of diuretics to relieve signs and symptoms is similar to HFrEF.
The epidemiology of new onset HFrEF and new onset HFpEF is shifting. The 
incidence and prevalence of heart failure seems to have changed over the 
past decades, and the first signs of a decline in incidence of heart failure were 
reported in the past 10 years.10, 26, 27 This decline may apply to HFrEF in 
particular, while the opposite may be true for HFpEF.22, 28 There are several 
possible explanations for this development; this decrease in the incidence 
of HFrEF may be due to the fact that while large myocardial infarctions are 
the primary cause of HFrEF, such patients are now treated with primary 
angioplasty, leading to smaller infarction sizes, and thus fewer patients with 
HFrEF. Another explanation is that the diagnosis of HFpEF remains a 
particular challenge. Underrecognition of heart failure is more common in 
patients with HFpEF than in those with HFrEF, as LVEF remains a key factor 
for many physicians. In many cases, the diagnosis of heart failure is not 
considered when the LVEF is normal. In other words, the diagnosis of 
HFpEF is more difficult than the diagnosis of HFrEF, because it is 
largely one of exclusion, whereas potential non-cardiac causes for the patient’s 
symptoms (such as anemia or chronic lung disease) must first be 
discounted.1, 29 Finally, it has been suggested that a large proportion of patients 
with new onset HFpEF is mainly seen in the outpatient setting or by the general 
practitioner, and is therefore not included in hospital registries or clinical trials.30
In short, the incidence and prevalence of HFpEF is rising, both in absolute terms 
and relative to HFrEF, and there are currently no evidence-based treatment 
Introduction
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options available. Additionally, there is increasing evidence that HFrEF and 
HFpEF follow different pathophysiologic pathways. Most data on HFrEF and 
HFpEF is derived from populations with prevalent heart failure, which leaves 
many unresolved issues regarding the development of both syndromes. 
Consequently, there is a need for prospective studies on the development 
of heart failure that distinguish between HFrEF and HFpEF. At the start of 
this thesis, in December 2009, several prospective studies on the 
development of heart failure in healthy subjects already existed,31-33 
however none distinguished between new onset HFrEF and HFpEF, 
due to lack of LVEF data. The PREVEND study offered an unique 
opportunity to study the natural development of both syndromes.
Study population
Data for this thesis were derived from the Prevention of REnal and Vascular 
ENdstage Disease (PREVEND) cohort, see Figure 2. The PREVEND study is 
a prospective, observational cohort study, aimed at assessing the impact of 
elevated urinary albumin loss in non-diabetic subjects on future cardiovascular 
and renal disease.34 From 1997 to 1998, all inhabitants of the city of Groningen, 
The Netherlands, aged 28 to 75 years (N = 85,421) were asked to send 
in a first morning urine sample and complete a short questionnaire on 
demographics and cardiovascular disease history, and 40,856 subjects 
responded (47.8%). All subjects with urinary albumin excretion (UAE) ≥10 
mg/l (N = 7,786) in their morning urine as well as a randomly selected control 
group with a UAE <10 mg/l (N = 3,395) were invited to an outpatient clinic for a 
detailed assessment of cardiovascular and renal risk factors, including filling out 
questionnaires, anthropometrics, and blood and urine sampling. After excluding 
subjects with insulin-dependent diabetes mellitus, pregnant women, and 
subjects unable or unwilling to participate, a total of 8,592 subjects completed the 
screening programme and underwent follow-up for an average of 12.5 
years. This community-based population from the city of Groningen is 
characterised by a low prevalence of cardiovascular risk factors at baseline, 
long follow-up and standardized measurements of multiple clinical 
and biochemical parameters.
The Prevention of REnal and Vascular ENdstage Disease Intervention 
Trial (PREVEND IT) is an investigator-initiated, single-center, double-blind, 
randomized, placebo-controlled trial with a 2x2 factorial design.35 Subjects 
were randomized to fosinopril 20 mg or matching placebo and to pravastatin 
40 mg or matching placebo. The PREVEND IT is a predefined sub-study of the 
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Size of random sample was arbitrarily set 
at 3,395 to obtain a total cohort size of 
approximately 10,000 (taking into
account a ±15% non-participation rate)
Figure 2 Design of the Prevention of Renal and Vascular Endstage Disease 
(PREVEND) cohort
microalbuminuria (one urinary albumin concentration ≥10 mg/l in an early 
morning spot urine and at least one 15 to 300 mg/24h in 2x24h urine samples), 
a blood pressure of <160/100 mmHg and no antihypertensive medication, 
a total cholesterol <8.0 mmol/l, or <5.0 mmol/l in case of previous myocardial 
infarction, and no lipid-lowering medication. From April 1998 to June 
1999, 864 subjects were willing to participate in the PREVEND IT and were 
randomized to study medication.
Objectives and thesis outline
Data on the incidence of new onset HFrEF and HFpEF and its distinct risk 
factors in community-based cohorts are scarce, and studies directly comparing 
new onset HFrEF vs. HFpEF are lacking. This thesis aims to elucidate the 
epidemiology, population characteristics and biochemical data for new 
onset heart failure in subjects from a community-based cohort. We will 
differentiate between new onset HFrEF and new onset HFpEF, 
based on LVEF at time of diagnosis. The primary objective 
is to describe epidemiology of new onset heart failure, clinical characteristics 
and biomakers of new onset HFrEF and HFpEF, which is discussed in the 
first part of this thesis. In the second part, we support the aforementioned 
results with several secondary analyses, by associating the prognostic 
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The changing face of heart failure: are we really making progress?
This editorial refers to ‘The epidemiology of heart failure, based on data for 
2.1 million inhabitants in Sweden’, by R. Zarrinkoub et al., 
doi: 10.1093/eurjhf/hft064
Approximately 1–2% of the adult population in developed countries has heart 
failure (HF), with the prevalence rising to ≥10% among persons 70 years 
of age or older.1 HF is the single most frequent cause of hospitalization in 
persons 65 years of age or older and its societal costs are enormous, thereby 
presenting a large public health problem.2 As the lives of patients with HF are 
prolonged by modern therapy, the prevalence of HF would be expected to
increase, while morbidity and mortality rates remain high.1 Indeed, the 
incidence and prevalence of HF seems to have changed over the past decades, 
and in the last 10 years the first signs of a decline in incidence of HF were 
reported.2, 3Interestingly, this decline may be particularly true for HF patients 
with reduced ejection fraction (HFrEF), while the opposite may be true for HF 
patients with preserved ejection fraction (HFpEF).4, 5 This decrease in the 
incidence of HFrEF may be due to the fact that while large myocardial 
infarctions are the primary cause of HFrEF, such patients are 
nowadays quickly treated by primary angioplasty, leading to smaller 
infarction sizes, and fewer patients with HFrEF.6
In this issue of the journal, Zarrinkoub and colleagues are presenting new data 
on prevalence, incidence, mortality and survival of congestive HF in Sweden.7 
Using high quality health registries with almost complete recording, the authors 
were able to identify inhabitants of Stockholm with prevalent and incident HF, as 
well as detailed registration of the date of death of any cause, for a period of five 
consecutive years. After adjustment for demographic composition, the results 
were also extrapolated to the entire Swedish population.
In their study, the estimated prevalence of HF in Sweden was 2.2%. In absolute 
numbers and for every age category, more men were diagnosed with HF, except 
for subjects exceding 100 years of age. The incidence of HF in 2010 was 
3.7/1000 person years in women and 3.9/1000 person years in men. From 
2006 to 2010, the prevalence of HF remained the same for men, whereas 
women showed a modest decrease. Remarkably, the incidence of HF decreased 
relatively by 24% during this follow-up period, and no difference was observed 




Figure 1 The changing face of heart failure.
for both men and women, but five year survival rate after diagnosis of HF was 
48% (45% in women vs. 51% in men; P<0.05), which is still remarkably poor 
in the current era. Finally, hypertension was the most common cardiovascular 
co-morbidity, followed by ischemic heart disease, atrial fibrillation and diabetes 
mellitus, cerebrovascular disease and chronic obstructive pulmonary disease.
Along with the observed decreased HF incidence and improved survival 
(and previous epidemiologic reports), the prevalence of HF remained stable 
during the follow-up period. Increased awareness of physicians for HF, improved 
pharmacological and device treatment are probably responsible for this 
decrease. The current study also shows valuable epidemiologic data with regard 
to concomitant diseases associated with HF development (Table 1, Zarrinkoub 
et al.).7 Prevalence of all co-morbidities, apart from hypertension, decreased 
during the follow-up period, which may explain decrease in HF incidence. 
These contemporary data are valuable since they provide more 
insight into the incidence and prevalence of HF in the current time. Also, the 
investigators examined a large study population and the quality of health 
registries in Stockholm appears to be high. Nevertheless, the data are limited by 
the fact that assessment of signs and symptoms of HF from chart review alone 
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was retrospective, and for example, physical findings of congestion such as 
jugular distention or subjective complaints of exertional dyspnoea and fatigue 
are easy to miss in everyday practice. Indeed, HF underrecognition is more 
common in patients with HFpEF, than in those with HFrEF, as a left ventricular 
ejection fraction (LVEF) is still very important for many physicians, and in many 
cases the diagnosis of HF is not considered when LVEF is normal.8, 9 In other 
words, the diagnosis of HFpEF is more difficult than the diagnosis of HFrEF, 
because it is largely one of exclusion, i.e. potential non-cardiac causes of the 
patient’s symptoms (such as anaemia or chronic lung disease) must first be 
discounted.1, 6 Also, it has been suggested that a large proportion of patient 
with new onset HFpEF is mainly seen in the outpatient setting or by the general 
practitioner, and are therefore not included in hospital registries.
HFpEF vs HFrEF: the changing face of heart failure
In recent years, there is an increasing awareness, that HFpEF is a 
different condition than HFrEF. Several cut-off values between 40 and 
50% of LVEF are proposed, to differentiate between both HF subtypes. A 
subject at risk for HFpEF is typically an elderly female with hypertension or atrial 
fibrillation, while males with coronary artery disease (and old myocardial 
infarction) comprise a typical risk profile for HFrEF.10, 11 For a long time, 
it was assumed that prognosis in patients with HFpEF was better than in those 
with HFrEF,12 but this may have been due to the fact, that in many HFpEF studies 
patients were included, that may not really have had HF.6 Indeed, in the
last few years various studies shave shown, that for patients with the 
same severity of HF (and a similar increase in natriuretic peptides), 
prognosis is equally poor for HFrEF and HFpEF.13, 14 The lack of 
distinguishment between both HF phenotypes makes interpretation of 
the results of Zarrinkoub and colleagues more difficult. It is clear that 
HFpEF is becoming more common, both in absolute and in relative 
numbers.4, 14, 15 Owan and colleagues have already shown in 2006 that 
the incidence of hospitalizations for HFpEF was increasing, while this 
was decreasing for HFrEF during the same follow-up period.4 
More recent studies confirm these findings, including a large study from
275 hospitals in the USA.15 Importantly, it is suggested that this rise in 
number of HFpEF patients is yet an underestimation of the true burden 
of HFpEF. Clinical underrecognition of HFpEF is a current topic, because 




are more common.6, 14 Recently, a similar observation was made in a large 
community-based cohort in the Netherlands, where the proportion of patients 
with new onset HFpEF, compared to new onset HFrEF, was initially relatively 
low, but there was a catch-up effect later on in the study.10 The male patient with 
a previous myocardial infarction is more likely to be included in hospital-based 
health registries, than the elderly woman with hypertension and/or diabetes. 
Thus, with regard to the observed overall decreased incidence of HF 
presented by Zarrinkoub and colleagues, we speculate this may be caused 
by a true decrease in new onset HFrEF, whereas the potential underestimated 
incidence of new onset HFpEF leads to a slightly false postive picture. This 
hypothesis is actually supported by the development of patient characteristics for 
prevalent HF in the study by Zarrinkoub. They showed that during follow-up, the 
prevalence of all concomitant diseases was found to be decreased, except for 
hypertension, which is the main underlying etiology (together with age) for 
HFpEF.10, 11 Considering the aforementioned epidemiologic trends, this might 
result in increased number of HFpEF in future studies (Figure 1). 
In conclusion, Zarrinkoub and colleagues7 provide an interesting update 
on the epidemiology of HF in a highly developed European country. The 
overall decrease in HF incidence suggests successful management of HF and 
confirms trends from recent epidemiologic studies. However, it should be noted 
that mainly changes in HFrEF may account for this decrease, while patients 
with HFpEF may (partly) not have been identified. Importantly, undertreatment 
of hypertension seems to continue to play an important role here. 
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Abstract
The incidence and prevalence of heart failure is increasing, especially heart 
failure with preserved ejection fraction (HFpEF) relative to heart failure with 
reduced ejection fraction (HFrEF). For both HFrEF and HFpEF, there is need 
to shift our focus from secondary to primary prevention. Detailed epidemiologic 
data on both HFpEF and HFrEF are needed to allow early identification of 
at-risk subjects. Current cohorts with new onset heart failure lack uniformity 
with respect to diagnosis, follow-up and population characteristics, but most 
importantly fail to distinguish between HFpEF and HFrEF. Studies on prevalent 
heart failure show ischemic heart disease as the predominant risk factor for 
HFrEF, while hypertension, atrial fibrillation and diabetes are risk factors for 
HFpEF. As it becomes increasingly clear that both subtypes of heart failure are 
different syndromes, new cohorts and trials are necessary to obtain separate 
data on both subtypes of heart failure.
Frank P. Brouwers 
 Hans L. Hillege 
Wiek H. van Gilst
 Dirk J. van Veldhuisen
Current Heart Failure Reports 2012;9(4):363-8
Chapter 2
Comparing heart failure with 
reduced ejection fraction to 
heart failure with preserved 
ejection fraction: an epidemiologic 
perspective
34
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Figure 1 From Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. 
N Engl J Med 2006; 355:251-9. Reproduced with permission from (scientific reference 
citation), Copyright Massachusetts Medical Society.
Introduction
Heart failure is a major cause of morbidity and mortality in the general population. 
Its prevalence in the population has increased dramatically over time.1 The 
incidence of heart failure is increasing as well, due to both better medical 
treatment and, most importantly, improved survival rates following preceding 
cardiovascular disease like myocardial infarction or hypertension.2-4 Heart 
failure is affecting men and women in near equal numbers, though women are 
historically under-represented in clinical HF trials.5, 6 Regardless of sex, heart 
failure is typically a disease of the elderly, with an estimated prevalence of heart 
failure of 23 million people worldwide in 2010.7 Due to advances in medical care 
and the exponential increase in lifestyle-related cardiovascular risk factors such 
as diabetes mellitus (DM), hypertension, obesity and persistently high global 
prevalence of nicotine use, the prevalence of heart failure in the United States 
is expected to affect up to 20% of the population by 2040.2, 8, 9 This will place a 
large economic burden on national health care systems.10, 11
In this context, the need to distinguish heart failure with reduced ejection fraction 
(HFrEF) from heart failure with preserved ejection fraction (HFpEF) becomes 
of great importance. The number of hospitalizations for HFpEF has increased 
over time, compared to a stable admission rate for patients with HFrEF, see 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Comparing HFrEF to HFpEF: an epidemiologic perspective
factors associated specifically with HFpEF, i.e. DM, hypertension and atrial 
fibrillation. Moreover, it has become clear that the prognosis of patients with 
HFpEF is probably as poor as for HFrEF.4 A complicating factor is the fact that 
despite a number of potentially favorable reports on treatment with angiotensin 
converting enzymes inhibitors (ACEi), angiotensin receptor blockers (ARB) 
and beta-blockers in HFpEF,15-17 no prospective trial has successfully reduced 
mortality or re-hospitalization for patients with HFpEF.18 For both HFrEF and 
HFpEF, there is need to shift focus from secondary to primary prevention, 
requiring a thorough understanding of the pathophysiology underlying both 
types, particularly HFpEF. Studies on the prevalence, incidence and prognosis 
of heart failure are becoming increasingly available; however, several issues 
need to be addressed. There is lack of consistency with regard to the diagnosis 
and validation of heart failure cases,19 but also regarding results and outcome 
parameters. More importantly, evidence on the incidence and epidemiology 
of HFrEF and HFpEF reported separately is minimal. In the ongoing, as yet 
unsuccessful search for evidence based treatment for HFpEF, it is essential to 
identify and characterize subjects with new onset HFpEF independently from 
HFrEF, and regard both types of heart failure as distinct diseases.
Cohorts with incident heart failure
Several cohorts have identified patients with a diagnosis of heart failure during 
follow-up. Table 1 summarizes these cohorts and refers to the year of first 
publication. Additional registries with only incidence and / or mortality rates, but 
no data on clinical characteristics were not taken into account. Reviewing this 
table raises a number of interesting points.
Most cohorts have been identified during the last decade and are derived 
from unselected populations. With new technology to aid in the diagnosis of 
heart failure, this subsequently increased awareness of the problem. This is a 
promising development and an important first step towards describing typical 
epidemiologic features of subjects at risk for developing heart failure. However, 
the criteria used to identify patients and validate a new diagnosis of heart 
failure are generally inconsistent. These range from criteria from Framingham,20 
the National Health and Nutrition Examination Survey (NHANES)21 and the 
European Society of Cardiology,22 to self-reported heart failure or a hospital 
discharge diagnosis based on ICD-coding. Although all separate methods to 
define new onset heart failure are well validated, it makes comparison between 




assigned to ascertain the diagnosis of new onset heart failure via individual 
case review.23-25 The different screening methods for new onset heart failure 
used in these cohorts usually result in high specificity, with no false positive 
cases of new onset heart failure. On the other hand, heart failure incidence 
rates are likely underestimated, as patients with signs and symptoms associated 
with heart failure who were not hospitalized will not have been detected. True 
incidence rates for new onset heart failure will therefore probably be higher.
Another interesting observation is that there are broad differences in population 
characteristics, which also make comparison of results between cohorts difficult. 
Mean age ranges from mid-fifties26 to octogenarian subjects25 and several 
cohorts consist of specifically selected subjects with diabetes, stable coronary 
artery disease or even Parkinson’s patients.26-30 There are also considerable 
differences in enrollment of subjects with different racial backgrounds between 
cohorts. The proportion of black men and women ranges from 12 to 25%,24, 27, 29, 31 
however it is not described in the majority of cohorts. Many large studies 
have already shown that the incidence of heart failure is substantially higher 
among blacks than among whites, especially among younger adults.32, 33 These 
racial differences are largely explained by known clinical risk factors, such as 
hypertension and DM,34 nonetheless inclusion of subjects with different racial 
backgrounds could bias results. Lastly, there is large variation in follow-up 
duration, from studies with one year follow-up to those with over ten years.20, 25, 35, 36
Finally, Table 1 illustrates that in the large majority of cohorts, no data is 
available on LVEF. This is an essential limitation, making the distinction between 
HFrEF and HFpEF impossible. Additionally, studies in which echo data is 
available have a low number of new onset heart failure cases or relatively short 
follow-up.37, 38 Compounding the issue, there is currently no consensus in the 
literature regarding a precise cut-off value for LVEF in the diagnosis of HFpEF 
versus HFrEF. While both Senni et al and Cowie et al use an LVEF cut-off 
of >50%,37, 38 studies with prevalent heart failure patients have used cut-off 
values ranging from 35 to 55%.22 The new 2012 heart failure guidelines from 
the European Society of Cardiology advise that a LVEF below 50% should be 
considered reduced.22 
HFpEF versus HFrEF
It is estimated that about half of all patients presenting with heart failure 
have a preserved LVEF.39 Several retrospective cohort studies have shown 
clinical differences between patients with prevalent HFpEF and HFrEF, which 
38
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underscores the necessity for considering each subtype of heart failure a distinct 
disease. At first clinical presentation, patients with HFpEF are older, more often 
female and obese than those with HFrEF. Furthermore, they are less likely to 
have coronary heart disease and more likely to have hypertension and atrial 
fibrillation.40-42 On the other hand, patients with HFrEF are more likely to have a 
history of ischemic heart disease, defined as either prior myocardial infarction or 
ECG abnormalities. Other risk factors which have been associated with HFrEF 
are DM and history of alcohol abuse.1, 8, 43 Renal failure is also a frequently 
occurring condition in both HFrEF and HFpEF, the so-called cardiorenal 
syndrome.44 Some studies have shown evidence of renal dysfunction being a 
more significant risk factor for new onset HFpEF than for new onset HFrEF45, 46 
by measuring cystatin C or urinary albumin excretion.47, 48
Mortality remains very high after the onset of symptoms,49-51 although
long-term mortality rates have improved over time.52 Several studies have 
shown equal mortality rates for patients with HFpEF and HFrEF.53, 54 Cause of 
death in patients with HFpEF is more often non-cardiovascular than in HFrEF 
patients, who have higher cardiovascular mortality. Furthermore, patients with 
HFrEF are at higher risk of sudden death compared to HFpEF patients. The 
TIME-CHF study also showed that patients who died experienced a median of 
four adverse events and one hospitalization within 60 days prior to death.53 
As mentioned earlier, current data on patient characteristics for new onset 
HFpEF compared to new onset HFrEF in a general, unselected population 
is limited. Two studies of incident cases of HFpEF have associated female 
gender and older age with increased risk for developing HFpEF.37, 38 Also, a 
diagnosis of HFpEF was more likely in an out-patient setting. Typical signs of 
heart failure, such as cardiomegaly and pulmonary edema, were less apparent 
and atrial fibrillation was more frequently present in patients with new onset 
HFpEF. A recent publication by the Framingham Heart Study also shows 
patient characteristics for both subtypes of heart failure.41 In 712 subjects 
with new onset heart failure, 46% were diagnosed with HFpEF, with a LVEF 
cut-off of 45%. Multiple patient characteristics at the time of initial heart failure 
presentation and pre-onset patient characteristics differed between participants 
with new onset HFpEF and HFrEF. Female gender and atrial fibrillation were 
independently associated with an increased risk for HFpEF, while presence 
of coronary heart disease, increased heart rate and potassium, and ischemic 




for HFrEF.41 Several clinical traits differed in prevalence across the spectrum of 
LVEF, suggesting that HFpEF and HFrEF are overlapping clinical syndromes. 
As the authors conclude, more studies defining cases with new onset heart 
failure are necessary to further define separate risk factor profiles for HFpEF 
and HFrEF. This would allow identification of subjects at risk for developing 
heart failure and could lead to targeted preventive efforts.
Epidemiologic Perspectives
Multiple studies have reported on epidemiologic characteristics of subjects with 
new onset and prevalent heart failure. However, studies distinguishing between 
new onset HFrEF and HFpEF are necessary, as both subtypes of heart failure 
should be considered different syndromes. There is increasing evidence that 
incidence rates of HFpEF are equal to HFrEF and that prognosis is equally poor. 
However, in contrast to HFrEF, there is currently no evidence based treatment 
for HFpEF.18  Along with the fact that hospitalizations for HFpEF are increasing 
relative to HFrEF,14 the burden of HFpEF on health care systems will expand 
exponentially in the near future. While most studies have reported on specific risk 
factors for overall new onset heart failure, like older age, increased NT-proBNP 
or urinary albumin creatinine ratio,36, 55 there is need for new studies presenting 
data on new onset HFrEF versus new onset HFpEF. Detailed epidemiologic 
data for subjects with new onset heart failure, compared to healthy subjects 
with no diagnosis of heart failure during follow-up are still lacking. Furthermore, 
clinical and biochemical characteristics with predictive capabilities for new onset 
HFpEF, in contrast to HFrEF, have also not been identified. The Framingham 
Heart Study has shown different clinical profiles before first clinical presentation; 
however the mean time from baseline to time of diagnosis is short. For effective 
preventive strategies, early identification of subjects at risk for developing heart 
failure is necessary to start treatment in an early stage. 
Conclusions
HFrEF and HFpEF are two different cardiovascular syndromes and both require 
a different approach. Ischemic heart disease remains the main cause for HFrEF, 
while atrial fibrillation, female gender and ageing are risk factors for HFpEF. 
However, more studies on the epidemiology of both specific types of new 
onset heart failure are necessary for early identification, risk stratification and 
preventive treatment.
40
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Abstract
AIMS: Differences in clinical characteristics and outcome of patients with 
established heart failure with preserved ejection fraction (HFpEF) and heart 
failure with reduced ejection fraction (HFrEF) are well established. Data on 
epidemiology and prediction of new onset HFpEF, compared with 
HFrEF have not been described.
METHODS AND RESULTS: In 8,592 subjects of the Prevention of 
REnal and Vascular ENdstage Disease (PREVEND), a community-based, 
middle-aged cohort study, we performed cause-specific hazard analyses 
to study the predictive value of risk factors and established cardiovascular 
biomarkers on new onset HFrEF versus HFpEF (left ventricular ejection 
fraction ≤40% and ≥50%, respectively). A P-value for competing risk (Pcr) 
<0.10 between HFrEF and HFpEF was considered statistically significant. All 
potential new onset heart failure cases were reviewed and adjudicated to 
HFrEF or HFpEF by an independent committee. During a median follow-up 
of 11.5 years, 374 (4.4%) subjects were diagnosed with heart failure, of which 
125 (34%) HFpEF and 241 (66%) HFrEF. The average time to diagnosis of 
new onset HFrEF was 6.6±3.6 years and 8.3±3.3 years for HFpEF (P <0.001). 
Male gender was associated with new onset HFrEF, while female gender 
with new onset HFpEF (Pcr <0.001). Higher age and increased NT-proBNP 
increased the risk for both HFpEF and HFrEF, although for age this was 
stronger for HFpEF (Pcr =0.018), while NT-proBNP was stronger associated with 
risk for HFrEF (Pcr =0.083). Current smokers, increased hs-TnT and previous 
myocardial infarction conferred a significantly increased risk for HFrEF, but 
not for HFpEF (Pcr =0.093, 0.091, 0.061, respectively). Conversely, a history 
of atrial fibrillation, increased urinary albumin excretion and cystatin C were 
significantly more associated with the risk for HFpEF, but not with HFrEF (Pcr 
<0.001, 0.061 and 0.033, respectively). The presence of obesity at baseline was 
associated with comparable prognostic information for both HFpEF and HFrEF.
CONCLUSION: Higher age, urinary albumin excretion, cystatin C 
and history of atrial fibrillation are strong risk factors for new onset 
HFpEF. This underscores differential pathophysiologic mechanisms for both 
subtypes of heart failure.
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Chapter 3A
Incidence and epidemiology of new 
onset heart failure with preserved 
versus reduced ejection fraction in 
a community-based cohort: 11 year 
follow-up of PREVEND
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Introduction
Heart failure is a progressive syndrome with high morbidity and mortality 
despite recent improvements of its treatment.1, 2 Due to the ageing population, it is 
expected that the incidence and prevalence of heart failure will increase 
exponentially in the next decade.3 Preventing new onset heart failure is 
increasingly important and requires knowledge of its risk factors.4,5 
Several studies have established risk factors for new onset heart failure, 
including higher age, hypertension and the presence of ischemic heart 
disease.6-8 Initially, studies aimed at identifying risk factors were based on 
a heart failure diagnosis on signs and symptoms only.3, 9 More recently, the 
diagnosis of heart failure was defined by reduced left ventricular ejection 
fraction (LVEF), with or without symptoms.4, 7 We now recognize two subtypes 
of heart failure: heart failure with reduced ejection fraction (HFrEF), and heart 
failure with preserved ejection fraction (HFpEF). Data on the incidence of 
new onset HFpEF and its risk factors in population based cohorts are scarce 
and studies directly comparing new onset HFpEF versus HFrEF are lacking.
In a community-based cohort, we identified all cases of new onset heart failure 
during 11 years of follow-up and adjudicated them as either HFrEF or HFpEF. 
Using available clinical and biochemical baseline characteristics, we identified 
risk factors for new onset HFpEF and HFrEF.
Methods
Study population
The study was performed using data of the PREVEND cohort study, which has 
been described elsewhere.10, 11 In summary, from 1997 to 1998, all inhabitants 
of the city of Groningen, The Netherlands, aged 28 to 75 years (N = 85,421) 
were asked to send in a first morning urine sample and complete a short 
questionnaire on demographics and cardiovascular disease history and 40,856 
subjects responded (47.8%). All subjects with urinary albumin excretion (UAE) 
≥10 mg/l (N = 7,786) in their morning urine as well as a randomly selected 
control group with a UAE <10 mg/l (N = 3,395) were invited to an 
outpatient clinic for detailled assessment of cardiovascular and renal risk factors, 
including filling in questionaires, measuring anthropometrics, and blood and urine
sampling. After excluding subjects with insulin-dependent diabetes mellitus, 
pregnant women, and subjects unable or unwilling to participate, a total of 8,592 




by the institutional medical ethics committee and conducted in accordance with 
the Declaration of Helsinki. All subjects provided written informed consent.
Definitions
Systolic and diastolic blood pressures were calculated as the mean of the 
last two measurements of the two visits, using an automatic Dinamap XL 
Model 9300 series device. Hypertension was defined as systolic blood 
pressure >140mmHg, diastolic blood pressure > 90mmHg or self-reported use of 
antihypertensive medication. Body mass index (BMI) was calculated as the ratio 
of weight to height squared (kg/m2) and obesity was defined as a BMI > 30kg/
m2. Hypercholesterolemia was defined as total serum cholesterol > 6.5 mmol/l 
(251 mg/dl) or a serum cholesterol > 5.0 mmol/l (193 mg/dl) if a history of 
myocardial infarction (MI) was present or when lipid-lowering medication 
was used. Type 2 diabetes was defined as a fasting plasma 
glucose >7.0 mmol/l (126 mg/dl), a non-fasting plasma glucose >11.1 mmol/l or 
use of anti-diabetic drugs. UAE was calculated as the average value from two 




N = 8,592 
No suspected HF 
Case by case review 
Suspected HF 
N = 586 
Expert panel review 
No incident HF (212) 
- HF before start  
  PREVEND (23) 
- inadequate signs /  
  symptoms (84) 
- insufﬁcient  
  evidence (61) 
- alternative  
  diagnosis (44) 
Incident HF (374) 
- 239 HFrEF 
- 135 HFpEF 
N = 8,006
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consecutive 24h urine collections. The glomerular filtration rate (eGFR) was 
estimated using the simplified Modification of Diet in Renal Disease 
(sMDRD) formula.12 Smoking was defined as current nicotine use or quit 
smoking within the previous year. History of MI was defined as
participant-reported hospitalization for at least 3 days as a result 
of this condition. Standard 12-lead electrocardiograms were recorded 
using the computer program Modular ECG Analysis System (MEANS),13 and AF 
was defined according to Minnesota codes 8.3.1 and 8.3.3.
Assays
At baseline, EDTA plasma samples were drawn from all participants for 
biomarker assessment. Aliquots of these samples were stored immediately 
after collection at -80°C until analyses. N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) and highly-sensitive C-reactive protein (hs-CRP) were 
measured, as described in detail elsewhere.14, 15 Highly-sensitive troponin T 
(hs-TnT) was measured using Modular Analytics serum work areas, with <10% 
coefficient of variation at the 99th percentile of the reference range (Roche 
Diagnostics). Urinary albumin concentration was determined by nepholometry, 
with a threshold of 2.3 mg/l and intra- and interassay coefficients variation of 2.2 
and 2.6%, respectively (BNII, Dade Behring Diagnostica, Marburg, Germany).
Heart failure and cardiovascular events
Follow-up for the present investigation was defined as time between the 
baseline visit to the outpatient department and the date of new onset heart 
failure, or 01 January 2010. Subjects were censored at the date they moved 
to an unknown destination or at the last date of follow-up (01 January 
2010), whatever date came first. Information on dates and causes of death 
for every participant were obtained from Statistics Netherlands16 and coded 
according to the 10th revision of the International Classification of Diseases (ICD).
The patient population of PREVEND, from the city of Groningen, has a low 
migration rate16 and is covered by two main hospitals in the region. Patient 
files were checked in both hospitals for presence of heart failure at baseline 
and for new onset heart failure, by recording signs, symptoms and objective 
evidence of heart failure. Permission to access hospital records was granted by 
the local Ethics Committees of both hospitals. Using criteria in accordance to 






HF 8569 8313 7966 7638 7312 6633 1273 
HFrEF 8569 8322 7991 7669 7351 6693 1287 

























Heart Failure Incidence; Total, HFrEF and HFpEF
586 individual cases were identified as suspected heart failure, as shown in 
Figure 1. An endpoint adjudication committee of seven independent experts 
in the field of heart failure, evaluated all cases suspected for the diagnosis of 
new onset heart failure. Each case was validated by two different experts by 
reviewing anonimized clinical charts, hospitalization and physician office records 
in order to ascertain the incidence of heart failure. In case of consensus, patients 
were classified as “definite new onset heart failure”, “definite no new onset heart 
failure” or “definite heart failure, with date of onset before time of recruitment 
in PREVEND”. In case of difference of opinion about an individual case, the 
committee made a joint decision. Based on LVEF at the time of diagnosis, heart 
failure was classified as HFrEF or HFpEF (LVEF ≤40% or ≥50%, respectively). 
The cut-offs were chosen due to the lack of consensus in the most recent ESC 
guidelines for diagnosis of new onset heart failure.17, 18 Subjects in the grey 
area, with a LVEF 41-49% (N = 8), were excluded from the analyses to prevent 
blending and dilution of differential epidemiological profiles. The etiology and 
date of onset of heart failure was also derived from clinical charts. Data on LVEF 
were available in 98.4% of cases with new onset heart failure. In six cases, 
diagnosis was confirmed through joint decision, because of insufficient data 
on LVEF. 
Figure 2 Cumulative incidence of new onset heart failure, divided by total new onset 
heart failure, heart failure with reduced ejection fraction and heart failure with preserved 
ejection fraction. Incidence of heart failure is adjusted for mortality during follow-up.
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By design, the PREVEND study overselected subjects with an elevated UAE 
(≥10mg/l). It should be clear that this is not a random sample of a general 
population, where all elementary units have an equal probability of being 
selected. Statistical formulas to calculate population parameter estimates 
should be used to account for the likelihood of selection. A design-based 
analysis was performed to overcome this overselection of subjects with 
elevated UAE. This statistical weighting method allows conclusions to be 
generalized to the general population.15, 19  Baseline continuous data are 
reported as mean (standard deviation) for normal data. NT-proBNP, hs-TnT, 
UAE, cystatin C, serum triglycerides and hs-CRP showed a log-linear 
functional shape with the response variable and were transformed to a 2-log 
scale and reported as median (interquartile range). This means that risk 
estimates should be interpreted as the relative risk if values were doubled (e.g. 
1 to 2 mg/l or 10 to 20 mg/24h). We fitted Cox proportional hazards models 
to the data and the Schoenfeld residuals were calculated to assess whether 
proportionality assumptions were satisfied. For multivariate regression 
analysis, we imported variables which reached significance (P<0.10) in univariate 
analysis. Two competing endpoints were distuingished: HFrEF and HFpEF. All 
Figure 3  Five year survival curve after diagnosis of new onset heart failure with reduced 
ejection fraction and heart failure with preserved ejection fraction
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variables from the multivariate analyses were explored using cause-specific 
hazard analyses, which allowed us to compare effects of explanatory variables 
on either HFrEF or HFpEF. To control for the type I error in the cause-specific 
hazard analysis (effect-by-covariate), and increasing power for the analysis, a 
P-value for competing risk (Pcr) between HFrEF and HFpEF of <0.10 is 
considered statistically significant.20, 21 Results are summarized as hazard 
(risk) ratios, with 95% confidence intervals based on robust standard error 
estimates. A value of P<0.05 (2-sided) was used as the nominal level of 
statistical significance. Individual relative hazards were estimated by 
post-estimation, based on the multivariate cause-specific cox proportional 
hazard analysis. To define the proportion of usable subject pairs in which 
outcome and prediction are concordant, we calculated the Harrell´s C 
coefficient, for the model for HFpEF and the model for HFrEF. Time to first 
event was estimated using cumulative incident curves, for total new onset 
heart failure and both subtypes and adjusted for mortality during follow-up. All 
analyses were performed using StataIC (version 11.0 software for Windows).
Results
During a median follow-up of 11.5 years (range 10.8-11.9), 374 
individuals (4.4%) were diagnosed with new onset heart failure, of whom 125 
(34%) were classified as HFpEF and 241 (66%) as HFrEF. The average time to 
diagnosis of new onset heart failure was 7.2 (±3.6) years; for HFrEF this 
was 6.6 (±3.6) years and 8.3 (±3.3) years for HFpEF (P<0.001). Figure 2 
shows the cumulative incidence of new onset heart failure and separately 
for HFrEF and HFpEF. Five-year all-cause mortality was higher for subjects 
diagnosed with new onset HFrEF, compared to new onset HFpEF (P=0.038), as 
depicted in Figure 3. Baseline characteristics are presented in Table 1 for subjects 
without heart failure during follow-up and for subjects with new onset heart 
failure during follow-up. At baseline, subjects who developed heart failure 
during follow-up were older, more likely male, had higher BMI, blood 
pressure and heart rate, worse renal function and more likely to have CV risk 
factors: i.e. hypertension, diabetes and hypercholesterolemia (Table 1). Glucose, 
total cholesterol, UAE, NT-proBNP, hs-TnT, cystatin C and hs-CRP were also 
higher at baseline for subjects with new onset heart failure (all P <0.001). Table 
1 also shows baseline characteristics for subjects with new onset HFrEF and 
HFpEF. Subjects with HFrEF during follow-up were more likely male, more 
smokers and had higher levels of creatinine, NT-proBNP and hs-TnT at baseline. 
During the follow-up period, there were 169 myocardial infarctions. In 25.4% of 
subjects, this was followed by new onset HFrEF (N = 37) or HFpEF (N = 6).
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Associations of clinical and biochemical characteristics with HFpEF 
and HFrEF
Table 2 summarizes the results of the Cox proportional hazard analysis 
and the cause-specific hazard analysis. Adjusted for age and gender, the 
presence or absence of obesity, hypertension, previous MI, atrial fibrillation,
diabetes mellitus and hypercholesterolemia was significantly associated 
with new onset heart failure. Also, higher levels of UAE, hs-CRP, cystatin C, 
NT-proBNP and hs-TnT were associated with higher risk for new 
onset heart failure. In multivariate analysis, age, male gender, 
obesity, previous MI, increased NT-proBNP and hs-TnT remained associated 
with an increased risk for new onset heart failure. Presence of diabetes and 
hypercholesterolemia at baseline showed a trend for increased risk 
for new onset heart failure, when multivariately adjusted (P=0.056 and 
0.096, respectively). The Harrell’s C coefficient for the model with total 
new onset heart failure was 0.87 (95% CI 0.84-0.90).
Cause-specific hazard analyses were performed to analyze possible 
competing risk between the two endpoints (HFrEF and HFpEF). There was a 
highly significant interaction between HFrEF and HFpEF for gender, indicating 
that male gender is associated with new onset HFrEF, while female gender is 
associated with new onset HFpEF (Pcr<0.001). Higher age and increased 
NT-proBNP predicted both new onset HFpEF and HFrEF, although for age 
this was significantly stronger for HFpEF (Pcr = 0.018), while for NT-proBNP 
this was significantly stronger for HFrEF (Pcr = 0.083). In addition, smokers, 
an increased hs-TnT and subjects with previous MI had a significantly 
increased risk for HFrEF, but not for HFpEF (Pcr = 0.086, Pcr = 0.091, 
Pcr = 0.058, respectively). History of atrial fibrillation, increased UAE 
and cystatin C were significantly more associated with the risk for 
HFpEF, but not with HFrEF. The presence of obesity at baseline was 
associated with comparable prognostic information for both HFpEF 
and HFrEF. Furthermore, the additional value of subjects categorized to 
values of hs-TnT below the detection limit (N = 4,728) was not significant 
in the cause-specific hazard model for HFrEF, nor for HFpEF (Pcr = 0.493).
The proportionality assumptions in the model were satisfied (Chi-squared 
test 36.05; P=0.141). For both HFrEF and HFpEF, two separate models were 
created, consisting of the significant variables from the above




had a Harrell’s C coefficient of 0.90 (95% CI 0.87-0.92) and the model 
for HFrEF a Harrell’s C coefficient of 0.88 (95% CI 0.84-0.91).
Discussion
The present study reports on detailed epidemiologic data on the 
comparison of new onset HFpEF versus HFrEF. Using a population-based cohort, 
we report a total incidence of new onset heart failure of 4.4% after 11.4 years 
of follow-up. Presence of obesity was a common risk factor for incidence of 
both subtypes of heart failure. Particular strong predictors for HFpEF were 
older age, female gender, atrial fibrillation, higher cystatin C and UAE. In 
contrast, male gender, previous myocardial infarction, smoking, hs-TnT and 
NT-proBNP were significant predictors specifically for HFrEF. This underscores 
differential pathophysiologic mechanisms for both subtypes of heart failure.
Incidence of heart failure
In this population-based cohort study, we identified 374 patients with a 
certain diagnosis of new onset heart failure. For this, we used the Heart 
Failure Guidelines from the ESC and each suspected case was validated by 
an expert committee. To prevent blending and dilution of epidemiologic profiles 
between HFrEF and HFpEF, we excluded eight subjects in the so-called grey area 
of LVEF 41-49%. In sub-analyses with strict cut-off values of 40% or 50%, results 
are similar to the current analyses. However, the current paper aims to identify 
differential epidemiologic risk profiles in contrast to evaluating the ideal cut-off 
for LVEF. By excluding subjects in the grey area of LVEF 41-49%, we present 
subjects with true new onset HFrEF and HFpEF. In contrast to other 
epidemiologic studies of new onset heart failure, there was no pre-selection 
during the screening process, with all 8,952 subjects of PREVEND being 
individually evaluated for suspected heart failure. Through this method 
we achieved a very limited underreporting of new onset heart failure in our 
cohort and no false-positives. Also, data on LVEF were available for almost 
all cases (98.4%) to accomplish accurate adjudication to HFrEF of HFpEF. 
Compared to other cohorts with new onset heart failure in the community, 
the incidence rate of heart failure cases is slightly higher, especially given 
the young mean age of subjects at baseline (49±12 years) in PREVEND. For 
example, Smith et al. and Velagaleti et al. report an incidence rate of 2.2% 
during 14 years of follow-up (mean age at baseline 58 years) and 3.4% 
during 9.4 years of follow-up (mean age at baseline 59 years), 
respectively.5, 22 However, the incidence of HFpEF compared to HFrEF
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(34% vs. 66%, respectively) is slightly lower, compared to other community- 
based studies.2, 23 It is most likely that the lower average age at baseline in 
the current study is responsible for this relatively low proportion of subjects 
with new onset HFpEF. The incidence of HFpEF is presumed to increase 
during prolonged follow-up. Despite lower age at baseline, through our 
thorough screening methods for identifying new onset heart failure we achieved 
accurate and true incidence rate for new onset heart failure in a population-based 
middle-aged cohort.
Clinical characteristics of new onset heart failure
Few studies have presented data on new onset heart failure in the 
community and especially studies regarding separate data for HFpEF and 
HFrEF are lacking.5, 22 Next to a multimarker strategy for the prediction of new 
onset heart failure, these studies have reported on specific risk factors for 
overall new onset heart failure, for example age, NT-proBNP, diabetes and 
urinary albumin creatinine ratio. Data on HFrEF and HFpEF separately is 
available from the Rochester Epidemiology Project and the Framingham Heart 
Study.23-25 However, the Rochester Epidemiology Project has few cases of new 
onset heart failure with known LVEF (N = 137), and no biochemical data. It was 
shown that female sex and age >90years were associated with HFpEF, while 
left bundle-branch block and myocardial infarction pattern on the ECG were 
associated with HFrEF.24 The Framingham Heart Study has one of the largest 
cohorts with new onset heart failure (N = 534) and reports on the same 
predictors for HFrEF and HFpEF as the Rochester Epidemiology Project, 
with the addition of atrial fibrillation for HFpEF.25 A recent paper by 
Ho et al. shows discriminating baseline characteristics of patients with 
new onset heart failure, for HFrEF compared to HFpEF.23 Multiple 
risk factors were associated with overall incident heart failure, where 
age, gender and prior MI acted as effect modifiers between risk for 
HFrEF and HFpEF. However, epidemiologic data of cases with new 
onset heart failure in the Rochester Epidemiology Project is evaluated at 
time of diagnosis, or shortly before diagnosis and presented as odds ratios. 
Furthermore, important biochemical data is missing in the Framingham 
Heart Study, including for instance NT-proBNP, hs-TnT. We add to previous 
investigations by describing detailed epidemiologic data, both clinical as well as 
biochemical data for new onset heart failure compared to healthy subjects with 
no diagnosis of heart failure during follow-up. With a mean time from baseline 




information on the incidence and the risk factors of both HFpEF 
and HFrEF and the existence of different risk profiles, many years 
before symptoms of heart failure become manifest.
We confirm earlier findings of significant risk factors for new onset heart 
failure, namely higher age, obesity, previous myocardial infarction, 
NT-proBNP and hs-TnT. Presence of hypertension, diabetes and 
hypercholesterolemia was however, unlike other studies, not associated 
with increased risk for new onset heart failure. This could be 
caused by the definitions utilized in PREVEND, where subjects were 
also classified as such if treated for the disease. However, a 
proxy of hypertension, UAE, was significantly associated with new 
onset HFpEF. Also, hypertension is a major risk factor for atrial fibrillation,
another predictor for HFpEF. We add to previous published data, 
when regarding HFpEF and HFrEF separately. Older females 
with a history of atrial fibrillation, increased UAE or cystatin C,
should be considered specifically at risk for developing HFpEF. 
Males with a previous myocardial infarction, smoking and increased
levels of NT-proBNP or hs-TnT have increased risk specifically 
for new onset HFrEF. 
Biomarkers
Biomarkers provide important information on disease etiology and clinical risk. 
In the current analyses, we did not use a multimarker approach to identify 
subjects at risk, but we took the strongest biomarker for different 
pathophysiologic domains: NT-proBNP, hs-TnT, hs-CRP and cystatin C. 
Except for NT-proBNP, there are currently no biomarkers registered to aid in 
early diagnosis of heart failure.17 This is especially relevant for HFpEF, where 
diagnosis is more difficult to make.18, 26 Our data show that NT-proBNP and 
hs-TnT were associated with new onset HFrEF. For new onset HFpEF however, 
cystatin C and NT-proBNP (although less strong than for HFrEF) were 
strong predictors. NT-proBNP, as a marker of myocardial wall stress, thus 
remains a powerful biomarker for identifying subjects at risk for either subtype 
of new onset heart failure. The value of hs-TnT in predicting incident heart 
failure has been described in older adults, but not for either HFrEF or HFpEF 
specifically.27 Our data show increased risk for new onset HFrEF, but not 
HFpEF, which indicates an early trend towards an ischemic etiology. 
Specifically, an increased hs-TnT could be reflecting increased 
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risk for developing myocardial infarction, which in turn increases 
the risk for HFrEF. A decreased kidney function, as determined 
by cystatin C, has been shown to be associated with left ventricular 
hypertrophy,28, 29 vascular stiffness,30, 31 and new onset heart failure.32, 33 This 
is in accordance with our findings, which associate higher levels of cystatin C 
with an increased risk for developing new onset HFpEF, while there was no 
increased risk for new onset HFrEF. In a study by Moran et al.33, cystatin C was 
associated with both new onset HFpEF and HFrEF, although the levels of 
cystatin C in their cohort were much higher, probably due to selection 
of older subjects. This may indicate that in asymptomatic subjects, cystatin C
could be an interesting marker for early cardiovascular disease progression, 
especially regarding HFpEF. Hs-CRP has been associated with 
increased risk for cardiovascular disease in PREVEND.14 However when 
adjusted for all CV variables, hs-CRP was not associated with a 
significantly increased riskfor either subtype of new onset heart failure.
Clinical consequences
Multiple intervention studies have clearly shown that patients with 
established HFrEF benefit from ACE-inhibitors, beta-blockers and 
mineralocorticoid receptor antagonists. But to date, not a single drug has 
proven to reduce mortality in patients with HFpEF nor is any drug 
recommended for the treatment of HFpEF in the current guidelines.34 Our data 
clearly shows distinct clinical risk profiles for new onset HFpEF and HFrEF. This 
implies that prevention of new onset HFpEF might need a different approach 
as compared to prevention of HFrEF. Apart from treatment of hypertension, 
strategies to reduce an elevated UAE and prevention of permanent atrial 
fibrillation may help to prevent or delay new onset HFpEF. Future studies are 
needed to further evaluate effective preventive treatment for both 
different risk profiles.
Strengths and limitations
The large, community based cohort and long follow-up, standardized biomarker 
and clinical parameter measurements and the thorough validation of incident 
heart failure diagnosis, with little loss to follow-up, are strengths of our study. Our 
study is limited by the fact that the PREVEND study subjects are predominately 
Caucasian and our results can therefore not be extrapolated to subjects from 
other ethnicities. Also, heart failure was identified retrospectively by chart 




heart failure, especially HFpEF, when diagnosis is not pursued in the 
symptomatic patient with normal ejection fraction. Then, the PREVEND 
cohort was enriched for increased albumin excretion. Although we corrected 
for this by conducting a design-based analysis, we cannot exclude that our 
results are affected by the study design. However, compared to the 
Framingham cohort, UAE was not higher in PREVEND and incidence 
of all-cause mortality and new onset heart failure is comparable to unselected 
general population studies.5, 22 Also, the multivariate cause-specific 
hazard model for HFrEF and HFpEF were adjusted for study design and
are therefore not affected by the enrichment for higher albuminuria levels.
Conclusions
These data show incidence rates of both new onset HFpEF and HFrEF in a 
community-based cohort. Moreover, a differential clinical risk profile at baseline 
for both subtypes of HF was found. Apart from higher age and female gender, 
an increased urinary albumin excretion, atrial fibrillation and cystatin C emerged 
as new risk indicators for HFpEF. Overall, our data suggest that a differential 
approach is indicated in order to prevent both HFpEF and HFrEF.
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Chapter 3B
Heart failure with preserved 
and reduced ejection fraction: 
different risk profiles for different 
diseases
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HFpEF and HFrEF: different risk profiles for different diseases
Approximately 15 million Europeans and 6 million Americans suffer from 
heart failure (HF), with annual direct and indirect costs in the billions.1 About 
half of patients have a preserved ejection fraction (HFpEF), while the others 
display a reduced EF (HFrEF).2,3 Clinical trials have unequivocally shown that 
treatments such as neurohormonal antagonists improve outcome in 
HFrEF, while similar trials in HFpEF have been neutral.1,2 Several reasons 
have been proposed for this differential response, including unique 
pathophysiologies in HFpEF and HFrEF, differing degrees of neurohormonal 
activation, significant pathophysiological heterogeneity within the broad 
population of HFpEF patients, and higher non-cardiovascular mortality
in HFpEF.1,2 It is also possible that the heart in HFrEF displays 
greater plasticity and amenability to reverse remodelling, while changes 
in the mechanical properties of the heart and vasculature 
in HFpEF might be less reversible by the time symptoms develop. 
Thus, interventions designed to prevent HFpEF might be more 
effective to reduce the global disease burden. To better inform strategies to 
prevent HFpEF (and HFrEF), detailed insight is needed into 
disease-specific risk factors.
Brouwers and colleagues have now presented exciting new data identifying 
common and distinct risk profiles for incident HFpEF and HFrEF.4 As part of 
the community-based Prevention of REnal and Vascular ENdstage Disease 
(PREVEND) study, 8,592 subjects living in Groningen, The Netherlands, 
underwent baseline medical examination along with blood testing and 
24h urine sampling. After a median follow-up duration of 11.5 years, the 
authors undertook the ambitious enterprise of carefully reviewing all medical 
records to identify subjects developing incident HF. The HF diagnosis was 
established according to contemporary clinical, laboratory, and radiographic 
criteria as adjudicated by a panel of experienced cardiologists.1 HFrEF was 
defined by EF ≤ 40% and HFpEF by EF ≥ 50%, meaning that the ‘middle group’ 
(EF 41– 49%) was excluded, though it is notable that only 1.3% of all HF subjects 
fell in this range. During the study period, 374 people developed HF (4.4%) of 
which 66% had HFrEF and 34% had HFpEF. The average time to diagnosis was 
7.2 years, but intriguingly subjects with HFpEF were diagnosed ~2 years later 
than those with HFrEF. In multivariable analysis, incident HF was associated 
with older age, male sex, obesity, history of myocardial infarction, N-terminal pro 




Figure 1 Top panels show risk factor profiles for incident HFrEF and HFpEF according 
to Brouwers et al.4 Arrow widths are reflective of the magnitude of the associated 
hazard ratios. Bottom panels identify different sub-phenotypes within the broader 
category of HF with preserved EF. ‘Non-HFpEF’ aetiologies are separated based upon 
fundamental differences in pathophysiology, clinical course and treatment. 
‘Common HFpEF’ phenotypes reflect pathophysiologic derangements noted in 
mechanistic studies where the ‘non-HFpEF’ aetiologies were excluded. These 
phenotypes are not mutually exclusive and several or all may coexist in a given patient.
These findings confirm previous studies examining risk factors for incident HF, 
but they say relatively little about the specific risk for the two HF phenotypes.
To explore this question, the authors then performed causespecific 
hazard analyses to determine competing risk factors for HFrEF and HFpEF. 
In this analysis, female sex, atrial fibrillation (AF), increased urinary albumin 
excretion (UAE), and increased cystatin C (a marker of decreased renal 
function) emerged as being preferentially associated with risk of HFpEF 
rather than HFrEF (Figure 1). In contrast, typical coronary risk factors, such 
as male sex, smoking history, hs-TnT, and prior myocardial infarction were 
preferentially associated with risk of HFrEF. Age and NT-proBNP were 
associated with increased risk for both HF phenotypes, but intriguingly age was 
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a stronger risk factor for HFpEF, while NT-proBNP was a stronger risk factor 
for HFrEF. Obesity conferred similarly increased risk in both HF types. The 
authors conclude that these data provide further evidence in support of the 
notion that HFpEF and HFrEF are distinct HF phenotypes with separate 
pathophysiologies. These data confirm and extend upon recent studies 
examining risk factors for HFpEF and HFrEF preceding and at the time of 
diagnosis.3,5–7 Strengths are the very high proportion of subjects with
EF assessment (>98%), and the fact that HF was identified in both 
outpatients and hospitalized subjects. However, the retrospective assessment 
of HF status from chart review alone is a weakness.
For example, physical findings of congestion such as jugular distention or 
subjective complaints of exertional dyspnoea and fatigue are easy to miss 
in everyday practice, or may simply not have been documented in the 
clinical records. This HF underrecognition is more common in patients with 
preserved EF, where the diagnosis continues to be less seriously entertained 
than when the EF is grossly reduced.2,8 Indeed, even when the patient with 
dyspnea is evaluated by a cardiologist, the diagnosis of HFpEF can be 
challenging to make, often requiring invasive assessment with or without 
provocative testing to render with confidence.8 In PREVEND, 
HF was suspected in a large number of subjects where sufficient 
evidence was not felt to be present or alternative causes were observed 
(189, >50% of the HF group), and one wonders how many of 
these subjects might have been reclassified as HFpEF with more 
intensive evaluation. Presumably, the EF was normal in all of these subjects, 
since the presence of dyspnea in a patient with low EF will invariably lead 
to the diagnosis of HF. In addition to the potential underdetection of HFpEF 
in this retrospective assessment, the young mean age at entry (49 years) 
probably contributes to the lower prevalence of HFpEF relative to HFrEF. 
Indeed, community-based studies from the Framingham group have 
reported a mean age at diagnosis of 79 years in HFpEF.5 Age was associated with 
increased risk for both HF phenotypes, but the impact was significantly greater 
for HFpEF. Thus, one would expect that as this population ages and is 
followed for a longer duration, HFpEF will ‘catch up’ in prevalence with HFrEF.
The findings of increased risk of incident HFpEF with female sex and AF are 




greater risk of HFpEF in women remain incompletely understood, there 
appear to be important sexual dimorphisms in ventricular–vascular structure and 
function that develop with ageing which may predispose to HFpEF in women.9 
The presence of AF is another consistent factor that increases HFpEF risk. The 
impact of AF is even more apparent when considering that its prevalence at 
entry into PREVEND was similar in patients destined to develop HFpEF 
and HFrEF, yet AF conferred greater risk only in HFpEF 
(hazard ratio 3.8). These data are congruent with observations from the 
CHARM programme, where the presence of AF was associated with 
increased risk of HF hospitalization and death relatively more in HFpEF 
than in HFrEF.10 It seems that the heart in patients with HFpEF (or at risk 
for HFpEF) is more reliant on atrial contraction to maintain haemodynamic 
compensation, and is thus more vulnerable to the deleterious effects of AF, 
leading to expression of the HF syndrome. These data support efforts 
to prevent the development of AF to help prevent HFpEF, 
in addition to diseases such as stroke.
Brouwers and colleagues also describe two previously unidentified risk 
factors for HFpEF, each of which is related to renal function: increased 
UAE and elevation in cystatin C. As with AF, baseline UAE and cystatin C 
levels were similar in subjects who ultimately developed HFpEF and HFrEF, 
meaning that greater burden of renal disease does not explain the association. 
Hypertension and diabetes were notably not predictive of HF risk, but each of 
these co-morbidities is in itself associated with renal dysfunction, albuminuria 
and AF, and this may explain the apparent lack of association. Loss of renal 
ability to dispose of excess volume would be expected to increase the risk 
of subclinical HF becoming manifest, and it appears that this vulnerability is 
greater in HFpEF. In line with this finding, ancillary data from the ALLHAT
trial showed that the diuretic chlorthalidone reduced incident HFpEF 
compared with other antihypertensives.11 In contrast, angiotensin-converting 
enzyme (ACE) inhibitors, which are well known to mitigate albuminuria,
were not found to prevent HFpEF.
Brouwers and colleagues are to be congratulated for taking a major step 
forward in understanding the pathogenesis of HFpEF, but there is still much 
to learn. Within the broad category of ‘HFpEF’, there are several aetiologies 
that are currently defined separately in practice, and others that may require 
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further study for proper taxonomic classification (Figure 1). For example, 
patients with HF caused by severe mitral insufficiency or aortic stenosis will 
clearly behave differently and respond to treatments differently from patients 
with hypertrophic cardiomyopathy, constrictive pericarditis, or high output 
HF. However, despite this heterogeneity, these entities continue currently to 
be lumped together into the category of ‘HFpEF’. As we move forward with 
epidemiological and physiological studies, these specific aetiologies of the 
HF syndrome should not be included under the broad term of HFpEF. Even 
when these ‘non-HFpEF’ causes are excluded, there are likely to be additional 
layers of pathophysiological heterogeneity in HFpEF that require better 
characterization. For example, we have recently shown that on average, 
cardiac output reserve predominantly limits exercise capacity in HFpEF,12 
and yet other groups have identified HFpEF patients with overly exuberant 
cardiac output responses,13 or abnormalities peripheral to the heart in the 
skeletal muscle and vasculature that more potently dictate functional limitation. 14 
Some HFpEF patients seem to express predominant diastolic limitations, yet 
most display numerous abnormalities in cardiovascular reserve, including 
diastolic dysfunction, systolic dysfunction, chronotropic incompetence, abnormal 
vasodilation, and endothelial dysfunction.15 It seems likely that these 
different HFpEF subphenotypes might have their own unique risk factors and 
treatments. Future studies that more rigorously characterize the specific 
phenotypes within the broader population of HFpEF may 
hold the greatest promise finally to prevent and treat this deadly 
and growing disease for which there is no effective therapy.
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AIMS: We sought to identify and quantify the value of biomarkers 
for the incidence of new onset heart failure (HF) in a 
community-based cohort and in subgroups based on cardiovascular risk. 
In addition, we evaluated the prognostic value of all biomarkers for HF with 
reduced (HFrEF) and preserved ejection fraction (HFpEF) separately.
METHODS AND RESULTS: We related 13 biomarkers, reflecting diverse 
pathophysiologic domains to the incidence of new onset HF in 8,569 heart 
failure free participants of Prevention of REnal and Vascular ENdstage 
Disease (PREVEND; mean age: 49 years, 50% male). Subjects were 
categorized in two risk groups, based on the presence or absence of previous 
cardiovascular history. Per biomarker, we evaluated incremental value using 
Harrell’s C coefficients. During a median follow-up of 12.5 years, 168 subjects 
(2.4%) were diagnosed with new onset HF in the low risk group (N = 6,915; 
Framingham Risk Score: 5.9%) and 206 (12.2%) subjects in the high risk group 
(N = 1,654; Framingham Risk Score: 18.6%). The risk association of natriuretic 
peptides, adrenomedullin, endothelin and galectin-3 with new onset HF was
stronger in the high risk group (all P<0.05 compared to low risk group). For 
troponin-T, hs-CRP, urinary albumin excretion and cystatin C, there was 
equal risk association for new onset HF between both risk groups. The best 
model for new onset HF was achieved by the combination of NT-proBNP 
and hs-TnT, which significantly increased model accuracy by 9.0% to 
0.81 (P<0.001) in subjects in the high risk group. Results for new onset 
HFrEF were similar to total HF. Except for a modest effect of cystatin C, 
no biomarker was associated with increased risk for HFpEF.
CONCLUSION: Risk stratification increases the incremental value per 
biomarker to predict new onset HF, especially HFrEF. However, we suggest that 
routine biomarker testing should be limited to the use of natriuretic peptides
and troponin T in patients with increased cardiovascular risk. There 
was no clinically relevant association of biomarkers with new onset 
HFpEF, irrespective of risk stratification.
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Introduction
Heart failure (HF) is a progressive syndrome with high morbidity and one 
of the major causes of death in Western countries.1-3 Since the discovery of 
natriuretic peptides, interest in using biomarkers alongside of clinical 
characteristics in order to guide early identification of subjects at risk has 
grown.4 Several new biomarkers have emerged, but to date their clinical value
remains under dispute. Proposed biomarkers include highly-sensitive 
troponin T (hs-TnT), urinary albumin excretion (UAE) or albumin to 
creatinine ratio, and highly-sensitive C-reactive protein (hs-CRP). 
The predictive value for new onset HF of novel biomarkers, like midregional 
proadrenomedullin (MR-proADM), galectin-3 or adiponectin, has not yet 
been well defined.5-7 Previous multimarker studies showed little 
or absent incremental value of biomarkers, including natriuretic 
peptides, on top of conventional clinical characteristics for predicting new 
onset HF in the general population. Therefore, routine measurements are 
considered not cost-effective.4,8,9 Identification of subgroups that might
benefit from biomarker testing is suggested as a more effective 
strategy.9 Another limiting factor is that most studies addressed HF 
in general, while we now acknowledge that HF with reduced ejection 
fraction (HFrEF) and HF with preserved ejection fraction
(HFpEF) are distinct subtypes with different pathophysiology. Only few 
studies have evaluated biomarkers for HFrEF and HFpEF specifically, but 
all were underpowered to draw definitive conclusions and were based 
on prevalent cases of HF.10,11
A large panel of biomarkers is available in the present study population, 
representing a wide range of pathophysiological pathways for cardiovascular 
(CV) disease, i.e.:  myocardial stress, myocyte injury, inflammation, renal 
dysfunction, extracellular matrix markers, renin angiotensin activation 
system, and other domains. We sought to identify and quantify the value 
of biomarkers for the prediction of new onset HF in a community-based 
cohort and in subgroups based on baseline CV risk. In addition, we evaluated 
the prognostic value of all biomarkers for HFrEF and HFpEF separately.
Methods
Study population




REnal and Vascular ENdstage Disease) cohort study, which has been 
described elsewhere.12,13 In summary, from 1997 to 1998, all inhabitants of 
the city of Groningen, The Netherlands, aged 28 to 75 years (N = 85,421) 
were asked to send in a first morning urine sample and complete a short 
questionnaire on demographics and CV disease history, and 40,856 
subjects responded (47.8%). All subjects with UAE ≥10mg/l (N = 7,786) in their 
morning urine as well as a randomly selected control group with a UAE <10 
mg/l (N = 3,395) were invited to an outpatient clinic for a detailed assessment 
of CV and renal risk factors, including filling out questionnaires, recording 
anthropometrics, and blood and urine sampling. After excluding subjects with 
insulin-dependent diabetes mellitus, pregnant women, and subjects unable 
or unwilling to participate, a total of 8,592 subjects completed the screening 
programme. For the current analysis, we excluded subjects with known HF 
diagnosis at baseline (N = 23), leaving 8,569 eligble subjects.14 The PREVEND 
study was approved by the institutional medical ethics committee and 
conducted in accordance with the Declaration of Helsinki. All 
subjects provided written informed consent.
Definitions
Systolic and diastolic blood pressures were calculated as the mean of the last 
two measurements of the two visits, measured using an automatic Dinamap 
XL Model 9300 series device. Hypertension was defined as systolic blood 
pressure >140mmHg, diastolic blood pressure >90mmHg, or self-reported use of 
antihypertensive medication. Body mass index (BMI) was calculated as the ratio 
of weight to height squared (kg/m2), and obesity was defined as a BMI>30kg/m2. 
Hypercholesterolaemia was defined as total serum cholesterol >6.5 mmol/l (251 
mg/dl) or a serum cholesterol >5.0 mmol/l (193 mg/dl) if a history of myocardial 
infarction (MI) was present or when lipid-lowering medication was used. Type 
2 diabetes was defined as a fasting plasma glucose >7.0 mmol/l (126 mg/dl), a 
non-fasting plasma glucose >11.1 mmol/l, or use of anti-diabetic drugs. UAE was 
calculated as the average value from two consecutive 24h urine collections. The 
glomerular filtration rate (eGFR) was estimated using the simplified Modification 
of Diet in Renal Disease formula.15 Smoking was defined as current smoking or 
smoking cessation within the previous year. History of MI of cerebrovascular 
accident (CVA) was defined as participant-reported hospitalization for at least 
3 days as a result of this condition. Standard 12-lead electrocardiograms were 
recorded using the computer program Modular ECG Analysis System, and atrial 
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fibrillation (AF) was defined according to Minnesota codes 8.3.1 and 8.3.3.16
Subjects were categorized in two risk groups, based on the presence or 
absence of  previous CV history (referred to as “high risk” and “low risk”, 
respectively). Previous CV history was defined as previous 
hospitalization for MI or CVA, or the use of anti-hypertensive, lipid-lowering or 
glucose-lowering drugs at baseline assessment. Anti-hypertensive 
drugs were defined as angiotension converting enzym inhibitors, angiotensin 
receptor blockers, diuretics or calcium antagonists. Lipid-lowering drugs were 
defined as any kind of statin. Glucose-lowering drugs were defined as oral 
anti-diabetic drugs. Information on medication use was obtained from the 
InterAction database (IADB), a community-based pharmacy database, 
contains detailed patient-specific drug prescription information on inhabitants 
of the city of Groningen and was linked to PREVEND data.17 Prescription drugs 
were classified according to the Anatomical Therapeutic Chemical system. 
All PREVEND participants gave informed consent to link their data with 
pharmacy-dispensing data. The individual Framingham Risk Score 
was calculated according to D’Agostino et al.18
Assays
At baseline, EDTA plasma samples were drawn from all participants for 
biomarkerassessment. Aliquots of these samples stored immediately 
after collection at -80°C until analyses. Assays for all biomarkers in PREVEND 
have been described in detail elsewhere: N-terminal pro-B-type natriuretic 
peptide (NT-proBNP),19 midregional pro-A-type natriuretic peptide 
(MR-proANP),20 MR-proADM,21 C-terminal-pro-Endothelin-1 (CT-proET-1),22 
galectin-3,23 hs-TnT,24 C-terminal pro-Arginine vasopressin (CT-proAVP), referred 
to as “copeptin”,25 procalcitonin,26 hs-CRP,27 cystatin C,21 UAE,28 renin,29 and 
aldosterone.29 For details on all assays, see supplementary material online.
New onset HF
Follow-up for the present investigation was defined as the time between the 
baseline visit to the outpatient department and the date of new onset HF up 
to January 1st, 2010. Subjects were censored at the date they moved to an 
unknown destination or at the last date of the follow-up, whatever date came 
first. Information on dates and causes of death for every participant was obtained
from Statistics Netherlands30 and coded according to the 10th revision of the 
International Classification of Diseases (ICD). Participants with a new diagnosis 




European Society of Cardiology31 and an endpoint adjudication committee 
ascertained the diagnosis of either HFrEF or HFpEF, as described elsewhere.14 
HF was classified as HFrEF or HFpEF based on left ventricular ejection fraction 
at the time of diagnosis. To prevent blending and dilution of epidemiological 
risk profiles between HFrEF and HFpEF, and to acknowledge the most recent 
trends in cut-off for HFrEF and HFpEF in accordance with the HF guidelines,31 
we have set the cut-off for HFpEF on ≥50% and the cut-off for HFrEF on ≤40%. 
Subjects in the grey area, with a LVEF 41-49% (N = 8), were excluded from the 
analyses to prevent blending and dilution of differential epidemiological profiles.
Statistical analysis
By design, subjects with an UAE ≥10 mg/l are overrepresented in the PREVEND. 
A design-based analysis was performed to overcome this overselection of 
subjects with elevated UAE. This statistical weighting method allows conclusions 
to be generalized to the general population.21,32 Baseline continuous data are 
reported as mean (standard deviation) for normally distributed data. Because 
of skewed distribution, NT-proBNP, MR-proANP, galectin-3, hs-TnT, copeptin, 
procalcitonin, hs-CRP, UAE, cystatin C, renin en aldosterone were transformed 
to a 2-log scale and reported as median (inter-quartile range). This means that 
risk estimates should be interpreted as the relative risk if values were doubled 
(e.g. 1 to 2 mg/l or 10 to 20 mg/24h). To evaluate time to HF diagnosis for 
both risk groups, we performed Kaplan-Meier analyses (log-rank) using 
cumulative incidence. Two competing endpoints were distinguished: HFrEF 
and HFpEF. We fitted Cox-proportional hazards models to the data and 
adjusted our multivariate model for age, gender, BMI, smoking status, systolic 
blood pressure, AF, plasma glucose and total cholesterol levels, in accordance 
with previous results.14 Schoenfeld residuals were calculated to assess 
whether proportionality assumptions were satisfied. We evaluted a P-value for 
interaction (Pint) between both risk groups, to compare the effects of biomarkers 
between both groups. To control for the type I error in the cause-specific 
hazard analysis (effect-by-covariate), a Pint between the high en low risk group 
of <0.10 is considered statistically significant.14,33 To define the proportion of 
usable subject pairs in which outcome and prediction are concordant, we 
calculated the Harrell´s C coefficient for both models and the incremental value 
of biomarkers on this coefficient. Results are summarized as hazard ratios, 
with 95% confidence intervals based on robust standard error estimates. We 
accounted for multiple testing using Bonferroni correction: for each risk group, 
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   Low risk  High risk   
    N=6,915 N=1,654 P-value 
Heart failure (HFrEF / HFpEF-N)   168 (110 / 53) 206 (131 / 72) 
HF cases (HFrEF / HFpEF -  %)    2.4 (1.6 / 0.7) 12.2 (7.9 / 4.4) 
Mean follow- up HF cases   8.6 (4.8-10.9) 7.3 (3.5-10.0) 0.002 
   HFrEF    7.8 (3.9-10.6) 6.1 (3.1-9.3) 
   HFpEF   9.9 (7.5-11.3) 8.7 (5.4-10.8) 
Framingham Risk Score (%)    5.9 (2.5-14.7) 18.6 (9.0-32.3) <0.001 
Age (yrs)    47+_12 59 11 <0.001 
Males (%)    49.1 52.7 0.009 
Caucasians (%)   95.5 95.7 0.795 
BMI (kg/m2)    26+_4 28 4 <0.001 
Waist circumference (cm)   87+_13 95 13 <0.001 
Systolic  BP (mmHg)    126+_19 140 22 <0.001 
Diastolic BP (mmHg)    73 10 78 10 <0.001 
Heart rate (bpm)   69 10 69 11 <0.001 
Smoking or quit smoking <1yr (%)    39.6 31.5 <0.001 
Selection criteria         
Previous myocardial infarction (%)    0.0 31.0 <0.001 
Previous stroke (%)    0.0 5.0 <0.001 
Anti -hypertensive medx   0.0 70.7 <0.001 
Anti-cholesterol medx    0.0 20.7 <0.001 
Anti -diabetes medx   0.0 7.0 <0.001 
Biochemical markers         
Glucose (mmol/l)    4.8 1.0 5.4 1.7 <0.001 
Cholesterol (mmol/l)    5.6 1.1 5.8 1.1 <0.001 
HDL (mmol/l)    1.34 0.40 1.23 0.36 <0.001 
LDL (mmol/l)    3.64 1.05 3.86 0.99 <0.001 
Triglicerides (mmol/l)    1.11 (0.81-1.61) 1.40 (1.03-1.99) <0.001 
Serum Creatinine (umol/l)    82 (73-91) 86 (76-97) <0.001 
Serum Creatinine (mg/dl)    0.9 (0.8-1.0) 1.0 (0.9-1.1) <0.001 
eGFR (ml/min/1.73m2)    82 14 75 16 <0.001   
NT-proBNP (ng/l)    33 (15-62) 66 (30-150) <0.001 
MR-proANP (pmol/l)    45 (33-61) 62 (44-92) <0.001 
MR-proADM (nmol/l)    0.37 0.12 0.46 0.18 <0.001 
CT-proET-1 (pmol/l)   33.8 13.6 39.4 17.1 <0.001 
Galectin-3 (ng/ml)    10.6 (8.9-12.7) 12.2 (10.0-14.8) <0.001 
Hs-TnT (ng/l)    2.5 (2.5-4.0) 4.0 (2.5-8.0) <0.001 
Copeptin (pmol/l)    4.6 (2.9-7.4) 5.0 (3.0-8.5) <0.001 
Procalcitonin (ng/l)    1.5 (1.3-1.9) 1.8 (1.4-2.2) <0.001 
Hs-CRP (mg/l)    1.14 (0.50-2.69) 2.01 (0.93-4.31) <0.001 
Cystatin C (mg/l)    0.76 (0.68-0.85) 0.85 (0.74-0.98) <0.001 
UAE (mg/24h)    8.9 (6.2-15.3) 13.5 (7.3-34.0) <0.001 
Renin (mIU/ml)    17.8 (11.2-27.6) 19.3 (10.5-35.7) <0.001 




























14 biomarkers were tested, and a P<0.004 (=0.05/13)  was considered 
statistically significant. All statistical analyses were performed using StataIC 
(version 11.2 software for Windows). Figures displaying hazard ratios (HR) 
were made in SigmaPlot 10, by plotting estimated HR (calculated in StataIC).
Results
Baseline characteristics for both risk groups are presented in table 1. Subjects 
in the high risk group (N = 1,654, 19.3% of the total population) were older, more 
often male, had higher BMI, blood pressure and heart rate, and worse renal 
function compared to subjects in the low risk group (N = 6,915). Glucose, lipid 
parameters and all evaluated biomarkers were also higher at baseline for subjects 
in the high risk group (P<0.001), with the exception of aldosterone (P=0.696). 
Figure 1 Cumulative incidence of new onset heart failure, divided by risk groups
* Continuous variables are presented as mean+standard deviation and compared with 
the use of Student’s t-test in case of normal distribution. In case of skewed distribution, 
continuous variables are presented as median (interquartile range) and compared 
using the Kruskall-Wallis test. Binary categorical  variables were compared using 
standard Chi-squared tests. HFrEF denotes  heart failure with reduced ejection 
fraction, HFpEF heart failure  with preserved ejection fraction, BMI body-mass index,
BP blood pressure blood pressure, HDL high density lipoprotein, LDL low 
density lipoprotein, eGFR estimated glomerular filtration rate,  NT-proBNP 
N-terminal pro-B-type natriuretic peptide, MR-proANP  midregional pro-A-type 
natriuretic peptide, MR-proADM midregional  proadrenomedullin, CT-proET-1 
c-terminal proendothelin-1, hs-TnT highly-sensitive troponin T, hs-CRP highly-sensitive 
























0 2 4 6 8 10 12
Follow-up (years)
Endpoint incidence; low baseline risk (N = 6,915)
Endpoint incidence; high baseline risk (N = 1,654)
P<0.001
Incidence of combined endpoint; by baseline risk groups
82
Clinical risk stratification optimizes value of biomarkers
The calculated median Framingham Risk Score was over three times higher 
in the high risk group (18.6% vs. 5.9%; P<0.001). During a median follow-up 
of 12.5 years (range 12.2-12.9; over 107,000 subjects years), 374 individuals 
were diagnosed with new onset HF, of whom 168 (2.4%) and 206 (12.2%) were 
in the low and high risk group, respectively. The median time to endpoint was 
8.6 (range 4.8-10.9) years in the low risk group and 7.3 (range 3.5-10.0) years 
for the high risk group (P=0.002). Figure 1 shows the cumulative incidence 
of new onset HF, divided by risk group and adjusted for all-cause mortality.
New onset HF
Table 2 summarizes the results of the Cox-proportional hazard analysis 
for all biomarkers on new onset HF (unstratified for risk groups, nor for 
HFrEF and HFpEF). After adjustment for age and gender, NT-proBNP, 
 Adjusted for  age, sex   
Multivariable 
adjusted**   
  HR (95% CI)  P-value   HR (95% CI)  P-value 
NT-proBNP  2.11   (1.79-2.48) <0.001  2.12   (1.76-2.55) <0.001 
MR-proANP  1.61   (1.32-1.98) <0.001  1.62   (1.31-1.99) <0.001 
MR-proADM  1.26   (0.96-1.65) 0.096  1.10   (0.85-1.43) 0.457 
CT-proET-1  0.98   (0.81-1.17) 0.791  0.96   (0.80-1.16) 0.703 
Galectin-3 1.18   (1.03-1.36) 0.021  1.10   (0.95-1.28) 0.216 
Hs-TnT  1.66   (1.49-1.85) <0.001  1.56   (1.38-1.77) <0.001 
Copeptin  1.02   (0.84-1.23) 0.876  0.93   (0.75-1.14) 0.483 
Procalcitonin  1.11   (0.98-1.25) 0.088  1.03   (0.88-1.20) 0.714 
Hs-CRP 1.42   (1.17-1.71) <0.001  1.27   (1.04-1.55) 0.022 
Cystatin C  1.45   (1.24-1.69) <0.001  1.39   (1.17-1.66) <0.001 
UAE  1.39   (1.26-1.53) <0.001  1.23   (1.11-1.37) <0.001 
Renin 1.12   (0.94-1.33) 0.197  1.13   (0.95-1.35) 0.156 
Aldosterone 1.04   (0.89-1.21) 0.656  1.00   (0.85-1.18) 0.990 
ARR  0.91   (0.77-1.07) 0.263   0.88   (0.75-1.04) 0.143 
 
Table 2 Relationship of single biomarkers with new onset heart failure in 8,569 
subjects free of heart failure*
* Hazard ratios for MR-proADM and CT-proET-1 are presented per increase of one 
standard deviation. Hazard ratios for all other biomarkers are presented 
per doubling of biomarker 
** adjusted for age, sex, BMI > 30kg/m2, smoking, systolic blood pressure, plas-
ma glucose, total cholesterol. HR denotes hazard ratio, CI confidence interval, 
NT-proBNP N-terminal pro-B-type natriuretic peptide, MR-proANP midregional 
pro-A-type natriuretic peptide, MR-proADM midregional proadrenomedullin, CT-
proET-1 c-terminal proendothelin-1, hs-TnT highly-sensitive troponin T, hs-CRP 





Figure 2  All biomarkers and their multi-adjusted relative risk for new onset heart failure, 
divided by risk groups. HF incidence in low risk and high risk group was 168 (2.4%) and 
206 (12.2%), respectively.
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MR-proANP, hs-TnT, hs-CRP, cystatin C and UAE were significantly associated 
with increased risk for new onset HF. In multivariate analysis, the same 
biomarkers remained statistically significant. The proportionality assumptions 
for every biomarker in the model for total HF were satisfied (P>0.100).
Hazard ratios for new onset HF, stratified for low and high risk, and their 
given interaction are depicted in Figure 2. After multivariable adjustment, higher 
NT-proBNP was associated with increased risk for new onset HF in both risk 
groups, although this association was significantly stronger for NT-proBNP 
in the high risk group (Pint=0.005). There was also an interaction present for 
the biomarkers MR-proANP, MR-proADM, CT-proET-1 and galectin-3 (all 
Pint<0.005; Pint<0.05 for galectin-3), indicating an increased risk for new 
onset HF specifically in subjects in the high risk category at baseline. Higher 
values of these biomarkers were not associated with risk for new onset HF 
in subjects in the low risk group. For hs-TnT, hs-CRP, UAE and cystatin C 
there was no interaction present, indicating that these markers are equally 
associated with outcome in both risk groups. Copeptin, procalcitonin, renin 
and aldosterone showed no association with increased risk for new onset HF.
The additional value of each biomarker to the model, compared to age and 
 Unstratiﬁed  population    Subjects with   Subjects with   
     low baseline risk (N=6,915)  high baseline risk (N=1,654)  
 Harrell's C statistic     Harrell's C statistic   Harrell's C statistic   
  Addition (%)  P-value   Addition (%)  P-value Addition (%)  P-value 
Age + sex*  0.826   (0.790-0.863)     0.787   (0.718-0.856)  0.743   (0.696-0.789)  
NT-proBNP   + 4.7%   <0.001    + 6.1%  0.007 + 6.3% 0.006 
MR-proANP   + 2.2%  0.008       + 5.2% 0.031 
MR-proADM                
CT-proET-1                
Galectin-3           + 1.3% 0.053 
Hs-TnT  + 2.5%  0.006       + 5.7% 0.011 
Copeptin               
Procalcitonin   + 0.7%  0.058           
Hs-CRP  + 1.9%  0.009    + 4.3%  0.027     
Cystatin C   + 1.0%  0.025           
UAE   + 1.6%  <0.001    + 2.0%  0.014 + 2.2% 0.024 
Renin                
Aldosterone            
ARR                
        
* no missing values for all biomarkers (N=7.132)  
 
Table 3 Harrell’s C statistic of individual biomarkers with new onset heart failure
* no missing values for all biomarkers (N = 7,132)
CI denotes confidence interval, NT-proBNP N-terminal pro-B-type natriuretic peptide, 
MR-proANP midregional pro-A-type natriuretic peptide, MR-proADM midregional 
proadrenomedullin, CT-proET-1, c-terminal proendothelin-1, hs-TnT highly-sensitive 
troponin T, hs-CRP highly-sensitive C-reactive protein UAE urinary albumin excretion, 




Figure 3A All biomarkers and their multi-
adjusted relative risk for new onset HFrEF, 
divided by risk groups. HFrEF incidence in 
low risk and high risk group was 110 (1.6%) 
and 131 (7.9%), respectively.
Figure 3B All biomarkers and their 
multi-adjusted relative risk for new onset 
HFpEF, divided by risk groups. HFpEF 
incidence in low risk and high risk group 
was 53 (0.8%) and 72 (4.4%), respectively.
gender alone, was subsequently calculated and summarized in Table 3. For the low 
risk group, NT-proBNP, hs-CRP and UAE modestly improved model fit by 6.1, 4.3 
and 2.0%, respectively; other biomarkers did not improve the model. The model 
for subjects with high baseline risk improved with the addition of NT-proBNP, 
hs-TnT, MR-proANP, UAE and galectin-3, in order of incremental value.
During the follow-up period, there were 169 myocardial infarctions, which was 
followed by new onset HF in 43 (25.4%) subjects (N = 26 in the low risk group; 
N = 17 in the high risk group, see Supplementary Table S2). A sub-analysis 
was performed without these 43 subjects, to account for possible bias in the 
risk association for all separate biomarkers with myocardial infarction, instead 
of new onset heart failure, HFrEF or HFpEF. This did not change the results.
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HFrEF vs. HFpEF
Hazard ratios for all biomarkers in both risk groups and their potential interaction 
are presented in Figure 3A (HFrEF) and Figure 3B (HFpEF). Results for new 
onset HFrEF were comparable to total new onset HF, where the same biomarkers 
were associated with increased risk for HFrEF in subjects with high baseline CV 
risk. For new onset HFpEF, there was an interaction present between risk groups 
for MR-proADM and CT-proET-1. However, the associated risk for HFpEF itself 
was not significant in both risk groups separately. Renal function, represented 
by cystatin C, was associated with new onset HFpEF, with comparable hazard 
ratios for both risk groups at baseline. The proportionality assumptions for 
every biomarker in the models for HFrEF and HFpEF were satisfied (P>0.100).
Model performance
The model with best performance for the prediction of new onset HF in the 
entire cohort was achieved by the combination of NT-proBNP, hs-TnT and UAE, 
which significantly increased model accuracy by 5.6% to 0.87 (P<0.001). These 
biomarkers were subsequently assessed in a multimarker score and 
dichotomized according to 75th percentile. Table 4 shows the univariate and 
multivariate hazard ratios (for total new onset HF) for the different combinations 
of the high and low values of these three biomarkers. All three entities alone 
were not associated with an increased risk for total new onset HF, whereas the 
combination of any two entities increased the risk substantially. Figure 4 shows 
the Cox-regression survival curves for different combination of biomarkers. 
When high levels of NT-proBNP, hs-TnT and UAE were all present, the adjusted 
 
          
   Univariate    Multivariate   
  N*  HF  HR  P-value    HR  P-value  
Low NT-proBNP, hs-TnT and UAE  3860 41 1.00   1.00  
Only high UAE  845 20 1.67 (0.91-3.05) 0.097   0.97 (0.51-1.87) 0.936 
Only high hs -TnT  462 22 4.80 (2.39-9.61) <0.001   1.94 (0.88-4.23) 0.098 
Only high NT-proBNP  922 34 3.47 (1.90-6.33) <0.001  2.17 (0.96-4.92) 0.062 
High hs -TnT + high UAE  262 27 8.56 (4.13-17.72) <0.001   2.32 (1.23-4.38) 0.009 
High NT-proBNP + high UAE  245 22 10.69 (5.38-21.21) <0.001   4.87 (2.21-10.75) <0.001 
High NT-proBNP + high hs-TnT  262 43 22.01 (12.56-38.51) <0.001   5.54 (2.75-11.16) <0.001 
High NT-proBNP + high hs-TnT + high UAE  274 75 43.52 (26.20-72.31) <0.001   7.28 (3.66-14.49) <0.001 
        
Table 4 Combination of biomarkers and outcome
* no missing values for all biomarkers (N = 7,132)
HF denotes heart failure, HR hazard ratio, NT-proBNP  NT-proBNP N-terminal 
pro-B-type natriuretic peptide, hs-TnT highly-sensitive troponin T, UAE urinary 
albumin excretion. Low NT-proBNP ≤73.5ng/l, high NT-proBNP >73.5ng/l; low 




hazard ratio was strongly increased: 7.28; 95% CI 3.66-14.49; P<0.001 for total 
new onset HF. 
Discussion
In the present study, we report that an array of biomarkers has limited value in 
predicting new onset HF in a large middle-aged cohort from the general 
population. However, the predictive value for new onset HF of several CV 
biomarkers substantially increased when a high baseline risk group was 
separately studied. In subjects with low CV risk, apart from the established 
biomarkers NT-proBNP and hs-TnT, no CV biomarkers were associated 
with new onset HFrEF. Finally, regardless of baseline risk group, no 
biomarkers were associated with new onset HFpEF, except for cystatin C, 
which showed a modest association. Dividing subjects from the 
general population based on previous history of CV disease, 
appears a useful tool to differentiate high risk from low risk individuals. 
Figure 4 Survival function for new onset heart failure stratified by different 
combinations or biomarkers. Low NT-proBNP ≤73.5ng/l, high NT-proBNP >73.5ng/l; 
low hs-TnT ≤5ng/l, high hs-TnT >5ng/l; low UAE ≤17.7mg/24h, high UAE >17.7mg/24h. 
NT-proBNP denotes N-terminal pro-B-type natriuretic peptide, hs-TnT highly-sensitive 















































Low NT-proBNP, low hs-TnT, low UAE 
Only high UAE 
Only high hs-TnT 
Only high NT-proBNP 
High hs-TnT + high UAE 
High NT-proBNP + high UAE 
High NT-proBNP + high hs-TnT 
High NT-proBNP + high hs-TnT + high UAE 
3860 3775 3665 3553 3461 3357 3201   Low NT-proBNP, low hs-TnT, low UAE 
845 824 804 780 749 722 672   Only high UAE 
462 448 430 404 387 370 344   Only high hs-TnT 
922 903 862 835 804 766 720   Only high NT-proBNP 
262 256 244 236 221 206 181   High hs-TnT + high UAE 
245 235 222 213 205 190 169   High NT-proBNP + high UAE 
262 246 225 204 183 162 140   High NT-proBNP + high hs-TnT 
274 242 209 172 144 119 94   High NT-proBNP + high hs-TnT + high UAE 
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Early detection of increased risk for diagnosis of a high mortality condition 
such as HFrEF and HFpEF could alert physicians and prompt preventive 
measures and treatment early in the disease process, and may 
be helpful in attenuating disease progression.
At least two large studies have performed multi-biomarker analyses for new 
onset HF. Velagaleti et al. identified NT-proBNP and albumin-to-creatinine 
ratio to be associated with new onset HF.8 Smith et al. associated natriuretic 
peptides with improved risk classification for HF in addition to conventional risk 
factors.9 Galectin-3 was recently shown to be associated with increased risk for 
new onset HF, on top of conventional risk factors and BNP in the community.6 
Similar to our analyses, these studies provide data from large community-based 
populations with long-term follow-up and show comparable incidence rates 
of new onset HF. However, both previous studies also showed that CV 
biomarkers have little or absent incremental value, on top of clinical 
characteristics, with or without the combination with NT-proBNP to predict 
new onset HF. This may be explained by the diversity of subjects at baseline 
(i.e. ethnicity, CV risk) and lack of power due to a low number of new onset HF 
cases. But probably more important, there is increasing evidence of 
substantial epidemiologic differences between subjects with 
new onset HFrEF and HFpEF long before time of diagnosis, 
and these phenotypes should be clearly distinguished.14,34 Our analysis adds 
several novel aspects. To increase the incremental value of 
several biomarkers, we divided our cohort using a combination of common 
clinical risk stratification of subjects and performed separate analyses 
for HFrEF vs. HFpEF. We also assessed biomarkers from multiple domains,
reflecting different pathological processes that are operative in HF.35
Clinical risk stratification: High vs. low risk at baseline
Using a simple clinical stratification, we incurred large differences in 
baseline CV risk (confirmed by the Framingham risk score), a substantial 
shorter follow-up time to incident HF events and an increased incidence 
of new onset HF. We confirm the predictive ability of NT-proBNP for new 
onset HF, and show increased ability of this biomarker for subjects with high 
baseline risk, compared to subjects with low baseline risk. We also confirm 
the association between higher circulating galectin-3 concentrations and the 




appears only significant in subjects with high CV risk. Similar results were 
obtained with novel CV biomarkers like MR-proANP, MR-proADM and 
CT-proET-1, which were only modestly associated with increased 
risk for developing HF in subjects with high baseline risk. Increased levels 
of hs-TnT, hs-CRP, cystatin C and UAE have been associated with worse 
prognosis in prevalent HF,36-39 but did not show differences in hazard 
ratios between both risk groups. In subjects with low CV risk at baseline, 
no novel CV biomarkers were associated with new onset HF.
No prospective data have been reported describing the predictive role of ANP 
for new onset HF to date, although it has been shown that increased ANP
independently predicts left ventricular hypertrophy in a general population 
and outcome in chronic HF patients.40,41 Natriuretic peptides showed the 
strongest prognostic value for new onset HF, specifically in subjects with 
high baseline CV risk. However, the prognostic value of these peptides is not 
independent of each other. MR-proADM and CT-proET-1, both involved in the 
homeostasis of the sodium and water balance, have shown promising results in 
predicting outcome in chronic HF patients,42,43 however their incremental 
value in predicting CV outcome is still under debate.9,44 This might be 
explained by the fact that both MR-proADM and CT-proET-1 are typically 
increased in those at risk for CV disease, such as elderly subjects, with 
or without chronic kidney disease, albuminuria or type 2 diabetes.21,42,45,46 
Through stratification of baseline CV risk, we were able to improve the 
ability of these biomarkers to predict new onset HF.
HFrEF vs. HFpEF
The modest incremental value of biomarkers in previous studies might be 
partly explained by lack of differentiation between HFrEF and HFpEF, which 
are known to represent different epidemiologic profiles, even years before 
diagnosis, and could therefore be considered different diseases.14,34 Our data 
support this notion, but also give new information on the ability of biomarkers 
to predict either HFrEF or HFpEF. Biomarkers were able to identify 
subjects at risk for HFrEF, but not HFpEF. This confirms that these phenotypes 
can not only be regarded as different disease states, but also that 
HFpEF patients are much harder to identify up front. Whether this is caused 
by specific underlying pathophysiology, the severity of the disease at initial 
diagnosis, or even the diagnosis itself, should be the focus of future research.
90
Clinical risk stratification optimizes value of biomarkers
Clinical implications
Compared to previous large biomarker studies, we have also associated 
several biomarkers with new onset HF. However, we must also emphasize 
the modest predictive value of all evaluated biomarkers in this community-
based cohort. By baseline risk stratification, several CV biomarkers increased 
the discriminatory power of the statistical model in the high risk group, in 
contrast with to the low risk group, where there was overall very modest 
incremental value of all evaluated biomarkers. Out of all possible combinations, 
the greatest improvement in model fit for high risk subjects was accomplished 
with both NT-proBNP and hs-TnT. Screening tactics for the general population, 
or beneficial effects of invididual risk stratification into low of high risk groups 
needs to be evaluated in future studies, especially for HFpEF. However, from 
the perspective of cost-effectiveness, we propose to refrain from measuring 
biomarkers in subjects with low baseline CV risk. Future studies are needed 
to evaluate the incremental value of other biomarkers, especially for HFpEF.
Strengths and limitations
The large PREVEND cohort, with over 107,000 patient years of follow-up and 
thoroughly validated cases of new onset HF, provides good opportunity for 
large-scale evaluation of biomarkers. We offer a broad range of biomarkers, 
reflecting multiple domains associated with HF development. In 
addition, we have identified new onset HFrEF next to HFpEF, giving insight into 
pathophysiologic pathways for both HF phenotypes. Our study is limited by 
the fact that the PREVEND study subjects are predominately Caucasian, 
so our results cannot be extrapolated to subjects of other ethnicity. Serial 
biomarker data are also not available. Furthermore, we aimed to study differential 
risk association for HF (and specifically for HFrEF and HFpEF) between 
low and high risk groups, and did therefore not include mortality as an 
additional competing risk state in the current analysis. Finally, the PREVEND 
cohort was enriched for increased albumin excretion. We therefore conducted 





In this community-based cohort, several biomarkers were associated with 
new onset HF. Risk stratification further increases the incremental value per 
biomarker to predict HF, especially HFrEF. However, we conclude from our data 
that routine biomarker testing should be limited to the use of NT-proBNP and 
hs-TnT in patients with an increased CV risk. There was no clinically relevant 
association of any biomarker with new onset HFpEF, irrespective of risk group.
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Abstract
AIMS: Heart failure with reduced and preserved ejection fraction (HFrEF, 
HFpEF, respectively) is associated with high mortality and morbidity. We 
developed a competing risk model for simultaneously predicting new 
onset HFrEF and HFpEF in individuals from a community-based cohort.
METHODS AND RESULTS: From 8,569 heart failure-free subjects of the 
Prevention of REnal and Vascular ENdstage Disease (PREVEND), a 
community-based, middle-aged cohort study, we identified 374 subjects with new 
onset heart failure, of whom 241 (66%) had HFrEF, according to the guidelines 
of the European Society of Cardiology. Weibull regression models were used 
with a subject’s age as the time scale to describe the cause-specific hazard 
functions of the state transitions included in our model. The model’s accuracy in 
predicting the 10-year cumulative incidences of new onset HFpEF and 
HFrEF was internally validated considering calibration and discrimination. 
21 easily available risk factors in daily clinical practice comprised the 
PREVEND risk model. The mean observed vs. predicted 10-year cumulative
incidence was 2.1% and 2.3% for HFrEF and 1.0% and 1.1% for HFpEF. 
Predictors for new onset HFpEF were cystatin C, UAE and systolic 
blood pressure. Specific predictors for HFrEF were smoking, hs-Troponin T, 
male gender and cholesterol. NT-proBNP and myocardial infarction 
predicted both outcomes, however stronger for HFrEF. BMI also predicted 
both outcomes, but stronger for HFpEF. The corresponding values 
of the c statistic were 0.70 for HFrEF and 0.60 for HFpEF.
CONCLUSION: We present the first available risk prediction model for 
early identification of subjects at risk for new onset HFrEF and HFpEF. Even 
in a well-defined community-based cohort with extensive follow-up, the 
prediction of new onset heart failure, in particular HFpEF, remains challenging.
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Introduction
Heart failure is a progressive syndrome with a high morbidity and is one of the 
major causes of death in Western countries.1-3 Variable mortality rates have been 
reported, accounting for the severity of the underlying disease and various other 
factors. For example, in most surveys, patients with HFpEF have a better survival 
compared with patients with HFrEF.4, 5 Multiple successful clinical trials showed 
substantially improved prognosis for patients diagnosed with HFrEF,6  whereas no
randomized clinical trial yet decreased mortality rates for subjects with HFpEF.7  
Most recent studies on new onset heart failure have shown clear distinctive 
clinical patterns between the two types of heart failure.8, 9 Since the difference 
in patient profiles, clinical outcomes and differential benefits of drug treatment, 
HFrEF and HFpEF should be considered separately when analyzing the risk 
of new onset heart failure. However, a risk prediction model that discriminates 
between subjects at risk for HFpEF and HFrEF has not yet been developed.
Recently, we identified all cases of new onset heart failure during 12.5 
years of follow-up in a community-based cohort and adjudicated them 
as either HFrEF or HFpEF.8 In the current investigation, we developed
a risk prediction model for both types of new onset heart failure, 
using regular and easily available clinical and biochemical measurements.
Methods
Study population
The study was performed using the data of the PREVEND (Prevention of REnal 
and Vascular ENdstage Disease) cohort study, which has been described 
elsewhere.10, 11 In summary, from 1997 to 1998, all inhabitants of the city of 
Groningen, The Netherlands, aged 28 to 75 years (N = 85,421) were asked 
to send in a first morning urine sample and complete a short questionnaire 
on demographics and cardiovascular disease history, and 40,856 subjects 
responded (47.8%). All subjects with a urinary albumin excretion (UAE) 
≥10mg/l (N = 7,786) in their morning urine as well as a randomly selected 
control group with a UAE <10 mg/l (N = 3,395) were invited to an outpatient clinic 
for a detailled assessment of cardiovascular and renal risk factors, including 
filling in questionnaires, recording anthropometrics, and blood and urine 
sampling. After excluding subjects with insulin-dependent diabetes mellitus, 
pregnant women, and subjects unable or unwilling to participate, a total of 8,592 




had a diagnosis of heart failure before the start of PREVEND.8 These patients 
were excluded from the present analysis. Thus in total, 8,569 heart failure-free 
subjects comprised the present study population. The PREVEND study was 
approved by the institutional medical ethics committee and conducted in 
accordance with the Declaration of Helsinki. All subjects provided 
written informed consent. 
Definitions 
Systolic and diastolic blood pressures were calculated as the mean of the last 
two measurements of the two visits, measured using an automatic Dinamap XL 
Model 9300 series device. Body mass index (BMI) was calculated as the ratio 
of weight to height squared (kg/m2). UAE was calculated as the average value 
from two consecutive 24h urine collections. Smoking was defined as current 
nicotine use or smoking cessation within the previous year. History of myocardial
infarction was defined as participant-reported hospitalization for at least three 
days as a result of this condition. Standard 12-lead electrocardiograms were 
recorded using the computer program Modular ECG Analysis System, and atrial 
fibrillation (AF) was defined according to Minnesota codes 8.3.1 and 8.3.3.12
Assays
At baseline, EDTA plasma samples were drawn from all participants for 
biomarker assessment. Aliquots of these samples were stored immediately 
after collection at -80°C until analyses. N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) and highly-sensitive C-reactive protein (hs-CRP) were 
measured, as described in detail elsewhere.13, 14 Highly-sensitive troponin T 
(hs-TnT) was measured using Modular Analytics serum work areas, with <10% 
coefficient of variation at the 99th percentile of the reference range (Roche 
Diagnostics).15 Urinary albumin concentration was determined by nepholometry, 
with a threshold of 2.3 mg/l and intra- and interassay coefficients variation of 2.2 
and 2.6%, respectively (BNII, Dade Behring Diagnostica, Marburg, Germany).10
Heart failure and cardiovascular events
As described before, follow-up for the present investigation was defined 
as time between the baseline visit to the outpatient department and the 
date of new onset heart failure, death or 01 January 2011.8 Subjects were 
censored at the date they moved to an unknown destination or at the last date of 
follow-up (01 January 2011), whichever date came first. Information on dates and 
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causes of death for every participant were obtained from Statistics 
Netherlands,16 and coded according to the 10th revision of the International 
Classification of Diseases (ICD). Participants with a new diagnosis of heart 
failure were identified using criteria described in the Heart Failure Guidelines of 
the European Society of Cardiology,6 and an endpoint adjudication committee 
ascertained the diagnosis of either HFrEF or HFpEF, as described elsewhere.8 
Based on left ventricular ejection fraction (LVEF) at the time of diagnosis, heart 
failure was classified as HFrEF or HFpEF (LVEF ≤40% or ≥50%, respectively).
Model structure
To predict the 10-year cumulative incidences of new onset HFpEF and 
HFrEF, we fitted a competing risk model to the observed outcomes in 
the study population.17 The model consisted of one starting state (free of 
heart failure) and three absorbing states reflecting the occurrence of three 
competing causes of failure: new onset HFpEF, new onset HFrEF, and death 
before the onset of heart failure (see Figure 1 for a schematic representation). 
The death state included eight subjects who developed new onset heart 
failure with a LVEF between 41% and 49% at the time of diagnosis, as these 
subjects are also no longer at risk for developing either new onset HFpEF or 
new onset HFrEF. The cause-specific hazard functions were assumed to have 
a proportional hazard structure with a Weibull baseline hazard function and 
a subject’s age as the time scale.18 To account for the overrepresentation of 
subjects with an elevated UAE (≥10 mg/l) in our study population, subjects 
were stratified into normal or elevated UAE and separate baseline hazard
functions were fitted to each stratum. The effects of the explanatory covariates 
on the baseline hazard functions were assumed to be the same in each 
stratum. A detailed description of the model’s regression equations and how these 
equations were combined to obtain absolute risk predictions is provided
in Appendix I.
Parameter estimation
To fit the cause-specific hazard functions to the observed outcomes in the 
PREVEND study population, the following procedure was followed. First, 
a set of routinely available candidate predictor variables (Appendix II) was 
established to build up the initial full models. Subsequently, model building 
was performed by applying a backward selection procedure with a nominal 




present in several of the candidate predictor variables, multiple imputation was 
performed to obtain five imputed data sets. Rubin’s rules were used to obtain 
pooled estimates of the regression coefficients and their standard errors.19, 20 
As age is used as the time scale of the cause-specific hazard 
functions, it is unnecessary to use it as a covariate in the regression 
equations. Age was therefore not included in the list of candidate 
predictor variables. In addition, as subjects were not observed from birth 
but rather from their time of entry into the study, the use of age as the 
time scale causes the data to be left-truncated. This delayed entry
into the risk set was accounted for when estimating the regression 
coefficients of the cause-specific hazard functions. Most variables entered 
the models as linear terms, except for triglycerides, creatinine, UAE, hs-CRP, 
and NT-proBNP, for which the log transformation was applied. For hs-TnT, the 
lower detection limit of 2.5 ng/l was reached for 57.5% of the subjects. This 
variable was therefore entered in the model by including the following two terms: 
a dummy variable indicating whether a subject’s hs-TnT value fell below the 
detection limit, and a continuous variable taking on the value log(hs-TnT –2.5) 
for subjects with an hs-TnT value above the detection limit and 0 otherwise.




Death before  
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Model validation
The model’s accuracy in predicting the 10-year cumulative incidences of new 
onset HFpEF and HFrEF was internally validated by considering calibration 
and discrimination. Calibration was assessed graphically by plotting for each 
decile of predicted 10-year cumulative incidence the mean predicted 10-year 
cumulative incidence against the observed 10-year cumulative incidence 
within this same decile. To account for competing risk, the observed 10-year
cumulative incidences were estimated by the empirical cumulative incidence 
estimator.17  Discrimination was assessed by calculating Harrell’s C discrimination
index,21 using Wolbers et al. adapted definition of the risk set to account 
for the occurrence of competing events that preclude the occurrence of the 
event of interest.22 
Results
Patient characteristics
During a median follow-up of 12.5 years (IQR: 12.2~12.9), 366 individuals (4.3%) 
were diagnosed with new onset HFpEF or HFrEF. Out of these patients, 125 
(34.2%) were classified as HFpEF and 241 (65.8%) as HFrEF. Eight individuals 
(0.1%) were diagnosed with new onset heart failure with a LVEF between 41% 
and 49%. 710 individuals (8.3%) died before the onset of heart failure. The 
average time to diagnosis of new onset heart failure was 7.8 (IQR 3.9~10.5) 
years (6.6 (3.5~10.0) years for HFrEF and 9.2 (6.4~11.0) years for HFpEF).
Baseline characteristics of subjects experiencing an event are depicted against 
event-free subjects in Table 1. Compared to subjects with new onset HFpEF, 
levels of creatinine, hs-TnT, and NT-proBNP were higher for subjects with 
new onset HFrEF. The proportions of males and smokers were also larger for 
subjects with new onset HFrEF compared to subjects with new onset HFpEF.
Predictors for HFrEF and HFpEF
The beta coefficients and corresponding hazard ratios for the final 
models of the cause-specific hazard functions are listed in Table 2. Specific 
risk factors for new onset HFpEF were cystatin C, UAE and systolic blood 
pressure. Specific predictors for new onset HFrEF were smoking, hs-TnT and total 
cholesterol. Increased levels of NT-proBNP and a previous history of myocardial 
infarction were both predictors for HFrEF and HFpEF, although more for HFrEF. 




than HFrEF. Figure 2 presents the predicted 10-year cumulative incidences of 
new onset HFpEF and HFrEF as a function of a subject’s age, stratified by 
gender and UAE level (normal or elevated UAE in their morning urine samples).
Model validation
The mean observed vs. predicted 10-year cumulative incidences were 1.00% 
vs. 1.07% for new onset HFpEF and 2.12% vs. 2.28% for new onset HFrEF. 
The calibration plots (Figure 3A and Figure 3B) show a good calibration for both 
  No HF / death   HFpEF  HFrEF  
Death 
before HF 
  N = 7,485   N = 125 N = 241 N = 718 
Demography          
Age (yrs)  47+-12   63 9 62 10 63 10 
Males (%)  #  47.4   48.0 73.4 67.3 
BMI (kg/m2)  26 4   29 5 28 4 27 4 
Smoking or quit <1 year (%)  #  37.4   28.8 43.5 44.1 
Systolic BP (mmHg)  127 19   149 25 145 22 142 23 
Diastolic BP (mmHg)  73 10   79 9 80 10 79 10 
Heart rate (bpm) 69 10   70 12 70 12 71 12 
Baseline Medical history          
Myocardial infarction (%)  4.1   19.5 28.8 16.1 
Stroke (%)  0.6  3.3 3.0 3.2 
Atrial ﬁbrillation (%)  0.8   5.0 4.6 2.8 
Laboratory values            
Glucose (mmol/l  4.8 1.0   5.6 2.1 5.4 1.7 5.4 1.9 
Cholesterol (mmol/l)  5.6 1.1   6.0 1.0 6.0 1.0 6.0 1.2 
HDL (mmol/l)  1.33 0.40   1.27 0.35 1.20 0.36 1.23 0.39 
LDL (mmol/l)  3.63 1.04  4.03 0.98 4.05 0.98 4.01 1.06 
Triglycerides (mmol/l)  1.14 (0.83-1.66)   1.36 (1.02-1.78) 1.41 (0.97-2.03) 1.33 (0.97-1.92) 
Cystatin C (mg/dl)  0.78 0.18  0.92 0.26 0.93 0.21 0.94 0.38 
Serum Creatinine (umol/l)  #  82 (73-91)   81 (72-96) 90 (80-102) 87 (76-99) 
UAE (mg/24h)  8.9 (6.2-15.5)   20.4 (9.9-57.8) 19.2 (9.3-50.8) 16.3 (8.7-46.1) 
Hs-CRP (mg/l)  1.16 (0.52-2.74)   2.05 (0.88-4.45) 2.48 (1.24-4.85) 2.29 (1.10-4.97) 
NT-proBNP (ng/l)  #  34 (15-65)   86 (37-167) 121 (45-355) 72 (32-157) 








































Table 1 Baseline characteristics of the PREVEND study population, divided by heart 
failure and death during follow-up*
HF, heart failure; BMI, body-mass index; BP, blood pressure; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; UAE, urinary 
albumin excretion; hs-CRP, highly-sensitive C-reactive protein; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; hs-TnT, highly-sensitive troponin T.
* Continuous variables are presented as mean ± standard deviation and compared 
with the use of Student’s t-test, in case of normal distribution. In case of skewed 
distribution, continuous variables are presented as median (inter-quartile range) 
and compared using the Kruskall–Wallis test. Binary categorical variables 
were compared using standard chi-squared tests.
# denotes significant differences were detected between subjects with new 
onset HFpEF and subjects with new onset HFrEF.
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HF outcomes: most of the dots are close to the diagonal line indicating perfect 
calibration. For the HFrEF outcome, the discriminating ability of our model was 
moderate with a value of the c statistic of 0.70. The model’s discriminative ability 
for the HFpEF outcome was lower with a c statistic of 0.60.
Software implementation
To allow for convenient application of our risk prediction model in practice, a 
user-friendly software implementation has been developed in Java. Detailed 
information is found in the supplementary material online.
   [h 1(t)]  [h 2(t)]  [h 3(t)]  
Disease state  HFpEF  HFrEF  Death before HF 





   13.027 (2.293) 
  89.012 (15.577) 
    5.992 (0.749) 
  97.936 (37.607) 
    4.907 (0.932) 
203.811 (71.130) 
    3.131 (0.492) 
337.985 (183.188) 
    6.662  (0.566)  
  82.444 (13.851)  
    5.742  (0.316)  













History of MI  
BMI  





 0.309 (0.077)         1.362 
 
  
-0.191 (0.099)         0.826 
  
 0.279 (0.089)         1.321 
 
 
 0.008 (0.004)         1.008 
 
  
 0.649 (0.244)         1.914 
 0.087 (0.020)         1.091 
 
  
 0.864 (0.462)         2.372 
-1.760 (0.556)         0.172 
 -1.040 (0.176)       0.353 
 




0.582 (0.059)       1.790 
 -0.184 (0.207)       0.832 
0.393 (0.071)       1.481 
 
0.011 (0.006)       1.011 
   0.577 (0.138)       1.781 
0.912 (0.155)       2.490 




 -0.918 (0.318)        0.399 
-0.669 (0.102)          0.512 
 0.128 (0.035)          1.137 
 0.217 (0.093)          1.242 
 0.042 (0.022)          1.043 
 0.148 (0.039)          1.160 
-0.229 (0.099)          0.796 
 0.185 (0.037)          1.204 
-0.156 (0.105)          0.856 
 0.120 (0.045)          1.127 
 
 0.009 (0.004)          1.009 
 0.499 (0.080)          1.647 
 0.368 (0.111)          1.445 
 
 0.597 (0.218)          1.817 
-0.173 (0.092)          0.841   
 0.759 (0.185)          2.135 
-0.927 (0.264)          0.396 
 
Table 2 Results from the stratified Weibull proportional hazards model (Equations 1 & 
2 in Appendix I)
HF, heart failure; SE, standard error; HR, hazard ratio; UAE, urinary albumin excretion; 
hs-CRP, highly-sensitive c-reactive protein; TGL, triglycerides; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; hs-TnT, highly-sensitive troponin T; DL, detection limit; 






The PREVEND model presented in this paper is the first heart failure
prediction model that differentiates between new onset HFpEF and HFrEF. 
Using 21 risk factors that are easily available in daily clinical practice, our risk 
prediction model showed good calibration for both heart failure outcomes. 
The model’s discriminative ability for the two outcomes was poor to moderate, 
even after inclusion of multiple common risk factors. However, the majority of 
subjects from the PREVEND study population were at very low risk of
developing new onset heart failure. Our model is therefore a suitable tool to 
Figure 2 Relationship between a subject’s age and predicted 10-year cumulative 
incidence of new onset HFpEF and HFrEF stratified by  both gender (male; female) 
and UAE level in their morning urine samples (normal UAE; elevated UAE)
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identify subjects at moderate or high risk of developing HFrEF or HFpEF, but it has 
little discriminative ability in those at low risk of developing new onset heart failure.
Several studies have presented risk models for survival or readmission for
patients after diagnosis of heart failure.23-25 On the other hand, few studies are 
available with regard to actual prediction of new onset heart failure. Currently, 
the Framingham Health Study (FHS) and the Atheroscleros Risk in Communities 
(ARIC) offer the only available risk prediction models for new onset heart 
failure.26, 27 However, new diagnostic parameters for heart failure (e.g. natriuretic
peptides) have emerged since. In 1999, the FHS has presented the first prediction 
model for congestive heart failure, predicting new onset heart failure during 
a four year follow-up period and has been widely used since. Using individuals 
within the age range of 45-94, significant predictors were age, left ventricular 
hypertrophy, heart rate, systolic blood pressure, coronary heart disease, 
valve disease, diabetes, BMI, and vital capactity and cardiomegaly 
as additional predictors.26 Another recent prediction model is derived from data 
of the ARIC study, in which >15,000 subjects aged 45-64 years, were followed 
for 15 years.27 The addition of NT-proBNP to their model, using the same 
variables as the FHS prediction model, increased risk prediction for new 
heart failure significantly. Both models derived from aforementioned 
Figure 3A Calibration plot of mean 
predicted vs. mean observed (1 standard 
deviation) 10-years cumulative incidence 
for new onset HFpEF by deciles of predicted 
cumulative incidence for new onset HFpEF
Figure 3B Calibration plot of mean 
predicted vs. mean observed (1 standard 
deviation) 10-years cumulative incidence 
for new onset HFrEF by deciles of 





studies give valuable insight into the pathophysiological processes preceding 
the first manifestation of heart failure and predict new onset heart 
failure fairly accurate. However, they are limited by the fact that some predictors 
are not easily available, such as left ventricular hypertrophy, cardiomegaly 
or presence of valve disease. This makes these models less applicable
in daily practice. Other limitations are the lack of differentiation 
between HFrEF and HFpEF, and there is no equivalent risk prediction 
model made using data from European subjects.
There is increasing evidence that HFrEF and HFpEF have different 
epidemiological profiles and should be considered and treated as separate 
diseases.8, 28 Our study confirms these findings by showing that a different set 
of risk factors is associated with the occurrence of these two outcomes. The 
incidence of HFrEF, but especially HFpEF, typically increases with age, mainly 
because of improvements in treatment of underlying co-morbidities. In our model, 
the effect of age was accounted for by using it as the time scale of the cause specific 
hazard functions. As a result, although the model was fitted under the assumption 
that the relative effect of the included cardiovascular risk factors remained 
constant across time (proportional hazards assumption), the absolute risk of 
developing new onset heart failure still differed between younger and 
older subjects.
The strongest predictors specifically for new onset HFpEF were cystatin C 
and UAE. That decreased renal function, as represented by cystatin C and 
UAE, was found to be an independent predictor of HFpEF is not new, as 
previous epidemiologic studies already showed that HFpEF patients 
more often have decreased renal function, than patients with HFrEF.8, 28, 29 
Finally, we observed a negative association between hs-CRP and new onset 
HFpEF. Although previous studies have shown increased levels of (hs-)CRP in 
patients with heart failure compared to heart failure-free subjects,30-32 CRP 
had not yet been shown to be associated with increased risk for heart failure. 
It does have increased risk for mortality. Our findings confirm hs-CRP as a 
predictor of non-heart failure related mortality.13, 33 Specific predictors for HFrEF 
were male gender, cholesterol and smoking. This could well be explained by 
the ischemic etiology of HFrEF, which occurs in approximately 40% of patients 
with HFrEF.9, 34 Further secondary prevention with regard to risk factors for 
atherosclerotic heart disease might further lower the risk for new onset HFrEF.
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Clinical implications
The current risk prediction model showed good calibration, however the 
model c-statistic showed poor to moderate discrimination. This low 
discriminative value is remarkable, especially when using multiple 
common clinical variables. Most, if not all variables are singly and multivariably 
adjusted associated with new onset heart failure, or specifically with HFrEF 
or HFpEF.8, 9 Nonetheless, it appears that even in a large, well-described 
community-based cohort, with a large well-validated cohort of new onset 
heart failure, the combination of multiple common clinical variables is 
insufficient to adequately predict new onset heart failure during long-term 
follow-up. Therefore, the clinical applicability of the current model remains 
uncertain, and our results need to be validated and challenged in additional 
studies. A recently published meta-analysis, reviewing prediction models 
for mortality in heart failure patients, showed similar model quality, with poor 
to moderate discrimination of the reviewed risk models, with inconsistent
performance.35 Although there was no differentiation between HFrEF and 
HFpEF, this postulates that heart failure cohorts consist of a large variety of 
subjects, with broad differences in clinical and biochemcial characteristics. 
The large etiologic differences between heart failure patients emphasize 
distinct pathophysiologic pathways and perhaps differentiating between HFrEF 
and HFpEF is insufficient to adequatly identify subjects at risk for heart failure.
Strengths and limitations
The large PREVEND cohort, with over 105,000 patient years of follow-up 
and thoroughly validated cases of new onset heart failure, provides good 
opportunity for large-scale evaluation of risk factors. In addition, we 
have identified new onset HFrEF next to HFpEF, giving insight into 
pathophysiologic pathways for both heart failure phenotypes. Our study is 
limited by the fact that the PREVEND risk model was not validated in 
another cohort. Also, PREVEND study subjects are predominantly Caucasian, 
so our results cannot be extrapolated to subjects of other ethnicities. Finally, the 
PREVEND cohort was enriched for increased albumin excretion. We therefore 





The current investigation presents the first available risk prediction model 
for early identification of subjects at risk for new onset HFrEF and HFpEF. 
However, with 21 common clinical variables, prediction of new onset heart 
failure in a community-based cohort, in particular HFpEF, remains difficult.
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Appendix I. Details of the competing risks analysis
We used Weibull regression models with a subject’s age as the time 
scale to describe the cause-specific hazard functions of the state 
transitions included in our model. In particular, for each of the three causes 
of failure (i.e., new onset HFpEF, new onset HFrEF, and death before the 
onset of heart failure), the cause-specific hazard functions were expressed as
          
          (1)
where b is a l x mk row vector of regression coefficients and Z is a mk x l
column vector that contains the subject’s covariate values for the risk 
factors found to be associated with the k-th cause of failure. To 
account for the overrepresentation of subjects with an elevated UAE in the 
PREVEND study, the parameters ak and bk defining the baseline hazard
functions were estimated seperately for subjects with normal and 
elevated UAE.
Given the cause-specific hazard functions, the cumulative incidence for cause 
k in the prediction window w, i.e., a subject’s probability of failing from cause k 
between A and A+w given that he or she was still event-free at time A, where 
A represents the subject’s age at the start of the prediction window, can be
expressed as 
            
           (2)
 
  
where D represents the cause of failure and the subject’s overall survival 
function, with the cumulative cause-specific hazard function of cause k up 
to time t. 
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Appendix II. List of candidate predictor variables
The following variables were considered as candidate predictors during model 
building:
-Sex
-Body mass index  
-Current smoker or quit smoking <1 year
-Systolic blood pressure 
-Diastolic blood pressure 
-Heart rate
-History of myocardial infarction 
-History of stroke








-24h urinary albumin excretion
-Highly-sensitive c-reactive protein













BACKGROUND: The Prevention of REnal and Vascular ENdstage Disease 
Intervention Trial (PREVEND IT) investigated whether treatment targeted at 
lowering urinary albumin excretion (UAE) would reduce adverse cardiovascular 
events. We obtained extended follow-up data to approximately ten years to 
investigate the long-term effects of fosinopril 20mg and  pravastatin 
40mg on cardiovascular outcomes in subjects with UAE ≥15mg/24h.
METHODS: The original PREVEND IT consisted of 864 participants and 839 
survivors after four years. For every survivor, the primary endpoint determined 
by the combined incidence of cardiovascular mortality and hospitalization for 
cardiovascular morbidity, was registered in several national databases and 
electronic hospital systems.
RESULTS: Mean total follow-up of the extended PREVEND IT was 9.5 years 
(range 9.4 to 10.7). Four years of treatment with fosinopril was not associated 
with a reduction in the primary endpoint compared to placebo (HR 0.87; 
95%CI 0.61-1.24 [P=0.42]) during long-term follow-up. After 9.5 years, 
subjects with a baseline UAE in the upper quintile (≥50mg/24hrs) had a total event 
rate of 29.5% and were at a higher risk of developing cardiovascular disease 
compared to less UAE (HR 2.03; 95%CI 1.38-2.97 [P<0.01]). In 
addition, four years of fosinopril treatment resulted in a risk reduction of 45% 
(95%CI 6%-75% [P=0.04]) in this group compared to placebo. Subjects 
originally assigned to pravastatin had no overall risk reduction 
in the primary endpoint (p=0.99).
CONCLUSIONS: Elevated UAE is associated with increased cardiovascular 
mortality and morbidity after 9.5 years of follow-up, with a doubling of the risk 
if the UAE is ≥50mg/24h. In this group, the benefits of four year treatment with 
fosinopril were sustained during post-trial follow-up for cardiovascular 
mortality and morbidity. We propose that UAE be used to estimate risk 
in the general population and that large clinical trials be designed to
confirm the hypothesis that ACE-inhibitor treatment may be beneficial in 
patients with mildly elevated UAE despite the absence of other co-morbidities.
Frank P. Brouwers
Folkert W. Asselbergs
 Hans L. Hillege
 Rudolf A. de Boer
Ron T. Gansevoort
Dirk J. van Veldhuisen
Wiek H. van Gilst
American Heart Journal 2011;161(6):1171-8
Chapter 6
Long-term effects of fosinopril and 
pravastatin on cardiovascular events 
in subjects with microalbuminuria. 
Ten years of follow-up of 
PREVEND IT
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Introduction
Microalbuminuria (MA) is associated with an increased risk of cardiovascular 
morbidity and mortality, both in patients with an increased risk profile1, 2 and 
in the general population.3, 4 The Prevention of REnal and Vascular ENdstage 
Disease Intervention Trial (PREVEND IT) was a double-blind, randomized, 
placebo-controlled trial to determine whether the ACE-inhibitor fosinopril and 
the HMGCoA-reductase inhibitor pravastatin would reduce the incidence of 
cardiovascular death and hospitalization for cardiovascular morbidity in a 
microalbuminuric population without hypertension and /or 
hypercholesterolaemia.3, 5 It was demonstrated that treatment with 
fosinopril significantly lowered blood pressure and urinary albumin 
excretion (UAE) and was associated with a trend in reducing 
cardiovascular events in subjects with UAE ≥15mg/24h and a significant
reduction in subjects with a higher UAE (≥50mg/24h). Pravastatin significantly
lowered total and LDL cholesterol, but had no significant effect 
on UAE and / or prognosis.
Due to the inclusion of relatively low risk subjects, the rate of cardiovascular 
adverse events was lower than expected. Therefore, the original PREVEND
IT was underpowered in demonstrating a significant effect of treatment 
on clinical outcome. Other clinical trials such as the West of Scotland 
Coronary Prevention Study (WOSCOPS),6 HOPE,7 and SOLVD8 showed 
preservation of clinical benefit by the assigned treatment of up to 
several years after the trial was ended, despite the fact that the large majority of 
patients were taken off study medication. Therefore, in order to assess the
long-term risk of our study population and whether the beneficial effects of 
treatment in the group with UAE ≥50mg/24h was preserved, we extended the 
follow-up of the original PREVEND IT by six years, to approximately 10 years.
Methods
Design
PREVEND IT is an investigator-initiated, single-center, double-blind, 
randomized, placebo-controlled trial with a 2x2 factorial design to assess the 
value of microalbuminuria as an indicator of increased cardiovascular risk 
in the general population. Subjects were randomized to 20mg fosinopril or 
matching placebo, and to 40mg pravastatin or matching placebo. Details of the 




reported previously.5 Briefly, the key entry criteria of the PREVEND IT were 
persistent microalbuminuria (one urinary albumin concentration ≥10 mg/l in an 
early morning spot urine test and at least one 15 to 300 mg/24h in two 24h 
urine samples), absence of antihypertensive and lipid-lowering medication, a 
blood pressure of <160/100 mmHg and total cholesterol of  <8.0 mmol/l or <5.0 
mmol/l in the case of previous myocardial infarction. From April 1998 to June 
1999, 864 subjects were included in the PREVEND IT and were randomized 
to study medication for the duration of four years (referred to as “active trial 
period”). At the end of this four year period, all subjects were taken off study 
medication and returned to the care of their general practitioners. We extended the 
follow-up for an additional 5.5 years after the active trial period was ended, 
resulting in a total follow-up time of 9.5 years. An independent data and safety 
monitoring committee regularly monitored the progress of PREVEND IT during 
the entire follow-up period. The study was approved by the Institutional Review 
Board and was conducted in accordance with the guidelines of the Declaration of 
Helsinki. Informed consent was obtained from all subjects before randomization.
Endpoint collection and follow-up
Follow-up was extended to 1 January 2009, an average of 5.5 years 
after the end of the active trial period. The composite primary endpoint is 
similar to the active trial.5 Mortality was divided into non-cardiovascular versus 
cardiovascular deaths. Documented hospitalization for cardiovascular 
morbidity was subdivided into nonfatal myocardial infarction, myocardial 
ischemia, heart failure, peripheral vascular disease and cerebrovascular 
accident.
Every surviving participant had a final visit three months following the end 
of the active trial period. Thereafter, a large proportion of the study subjects 
continued their participation in the ongoing PREVEND-program (N = 530) and
visited the outpatient clinic every three to four years.3 Follow-up for all other 
surviving subjects (N = 271) was collected via personal communication 
and electronic hospital files. Data on mortality were retrieved 
from the municipal register. Cause of death was obtained through 
the Dutch Central Bureau of Statistics and was coded according 
to the 10th revision of the International Classification of Diseases. 
Follow-up on hospitalization for cardiovascular morbidity was derived from 
records held by PRISMANT, the Dutch national registry of hospital discharge 
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Figure 1 Primary endpoint Kaplan-Meier estimates of incidence of cardiovascular 
events in fosinopril and matching placebo (A) and pravastatin and matching placebo 





Chapterdiagnoses. In addition, personal communication was used to obtain data from 
subjects lost to follow-up. The date of admission was used as the date of the 
event. Details of each cardiovascular event were obtained from the treating 
physician.  The independent endpoint committee of the active trial period
reviewed all endpoints and the members had no knowledge of subject’s 
treatment assignments. 
At follow-up visits in the ongoing PREVEND program, various clinical and 
biochemical measurements were performed and two 24h urine collections 
Figure 2C Mean total cholesterol levels by 
treatment and visit.
Figure 2A Median urinary albumin excretion 
(mg/24h) by treatment and visit.
Figure 2B Mean blood pressure by 
treatment and visit. 
SBP=systolic blood pressure;  DBP=diastolic 
blood pressure.
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were obtained. Systolic and diastolic blood pressure measurements were 
calculated as the mean of the last two of ten consecutive measurements 
with an automatic Dinamp XL model 9300 series device (Johnson-Johnson 
Medical Inc). Plasma glucose, serum total and LDL cholesterol, and serum 
creatinine were determined by Kodak Ektachem dry chemistry (Eastman 
Kodak). Urinary albumin concentrations were determined by nephelometry 
with a threshold of 2.3 mg/l and intra-assay and interassay coefficients of 
variation of less than 2.2% and 2.6%, respectively (Dade Behring Diagnostic).
 
  Fosinopril Pravastatin 
  Placebo Active  Placebo Active 
Variables (N = 433) (N = 431)  (N = 431) (N = 433) 
Age (years) 51.5±11.4 51.1±12.2  50.5±11.7 52.1±11.9 
Male Gender (%) 63.7 66.1  62.2 67.7 
White (%) 97.0 95.1  96.8 95.4 
Smoking (%)      
     Past 31.4 34.4  34.1 31.6 
     Current 43.6 36.2  37.6 42.3 
Systolic blood pressure (mmHg) 131±18 129±17  130±17 131±18 
Diastolic blood pressure (mmHg) 76±10 76±10  76±10 77±10 
Cholesterol (mmol/l)       
     Total 5.7±1.0 5.8±1.1  5.8±1.0 5.8±1.0 
     HDL 1.0±0.4 1.0±0.3  1.0±0.4 1.0±0.3 
     LDL 4.0+0.9 4.1±1.0  4.0±1.0 4.1±1.0 
Triglycerides (mmol/l)  1.3 (0.9-1.9) 1.4 (0.9-2.0)  1.3 (0.9-1.9) 1.4 (0.9-2.0) 
Glucose (mmol/l)  5.0±1.2 4.9±1.0  4.9±0.9 5.0±1.2 
Serum creatinine (µmol/l)  89±14 92±14  90±14 91±14 
Albuminuria (mg/24h)  22.1 (15.3-39.4) 23.5 (16.8-43.9)  23.5 (16.1-42.5) 22.2 (15.6-40.8) 
Body mass index (kg/m2) 26±5 26±4  26+4 26+4 
Diabetes Mellitus (%) 2.8 2.3  2.3 2.8 
Prior event (%) 2.5 4.2  4.4 2.3 
     Myocardial Infarction (%) 0.2 0.7  0.7 0.2 
     Angina Pectoris (%) 0.5 0.7  0.5 0.7 
     Coronary angioplasty of bypass (%) 0.5 1.2  0.9 0.5 
     Heart Failure (%) 0.0 0.0  0.0 0.0 
     Cerebrovascular accident (%) 0.2 1.4  1.2 0.5 
     Peripheral vascular disease (%) 0.5 0.7  0.7 0.5 
Aspirin and antiplatelet agents (%) 2.8 2.1  3.5 1.4 
Beta-Blockers (%) 1.4 0.7  1.4 0.7 
Nitrate (%) 0.5 0.5  0.9 0.0 
Diuretics (%) 0.7 0.7  0.9 0.5 
Calcium channel blockers (%) 0.9 0.9  1.2 0.7 
Digoxin (%) 0.9 0.7 0.9 0.7 




Figure 3 Primary endpoint in UAE ≥50mg/24h Kaplan-Meier estimates of incidence of 
cardiovascular events in the fosinopril and placebo group, divided by a UAE more than 
or less then 50mg/24h. 
*compared to UAE≥50mg/24h, fosinopril
Statistical analysis
Baseline characteristics are given as mean ± standard deviation. In case of 
a skewed distribution, the median (interquartile range) was used. Two-way 
ANOVA was used firstly to test whether the dependent variable changed 
significantly with each of the two treatments while taking into account the 
effects of the other treatment, and secondly, to test whether the effect of 
fosinopril, for example, did not depend on pravastatin. Because of the skewed 
distribution, UAE was transformed to natural logarithm. Time to first 
occurrence of outcome are presented as Kaplan-Meier estimates, and statistical 
differences between placebo and active treatment were analyzed by log-rank. 
Furthermore, results are summarized by hazard (risk) ratios or relative risks with 
95% CIs based on robust standard error estimates. The impact of baseline UAE
 was evaluated by dichotomization of the parameter into the lowest four quintiles 
against the highest quintile (UAE ≥50mg/24h) as was done during the active
 trial.5 All analyses were by design performed on an intention-to-treat basis, unless 
stated otherwise. Probability values were two-sided and were required to be <0.05 
to be significant. All calculations were performed with SPSS version 16 software.
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  Total Follow -up period  
  Fosinopril   Pravastatin  
  Placebo Active   Placebo Active  
 (N = 431) (N = 431)  (N = 431) (N = 431) 
Primary endpoint *       
 no. (%)  64 (14.8)  56 (13.0)   60 (13.9)  60 (13.9)  
 Hazard Ratio [95% CI]  1.00 0.86 [0.60 -1.23]  1.00 1.01 [0.71 -1.44] 
 p value  0.42   0.97 
      
Mortality       
All causes      
 no. (%)  32 (7.4)  35 (8.1)   29 (6.7)  38 (8.8)  
 Hazard Ratio [95% CI]  1.00 1.08 [0.67 -1.74]  1.00 1.32 [0.82 -2.14] 
 p value  0.77   0.26 
Cardiovascular causes      
 no. (%)  12 (2.8)  9 (2.1)   11 (2.6)  10 (2.3)  
 Hazard Ratio [95% CI]  1.00 0.74 [0.31 -1.75]  1.00 0.92 [0.39 -2.16] 
 p value  0.49   0.84 
       
Hospitalization for       
Nonfatal myocardial infarction       
and/or – ischaemia      
 no. (%)  32 (7.4)  34 (7.9)   36 (8.4)  30 (6.9)  
 Hazard Ratio [95% CI]  1.00 1.05 [0.65 -1.70]  1.00 0.84 [0.52 -1.36] 
 p value  0.84   0.47 
Heart Failure       
 no. (%)  3 (0.7)  1 (0.2)   1 (0.2)  3 (0.7)  
 Hazard Ratio [95% CI]  1.00 0.33 [0.03 -3.18]  1.00 3.02 [0.31 -28.99] 
 p value  0.34   0.34 
Peripheral vascular disease      
 no. (%)  8 (1.8)  6 (1.4)   7 (1.6)  7 (1.6)  
 Hazard Ratio [95% CI]  1.00 0.74 [0.26 -2.14]  1.00 1.00 [0.35 -2.86] 
 p value  0.58   1.00 
Cerebrovascular accident      
 no. (%)  19 (4.4)  12 (2.8)   14 (3.2)  17 (3.9)  
 Hazard Ratio [95% CI]  1.00 0.63 [0.30 -1.29]  1.00 1.22 [0.60 -2.47] 
 p value  0.21   0.59 
Total cardiovascular morbidity †       
 no. (%)  59 (13.6)  53 (12.3)   56 (13.0)  56 (12.9)  
 Hazard Ratio [95% CI]  1.00 0.89 [0.61 -1.29]  1.00 1.00 [0.69 -1.45] 
  p value  0.54   0.99 
Table 2 Total event outcome
* The sum of all events does not compute with the total number given, because multiple 
events in one subjects are counted as one.





Baseline characteristics of all randomized subjects are summarized in Table 1. 
These characteristics represent the PREVEND IT population at the beginning 
of the active trial period in 1997 and show a middle-aged population with a low 
prevalence of conventional cardiovascular risk factors, cardiovascular history or 
use of cardiovascular drugs. Mean follow-up was 9.5 years (range 9.4 to 10.7) 
from the start of the trial to 1 January 2009. Due to emigration, two subjects 
(0.2%) were lost to follow-up. Alongside study drugs, open label ACE-inhibitor 
usage was 0.0%, 4.3% and 10.6% at baseline screening, four and eight years 
later, respectively, for the entire study population. For statin usage, this was 
0.0%, 3.2% and 11.6%. Rate of ACE-inhibitor and statin use remained similar in 
all former randomized groups during the entire follow-up period.
The incidence of the primary endpoint increased from 5.2% in the active trial 
to 13.9% after 9.5 years of follow-up. Subjects assigned to fosinopril during 
the active trial period had a non-significant risk reduction of 13% (HR 0.87; 
95%CI 0.61-1.24 [P = 0.42]) during the entire follow-up period, which is in 
accordance with a number needed to treat (NNT) of 55 subjects for 9.5 
years. Subjects originally assigned to pravastatin had no risk reduction 
during the entire follow-up period (HR 1.00; 95%CI 0.70-1.43 [P = 0.99], NNT 
= 1555), as shown in Figures 1A and 1B. An overview of outcomes is shown in 
Table 2. Both fosinopril and pravastatin use was not associated with a 
significant risk reduction for a specific endpoint. 67(7.8%) subjects died during 
the entire follow-up period. Both fosinopril (P=0.77) as pravastatin 
 
  UAE≥15mg/24h  UAE ≥50mg/24h  
 Placebo (N = 433) 
Fosinopril  
(N = 431) HR [95% CI]   
Placebo 
(N = 78) 
Fosinopril  
(N = 98) HR [95% CI]  
Primary endpoint  64 (14.8%)  56 (13.0%)  0.87 [0.61 -1.24]  23 (29.5%)  16 (16.3%)  0.51 [0.27 -0.97] *  
        
Mortality         
All causes 31 (7.2%)  32 (7.4%)  1.02 [0.62 -1.67]  11 (14.1%)  8 (8.2%)  0.54 [0.22 -1.35] 
CV causes 12 (2.8%)  11 (2.6%)  0.74 [0.13 -1.76]  5 (6.4%)  3 (3.1%)  0.45 [0.11 -1.88] 
         
Hospitalization for         
Non fatal MI  32 (7.4%)  34 (7.9%)  1.05 [0.65 -1.70]  10 (12.8%)  11 (11.2%)  0.80 [0.34 -1.89] 
Heart failure  3 (0.7%)  1 (0.2%)  0.33 [0.03 -3.18]  2 (2.6%)  0 (0.0%)  0.01 [0.00 -1198.48]  
PVD  8 (1.8%)  6 (1.4%)  0.74 [0.26 -2.14]  3 (3.8%)  1 (1.0%)  0.24 [0.03 -2.31] 
CVA  19 (4.4%)  12 (2.8%)  0.63 [0.30 -1.29]  6 (7.7%)  3 (3.1%)  0.38 [0.10 -1.53] 
Total CV morbidity  59 (13.6%)  53 (12.3%)  0.89 [0.61 -1.29]  21 (26.9%)  15 (15.3%)  0.53 [0.27 -1.02] 
      
Table 3 UAE≥15mg/24h vs. UAE≥50mg/24h
* P < 0.05
UAE denotes urinary albumin excretion; HR hazard ratio; CV cardiovascular, MI 
myocardial infarction; PVD peripheral vascular disease; CVA cerebrovascular accident
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(P=0.26) showed no significant reduction in total mortality compared to 
placebo. Regarding cardiovascular mortality (N = 21; 2.4%), treatment with 
either fosinopril (HR 0.74; 95%CI 0.31 to 1.76 [P = 0.49]) or pravastatin (HR 0.92; 
95%CI 0.39 to 2.16 [P = 0.84]) had no significant beneficial effect (see Table 2).
At the end of the active trial period, the median UAE was significantly 
lowered in the fosinopril group compared to placebo (P<0.05). Three months 
after cessation of fosinopril, median UAE had increased significantly from 
18.5 to 24.5mg/24h (IQR 13.3-51.2, [P<0.01]) and remained stable during 
extended follow-up, as shown in Figure 2A. Regarding blood pressure, a 
significant decrease in systolic and diastolic blood pressure was achieved with 
fosinopril during the active trial period compared to placebo. Three months 
after stopping fosinopril, blood pressure returned to baseline levels and 
remained stable during extended follow-up, as illustrated in Figure 2B. In the group 
originally assigned to pravastatin, blood pressure and UAE levels were 
unaffected by treatment compared to placebo and remained stable during 
extended follow-up.
A similar development occurred with total and HDL cholesterol levels. 
After a significant decrease by statin treatment compared to placebo, total 
cholesterol and HDL cholesterol returned to baseline levels three months 
after the active trial period. Levels of total cholesterol remained stable 
during extended follow-up, refer to Figure 2C. Fosinopril had no effect on 
cholesterol levels over the entire follow-up period compared to matching placebo.
Subjects with a UAE in the upper quintile (≥50mg/24h, median 77.7mg/24h) 
were at increased risk of developing a cardiovascular event compared to 
subjects with lower UAE (<50mg/24h, median 19.3mg/24h) during long-term 
follow-up (HR 2.03; 95%CI 1.38-2.97 [P<0.01]). Additionally, subjects with UAE 
≥50mg/24h and originally assigned to fosinopril, had a reduction in incidence of 
the primary endpoint from 29.5% to 16.3% (HR 0.51; 95%CI 0.27-0.97 [P=0.04]) 
during 9.5 years of follow-up (refer to Table 3). This is in accordance with NNT=8 
subjects for 9.5 years. Furthermore, subjects with UAE ≥50mg/24h originally
endpointy assigned to the placebo group were almost three times more at risk 





This extended follow-up of the PREVEND IT reports on two major findings: 
1) Elevated UAE (≥15mg/24h) is associated with increased cardiovascular 
mortality and morbidity (13.9%) in apparently healthy subjects without any 
other indication for primary prevention, after 9.5 years of follow-up. In 
addition, this risk doubles if the UAE is ≥50mg/24h (29.5%). 2) Treatment with 
fosinopril during the active trial period significantly reduced mortality and 
morbidity in the group of subjects with UAE ≥50mg/24h, thereby lowering their 
level of risk to subjects with lower UAE, which has been reported previously.5 This 
benefit persisted and was even more pronounced during long-term follow-up, 
despite a similar rate of ACE-inhibitor use after the end of the active trial period. 
In our view, these findings support our hypothesis that elevated UAE, also 
below the conventional microalbuminuria cut-off values of 30-300mg/24h is 
an unfavorable marker for the development of cardiovascular disease after 
long-term follow-up, even in the absence of other cardiovascular risk factors. 
In addition, the protective effect of fosinopril treatment during the active trial 
period most likely underestimates the effects of a more prolonged treatment. 
In the case of pravastatin, however, our results after 9.5 years of follow-up 
show no direct effect on UAE. With evaluation of the effect of pravastatin on 
outcome, we see trend for a slightly lowered risk reduction for cardiovascular 
mortality and hospitalization for nonfatal myocardial infarction and / or ischemia.
Several trials have indicated that microalbuminuria is associated with a more 
adverse cardiovascular outcome.4, 9, 10 However, treatment aimed at reducing 
cardiovascular events by lowering UAE in a general population, with no 
indication for preventive treatment, was only investigated in PREVEND IT. 
While the event-rate during the active trial period was lower than 
expected, we observed an event rate of 13.9% after 9.5 years of follow-up, 
increasing power and providing corroborative evidence of UAE 
for being an important additional marker of early cardiovascular disease, 
in the absence of other cardiovascular risk factors.
The initial report of PREVEND IT showed that treatment with fosinopril was 
associated with a trend in reducing cardiovascular events.5 During the extended 
follow-up presented herein, a postponed benefit of four years treatment with 
fosinopril and/or pravastatin was not observed. However, fosinopril showed a 
long-term beneficial effect in subjects with an UAE ≥50mg/24h, which confirms 
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the observations from the active trial period. This outcome is in accordance with 
results of other extended trials with ACE-inhibitors, like the extended HOPE.7
It remains unclear why ACE-inhibitors would exert beneficial effects 
even long after cessation after the active trial period. One possible 
explanation could be that ACE-inhibitors cause structural changes, which 
persist after cessation of the drug. PREVEND IT provides some unique
insights to verify this hypothesis. It was observed that after the active 
trial period, levels of UAE and blood pressure rapidly returned to their 
baseline levels in the subjects who received fosinopril for four years, as shown in 
Figure 2A-B. These findings indicate that the beneficial effects of fosinopril 
on lowering albuminuria and blood pressure diminish directly after cessation.
For subjects with UAE ≥50mg/24h, fosinopril treatment significantly reduced the 
incidence of the primary endpoint compared with lower UAE levels, even after 
stopping study medication. The survival curves tend to become parallel during 
the extended trial period, but do not converge after long-term follow-up. Since 
blood pressure and UAE levels returned to normal directly after drug cessation, 
there may be other mechanisms underpinning this observation, for example 
potential long-term vascular and cardiac preservation via neurohormonal 
factors, or preservation of endothelial integrity and function, all exerting 
protective effects long after fosinopril had been stopped.
The results of PREVEND IT are in line with various additional trials, which 
show a beneficial effect of ACE-inhibitors on cardiovascular disease7, 11-14 and 
long-term post-trial benefits which have been reported.8, 15, 16 However, these 
studies focus mostly on diabetics,17, 18 subjects with chronic kidney disease19 
or heart failure,20 whereas PREVEND IT targets asymptomatic subjects with 
only slightly elevated levels of UAE. In addition, only a very few number of 
trials since PREVEND IT have focused on UAE targeted therapy to prevent 
cardiovascular disease. The PEACE trial, which was performed in a 
population with stable coronary artery disease, reported similar results. 
The effect of treatment with the ACE-inhibitor trandolapril increased as the 
estimated glomerular filtration rate (eGFR) decreased.12, 21 Since 
the overall renal function in PEACE was relatively high, just as in 
PREVEND IT, treatment with trandolapril showed lack of benefit over the 
entire cohort. The MICRO-HOPE trial examined diabetic subjects with 




cardiovascular outcome was observed.22 Our analysis shows that similar 
effects may be obtained in subjects at a substantially lower risk level than those 
subjects studied in previous trials. In addition, four years of treatment with fosinopril 
significantly reduces cardiovascular events in subjects with an UAE ≥50mg/24h 
during long-term follow-up. This underscores the notion that UAE targeted
therapy may be beneficial not only in subjects with hypertension, diabetes 
mellitus or chronic kidney disease, but also in aparently healthy subjects 
with UAE ≥50mg/24h.
Study limitations
At the end of PREVEND IT, a modest crossover between treatment groups 
was present. However, the absolute crossover numbers are limited and if 
there was any effect of this crossover, it would cause an underestimate of our 
results. Also, drug exposure during extended follow-up, after the study 
medication was stopped, may have influenced the outcome. The study 
population in this trial was at fairly low risk. Less than 3% of the 
participants were diabetic and evidence of prior cardiac events such as 
myocardial infarction, bypass surgery or heart failure were all less than 1% each. 
Given the low risk of this population, the number of cardiovascular events was 
consequently low. The sample size of 864 subjects was also modest, making this 
study underpowered to demonstrate a beneficial effect of treatment on outcome.
Conclusions
Elevated UAE is associated with a significant increase in cardiovascular 
mortality and morbidity with doubling of the risk if the UAE is ≥50mg/24h. In this 
group, treatment with fosinopril significantly reduced mortality and morbidity. 
This benefit persisted during and was even more pronounced after the entire 
follow-up period when compared to the active trial period. We propose that UAE 
be used to estimate risk in the general population and that large clinical trials be 
designed to confirm the hypothesis that ACE-inhibitor treatment may be beneficial 
in patients with mildly elevated UAE despite the absence of other co-morbidities.
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Abstract
OBJECTIVE: Experimental studies have shown that adrenomedullin (ADM) 
plays animportant role in circulatory homeostasis. Mid-regional pro-ADM 
(MR-proADM) is a stable form of ADM. Observational studies found an 
important association with age, BMI and kidney function. We aim to 
evaluate the prognostic performance of MR-proADM in the general 
population, controlling for these potential confounders.
DESIGN: Prospective cohort study 
METHODS: We studied 7,903 subjects (mean age 49±13 years, 49% 
male) derived from the Prevention of REnal and Vascular ENdstage 
Disease (PREVEND) cohort, with a median follow-up of 10.5 years.
RESULTS: Mean baseline MR-proADM was 0.39±0.14 nmol/l. In 
cross-sectional analyses, age, blood pressure, C-reactive protein,
cystatin C, N-terminal pro-B-type natriuretic peptide and urinary albumin 
excretion remained as independent determinants of MR-proADM. In 
prospective analyses, MR-proADM was associated with the primary endpoint 
(combined cardiovascular mortality and cardiovascular morbidity), with 
event rates ranging from 8% in the lowest quintile to 45% in 
the highest quintile, (P for trend <0.001), independent of age, sex, 
components of the Framingham Risk Score (FRS) and other cardiovascular 
markers. Overall Net Reclassification Improvement against the FRS was 
2.2%, which was non-significant. We, however, observed significant 
modification of the effect of MR-proADM on outcome by age. In subjects 
≤70years (N = 7,475), 8.8% was correctly reclassified in a higher risk category 
(P=0.017) and 3.4% to a lower risk category (P<0.001). In subjects 
>70years (N = 428) there was no improvement of reclassification (P=0.32).
CONCLUSION: This study gives a detailed overview of the distribution 
of ADM in a general population and provides evidence of ADM as a potent 
and interesting biomarker in predicting cardiovascular events. These results 
seem especially applicable to younger subjects.
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Chapter 7
Influence of age on the prognostic 
value of mid-regional 
pro-adrenomedullin in the 
general population
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Introduction
Adrenomedullin (ADM) was first discovered in the early nineties in 
phaeochromocytoma cells.1 It is a multifunctional, 52 amino acid 
peptide hormone expressed in numerous tissues.2 It is thought to originate 
primarily in endothelial cells, where cellular stress, ischemia and hypoxia 
result in increased expression,2 together with nitric oxide and endothelin.3 
The physiological function of ADM is still under investigation, but it has been 
suggested it exerts effects similar to those of brain-type natriuretic 
peptide (BNP) and atrial natriuretic peptide (ANP).4, 5 It is capable of promoting 
vasorelaxation, natriuresis, diuresis and cardiac output, thus contributing to 
maintaining circulatory homeostasis.6, 7 A substantial amount of data also 
suggests that ADM acts as a protective factor for blood vessels, primarily by 
counteracting vascular damage and remodelling.3, 8 These qualities make ADM 
an interesting candidate novel biomarker for cardiovascular (CV) outcome.
The mid-regional portion of pro-adrenomedullin (MR-proADM) is more 
stable than ADM and therefore better suited for clinical practice and 
assessment in stored samples.9 MR-proADM is elevated in females and
increases with age.10 It is also elevated in subjects with hypertension and has 
prognostic value for CV mortality and morbidity in subjects with myocardial
infarction,11-13 heart failure,13-15 chronic kidney disease6 as well as subjects with 
hypertension and increased left ventricular mass.16 MR-proADM
was recently shown to be effective in predicting 90-day mortality risk in 
patients admitted with acute heart failure, with additive prognostic value 
over BNP alone.17 Epidemiologic data on MR-proADM levels in the general 
population remain scarce, with published data from only one cross-sectional 
study.10 The present study aims to provide insight into the 
distribution of MR-proADM and investigate its prognostic performance for 
CV mortality and morbidity in the general population. Observational 
studies show an important association with age, body mass index (BMI) and 
kidney function,10, 18 but it is unclear whether these associations affect the 
predictive value of MR-proADM for CV outcome. In addition, the prognostic 
value and potential additive value of MR-proADM are compared to those of 
conventional CV risk factors (Framingham Risk Score, FRS) and adjusted for 
novel and relevant covariates, including N-terminal-proBNP (NT-proBNP), 






This study was performed in subjects participating in the Prevention of 
REnal and Vascular ENdstage Disease (PREVEND) study.19 The objective 
of the PREVEND program is to prospectively investigate the natural course 
of increased levels of UAE and assess the value of microalbuminuria as an 
indicator of increased CV and renal risk in the general population. Details of 
PREVEND have been described elsewhere.19-21 In summary, from 1997 to 1998, 
all inhabitants of the city of Groningen, The Netherlands, aged 28 to 75 years 
(N =  85,421) were asked to send in a morning urine sample and complete a 
short questionnaire on demographics and CV history. Response was received 
from 40,856 subjects (47.8%). All subjects with a UAE ≥10 mg/l (N = 7,786) 
in their morning urine together with a randomly selected control group with a 
urinary albumin concentration <10 mg/l (N = 3,395) were invited to the 
outpatient clinic. After exclusion of subjects with insulin-dependent diabetes 
mellitus, pregnant women, and men and women unable or unwilling to 
participate, a total of 8,592 subjects completed the screening 
program, as shown in Figure 1. 7,903 individual blood samples, taken 
at baseline, were suitable for analysis of MR-proADM levels and eligible 
for the current analysis. The PREVEND study was approved by 
the local medical ethics committee and conducted in accordance 
with Declaration of Helsinki guidelines. All subjects provided written 
informed consent.
Assays
Plasma samples were drawn from all PREVEND participants at baseline 
and aliquots were stored at -80°C prior to analysis. Detection of MR-proADM 
was performed using a immunoassay (B.R.A.H.M.S., GmbH/ThermoFisher 
Scientific, Hennigsdorf, Germany).9 The interassay coefficients of variation was 
<20% for values >0.12nmol/l (analytical range 0.08-14.7nmol/l). NT-proBNP 
measurements were performed in plasma on an ElecsysTM 2010 analyser, 
a commercially available electrochemiluminescent sandwich immunoassay 
(Elecsys proBNP, Roche Diagnostics, Mannheim, Germany).22 The intra- and 
interassay coefficients of variation were 1.2-1.5% and 4.4-5.0%, respectively 
(analytical range 5-35.000 pg/ml). UAE, hs-CRP and serum cystatin C were 
determined by nephelometry (BNII, Dade Behring Diagnostic, Marburg, 
Germany). Intra- and interassay coefficients of variation were less than 2.2% 
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and 2.6% for UAE, respectively; less than 4.4% and 5.7% for hs-CRP, 
respectively; and less than 4.1% and 3.3% for cystatin C, respectively. Serum 
creatinine, plasma cholesterol and glucose were determined in one laboratory 
by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA), using 
an automated enzymatic method. The intra- and interassay variation coefficient 
of serum creatinine were respectively 0.9% and 1.1%. Serum triglycerides were 
measured enzymatically. A commercially available assay system was used to
assess high-densitiy lipoprotein (HDL) cholesterol (Abbott Inc., 
Abbott Park, IL, USA). 
Risk factor definition
Hypertension was defined as systolic blood pressure >140 mmHg or diastolic 
blood pressure >90 mmHg or the use of antihypertensive medication. 
BMI was calculated as the ratio of weight to height squared (kg/m2). 
Hypercholesterolemia was defined as total serum cholesterol of >6.5 mmol/l 
(251 mg/dl) or the use of lipid-lowering therapy. Diabetes was defined as fasting 
plasma glucose >7.0 mmol/l (126 mg/dl) or non-fasting plasma glucose >11.1 
mmol/l or the use of antidiabetic medication. Estimated glomerular filtration rate 
(eGFR) was calculated using the simplified Modification of Diet in Renal Disease 
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9,966
UAC ≥ 10 mg/L
30,890




































Size of random sample was arbitrarily set 
at 3,395 to obtain a total cohort size of 
approximately 10,000 (taking into




(sMDRD) formula.23 Smoking was categorized as no smoking, or smoking (current 
or stopped <1 year ago). Ten-year risk for CV events according to the FRS was 
calculated as described by D’Agostino24 and divided into three risk categories:
low (<10%), intermediate (10-20%) and high (>20%), as recommended by 
Wilson.25
Cardiovascular events
Follow-up for the present investigation is defined as time between 
baseline urine collection and the date of a first cardiovacular event or 1 
January 2009. The composite primary endpoint was defined as the combined 
incidence of CV mortality and CV morbidity after baseline screening. CV 
morbidity was defined as hospitalization with a primary discharge diagnosis 
of documented non-fatal myocardial infarction or myocardial ischemia, 
cerebrovascular accident and / or peripheral vascular disease. The date of 
admission was used as the date of the event. Data on mortality 
(including cause of death) were retrieved from Statistics Netherlands and coded 
according tot the 10th revision of the International Classification of Diseases.26 
Follow-up data on hospitalization for CV morbidity were derived from records 
held by PRISMANT, the Dutch national registry of hospital discharge diagnoses.27
Figure 2 The distribution of MR-proADM in PREVEND.
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By design, the PREVEND study overselected subjects with an elevated 
UAE to acquire sufficient subjects with microalbuminuria. It should be 
clear that this is not a random sample of a general population, where all 
elementary units have an equal probability of being selected. Statistical formulas 
to calculate population parameter estimates should be used to account for the 
likelihood of selection. A design-based analysis was performed to overcome this 
overselection of subjects with elevated UAE. This statistical weighting 
method allows conclusions to be generalized to the general population.28 
P-values for trend were calculated between quintiles of MR-proADM. Because 
of skewed distribution, NT-proBNP, UAE, cystatin C, serum triglycerides and 
hs-CRP were transformed to their natural logarithms. Results are summarized 
as hazard (risk) ratios (HR) with 95% confidence intervals (CI). To assess which 
factors are most strongly associated with MR-proADM, we first performed 
univariate linear regression analyses, followed by multivariate backward linear 
regression analyses using bootstrapping (1000x, entry criterium 70%; default 
p-value for model entry <0.05, default p-value to remain in model <0.10). To avoid 
multi-colinearity in the latter analyses, we selected the strongest variable 
from strongly related domains (waist for the waist/bmi domain, systolic blood 
Figure 3 Time to first event by Kaplan-Meier estimates for MR-proADM on the primary 
endpoint.
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pressure from the blood pressure/hypertension domain, cystatin C from 
renal domain). Kaplan-Meier estimates of the distribution of times from baseline 
to CV events were generated; log-rank tests were calculated to compare the 
survival curves between the groups. Multivariate Cox proportional 
hazards regression analysis was performed, with all significant parameters from 
the univariate analysis and other relevant covariates from previous studies. 
MR-proADM was entered linear and log-transformed, to assess best fit. We 
observed a significant statistical interaction between log-transformed 
MR-proADM and age with CV event outcome. Therefore, an interaction variable 
was added to the model and hazard ratios derived from this Cox proportional 
hazards model were plotted in a figure. Subjects were classified as young, 
middle-aged and old age (30, 50, 70 years respectively) to assess 
interpretation of clinical value. To assess the additive value of MR-proADM 
over the FRS, we evaluated the Intergrated Discrimination Improvement 
(IDI) and Net Reclassification Improvement (NRI) indices for MR-proADM 
(as a continuous variable) according to FRS (divided in risk categories). 
Subjects with a history of CV disease at baseline were excluded from the 
Univariate regression analysis     Multivariate regression analysis 
 Standardized P r   Standardized P 
   coefﬁcient       coefﬁcient   
Age (yrs) 0.44 <0.001 0.20  0.32 <0.001 
Female Gender -0.06 0.019 <0.01  -0.12 <0.001 
Smoking / quit smoking <1yr  0.12 <0.001 <0.01  0.18 <0.001 
BMI  (kg/m2) 0.26 <0.001 0.07  0.16 <0.001 
Systolic BP (mm  Hg)  0.24 <0.001 0.06    
Diastolic BP (mm  Hg)  0.16 <0.001 0.03    
Heart rate (bpm) 0.05 <0.001 <0.01  0.03 0.014 
Myocardial infarction  0.50 <0.001 0.01    
Cerebrovascular accident 0.52 0.008 <0.01    
Hypertension 0.53 <0.001 0.06    
Hypercholesterolemia 0.38 <0.001 0.03    
Diabetes Mellitus  0.76 <0.001 0.02  0.23 0.016 
Glucose (mmol/l)  0.19 <0.001 0.03    
Total cholesterol (mmol/l)  0.17 <0.001 0.03    
HDL cholesterol (mmol/l)  -0.10 <0.001 0.01    
Triglycerides (mmol/l)  0.15 <0.001 0.02    
C-reactive protein (mg/l)  0.19 <0.001 0.04    
NT-proBNP (ng/l)  0.22 <0.001 0.05  0.12 <0.001 
UAE  (mg/24h)  0.15 <0.001 0.02    
Cystatin C (mg/l)  0.27 <0.001 0.09  0.15 <0.001 
eGFR (ml/min/ 1.73m2) -0.31 <0.001 0.10    
Table 2 Univariate and multivariate analysis investigating associations between 
subject characteristics and MR-proADM levels
Dependent factor: Mid-regional portion of pro-adrenomedullin (MR-proADM). BMI=body 
mass index; BP=blood pressure; HDL cholesterol=high-density lipoprotein cholesterol; 
NT-proBNP=N-terminal pro-B-type natriuretic peptide; UAE=urinary albumin excretion; 




analysis with the FRS. We evaluated the NRI in the entire population and in 
age strata because of the interaction with age. All reported probability values 
are two-tailed and P<0.05 was considered statistically significant. All analyses 
were performed using StataIC (version 11.0 software for Windows).
Results
The frequency distribution of MR-proADM is shown in Figure 2. The 
distribution appears normal with a few positive outliers and 90% of measurements 
below 0.55 nmol/l. Mean (SD) MR-proADM at baseline was 0.39 (±0.14) 
nmol/l, mean age was 49 (±13) years and 49% was of male sex. Baseline 
characteristics for all subjects and for subjects classified by 
quintiles of MR-proADM are summarized in Table 1. Compared to lower 
quintiles, individuals in higher quintiles were significantly older, had higher BMI, 
cholesterol and glucose levels, higher blood pressure and heart 
rate, and suffered more from CV disease at baseline (all P for trend 
<0.001). Hs-CRP, UAE, cystatin C and NT-proBNP levels were also 
significantly elevated in higher quintiles (all P for trend <0.001).
Figure 4 HRs of the mid-regional portion of pro-adrenomedullin (MR-proADM)
on cardiovascular (CV) events (combined CV mortality and CV morbidity) 
by age. Reference HR is the mean MR-proADM and mean age in PREVEND.
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In univariate analysis, all investigated subject characteristics except 
HDL-cholesterol, eGFR and female gender, correlated positively with 
MR-proADM, with strongest associations for age (R2=0.20), eGFR (R2=0.10), 
cystatin C (R2=0.09), waist circumference (R2=0.09), NT-proBNP R2=0.08), 
BMI (R2=0.07), blood pressure (R2=0.07) and hypertension (R2=0.07) (Table 
2). In a backward multivariate analysis, age, waist circumference, heart rate, 
NT-proBNP, cystatin C, smoking status and presence of diabetes mellitus 
remained significantly associated with MR-proADM (model R2=0.28, Table 2).
A total of 7,903 subjects were followed for a median of 10.5 years (IQR 
9.9–10.8). The pre-specified primary endpoint occurred in 752 subjects 
(9.5%). The incidence of CV events increased with increasing quintiles of 
MR-proADM, from 8.0% in the bottom quintile (<0.21 nmol/l) to 44.4% in the 
top quintile (≥0.59nmol/l) (P<0.001 for trend). A Kaplan-Meier analysis of time 
to first CV event according to quintiles of MR-proADM is shown in Figure 3.
In total, 576 subjects (7.3%) died during follow-up, of whom 145 (25.2%) of CV
causes. All cause mortality increased with increasing quintiles 
of MR-proADM, from 7.6% in the bottom quintile to 48.1% in the top quintile 
(P<0.001 for trend). The incidence of CV-related mortality also increased 
with higher levels of MR-proADM (P<0.001).
In Cox proportional hazard regression analyses, log-transformed MR-proADM 
was significantly associated with increased risk for CV events, in both 
crude models and models adjusted for Framingham CV risk factors (age, 
                
 Framingham Risk Score 
Model with Framingham Risk Score and MR-proADM 
  
  <10% risk 10-20% risk >10% risk Total no. 
 Participants with CV event         
 <10% risk 152 (89.4) 18  10.6) 0 (0) 170 
 10-20% risk 9  (7.0) 97 (75.2) 23 (17.8) 129 
 >20% risk 0 (0) 13 (7.8) 153 (92.2) 166 
 Total no. 161  128  176  465 
 Participants with no CV event         
 <10% risk 4826 (98.1) 95 (1.9) 0 (0) 4921 
 10-20% risk 138 (16.4) 659 (78.2) 46 (5.4) 843 
 >20% risk 0 (0) 71 (16.0) 372 (84.0) 443 
 Total no. 4964   825   418   6207 
         
Table 3  Reclassification of participants without CV disease at baseline *
* Subjects with a history of CV disease at baseline were excluded for the 
analysis with the FRS. Data presented as number (percent). The Net Reclassification 




gender, blood pressure, HDL cholesterol, diabetes mellitus and smoking) and 
other CV markers (NT-proBNP, hs-CRP and UAE). The latter was not the 
case for all-cause mortality. A significant interaction between MR-proADM and 
age was found for incident CV events (P=0.002). The adjusted increase in 
predicted hazard for CV risk with higher MR-proADM obtained from the 
Cox proportional hazard analysis is depicted against age in Figure 4. A 
subject with a mean age (50 years) and mean MR-proADm (0.39 nmol/l) 
was used as a referent. The figure shows that in older subjects (70 years), 
variation in MR-proADM levels is not associated with CV disease risk, unlike for 
middle-aged (50 years) and younger subjects (30 years). In a middle-aged 
subject, there is an almost linear relationship between MR-proADM and CV 
risk. In a younger subject, the relationship with CV risk increase is closer to 
exponential.
The Integrated Discrimination Improvent (IDI) index for the model (the same 
model used in the Cox proportional hazard regression analysis) including 
MR-proADM was significant: P=0.002 (outcome variable: CV mortality and 
morbidity). After excluding subjects with a previous CV history, the area 
under the curve (AUC) for the FRS in our population is 82% for predicting CV 
events. Adding MR-proADM to FRS improved the AUC by 0.5% (P<0.001; 
c-statistics). In the entire population, the NRI of MR-proADM over the FRS was 
nearly significant (P=0.08) and was mainly driven by correct reclassification 
to a lower risk category in 4% of subjects who did not have a CV event 
(P<0.001). Given the interaction between MR-proADM and age for CV risk, we 
repeated the NRI analysis in subjects ≤70yrs of age (N = 7,475). This resulted in 
reclassificaiton of 413 subjects (P=0.003) and we observed a significant 
up-reclassification in 41 subjects with a CV event (P=0.017), as well as a significant 
down-reclassification in 209 subjects without a CV event (P<0.001), see Table 3.
Discussion
This study describes the association between plasma MR-proADM and 
CV event risk and outcome in the general population. MR-proADM appears 
to be a strong independent predictor of CV events, in particular in younger 
subjects (≤70yrs), and adds to existing conventional and novel CV risk markers 
prediction models. The large PREVEND cohort, with almost 83,000 subject-years 
of follow-up, provides good opportunity for large-scale evaluation of this 
emerging biomarker and provides new insights into its association with 
CV disease.
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Reliable quantification of ADM has been hampered by its short half-life, the 
immediate binding of ADM to receptors in the vicinity of its production site 
and technical difficulties.9, 29 Limited general population data are available on 
the stable equivalent of ADM, MR-proADM. Smith et al. and Melander et al. 
measured MR-proADM in a general population cohort, finding mean (SD) 
MR-proADM levels of 0.42 (0.13)10 and 0.46 (0.13),30 respectively. Bhandari 
et al. examined hypertensive subjects and found much higher levels of 
MR-proADM, with a mean (SD) of 0.59 (0.18) in subjects without left ventricular 
hypertrophy (LVH) and 0.73 (0.25) in subjects with LVH.16 In another study 
by Dieplinger et al., MR-proADM was assessed in a population with mild to 
moderate renal dysfunction and found higher levels of MR-proADM, 
increasing with worsening renal function,7 from 0.43 to 1.34 nmol/l in 
subjects with eGFR >90 and <30. respectively. All studies - including 
ours - found a relatively normal distribution of MR-proADM, with only a 
small number of outliers at the high end of the distribution curve. The mean 
(SD) MR-proADM in our population was 0.39 (0.14), lower than in the studies 
mentioned above. This difference may be eplained by the fact the PREVEND
cohort is comprised of relatively young subjects (mean age 49 years) 
with low prevalence of co-morbidities at baseline. In line with other studies, 
the strongest correlations were found with age and kidney function 
in both univariate and multivariate analyses. Waist circumference, BMI and 
blood pressure were also correlated with MR-proADM in our cohort, 
but in the multivariate model, only waist circumference remained 
significantly associated. MR-proADM may be most affected by ageing and 
kidney function, but may also be influenced by pressure and volume 
load, as reflected by the independent association with blood 
pressure and NT-proBNP.
In our cohort, we evaluated the association between MR-proADM and 
CV events, i.e. combined CV mortality and morbidity. The highest event 
rates were found in the higher range of plasma MR-proADM values (5th 
quintile: >0.59 nmol/l) compared with lower values. The incidence of CV events 
followed a logarithmic increase for higher values of MR-proADM, indicating 
that subjects with the highest levels of MR-proADM are most at risk for CV 




In crude, unadjusted models, the predictive value of MR-proADM for 
all-cause and CV mortality and CV morbidity is high. Interestingly, when 
adjusted for common variables such as the conventional CV risk factors (FRS) and 
several emerging CV risk factors, including hs-CRP and NT-proBNP, the 
predictive value of MR-proADM increases for CV events. MR-proADM was 
not an independent predictor for all-cause mortality after adjusting for the 
CV risk factors mentioned above. For CV mortality, the predictive value of 
MR-proADM on outcome did not reach statistical significance (P=0.33), but 
this may be due to lacking power, given the limited number of fatal CV events.
Survival analyses showed a significant interaction between MR-proADM 
with age for prediction of CV events, which is consistent with the strongest 
association with the primary endpoint in younger subjects. NRI analyses 
resulted in a significant reclassification in middle-aged and young 
subjects, with subjects with a CV event correctly reclassified into a higher risk 
category and event-free subjects into a lower risk category. This 
reclassification was not present in subjects >70yrs (P=0.32), suggesting added 
prognostic value for younger subjects in particular. The reason for this 
interaction with age remains unknown. A possible explanation may be that in 
older subjects, upregulation of ADM is at the end of its dose-effect relationship, 
while correlation with outcome is visible primarily in early, subclinical stages of 
CV disease. CV risk stratification using biomarkers can help identify 
subjects in the community who may benefit most from preventive 
therapeutic intervention. In populations with low to intermediate risk for CV 
disease, data on the additive value of established and / or novel 
biomarkers is conflicting. Our results are in agreement with previous 
publications regarding the prognostic performance of MR-proADM. 
Most data were obtained in different cohorts with co-morbidities,11-13,15 
but also in the community.30 Our results provide valuable knowledge 
about MR-proADM as an effective predictive biomarker for future CV 
events in younger subjects without other co-morbidities or history of 
CV disease. Whether specific preventive strategies or treatment 
may be of benefit for subjects with increased MR-proADM remains to be 
addressed before this biomarker can be used for routine screening.
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Conclusion
This study gives a detailed overview of the distribution of MR-proADM in the 
general population and provides evidence for the value of MR-proADM as a 
potent and interesting biomarker for predicting CV events. We postulate that 
MR-proADM may be particularly valuable as a biomarker in younger subjects.
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BACKGROUND: The PREVEND IT trial reported on a high cardiovascular 
(CV) event rate in subjects with a baseline urinary albumin excretion (UAE) rate 
of ≥50mg/24h. Here, we report on the observed ten-year CV outcome of this 
population and compare this with the predicted Framingham Risk Score 
(FRS). In addition, we evaluated the effect of four years of fosinopril 
treatment on this relation.
METHODS AND RESULTS: From the PREVEND IT cohort, 833 
subjects without history of CV disease, randomized to fosinopril (N = 412) or 
placebo (N = 421), were studied. The primary endpoint included CV mortality 
and adjudicated hospitalization for CV disease during a ten-year follow-up 
period. Mean age was 51±12 years and 65% were males, while prevalence of 
diabetes (2.6%) and use of CV drugs (3.5%) was low. Subjects were 
categorized to high UAE (≥50mg/24h) or low UAE (<50mg/24h). After ten years 
of follow-up, the event rate in the high UAE group was almost twice as high 
as predicted by the FRS (29.5% vs. 17.2%). Treatment for four years with 
fosinopril reduced the event rate to comparable levels of that predicted by 
FRS. The addition of UAE ≥50mg/24h to the FRS improved the Integrated 
Discrimination Improvement (P=0.033) and increased the area under 
the curve by 0.54% (P=0.024).
CONCLUSIONS: The ten-year CV risk of subjects with an elevated UAE 
(≥50mg/24h) is substantially underestimated by the FRS. Treatment with 
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Background
Cardiovascular (CV) disease may be predicted by a variety of clinical, 
biochemical, and surrogate risk factors. Of these, endothelial dysfunction has 
also been linked to the development of atherogenesis.1, 2 Increased levels 
of urinary albumin excretion (UAE) do not only provide an indication of early 
renal dysfunction, but functions also as a marker of endothelial dysfunction.3 
Many trials have reported on a high prevalence of elevated UAE in high risk 
subjects suffering from diabetes,4, 5 renal failure,6 heart failure,7, 8 but also in 
subjects from the general population.9 An increased UAE was in every cohort 
associated with worse outcome. Recently, the Prevention of REnal and Vascular 
ENdstage Disease Intervention Trial (PREVEND IT) confirmed these results 
and reported on a CV event rate of almost 30% in subjects with a baseline UAE 
≥50mg/24h after 10 years of follow-up.10 Some have proposed that UAE may 
be a useful surrogate marker for CV disease. It is unclear whether conventional 
CV risk prediction models, like the Framingham Risk Score (FRS) can be used 
in a population with albuminuria.11, 12 In addition, it remains unclear whether 
addition of UAE could significantly improve prognostic performance of the 
FRS. In this analysis, we retrospectively investigate the quality of the CV risk 
estimations by the FRS by comparing it to the observed outcome in PREVEND IT.
Material and methods
Study population
The study was performed using data of the PREVEND IT study, which has 
been described elsewhere.10, 13 Briefly, the aim of PREVEND IT was to 
assess the value of albuminuria as an indicator of increased CV risk in the 
general population. The key entry criteria of the PREVEND IT were persistent 
microalbuminuria (one urinary albumin concentration ≥10 mg/l in an early 
morning spot urine test and at least one 15 to 300 mg/24h in two 24h urine 
samples), absence of antihypertensive and lipid-lowering medication, a 
blood pressure of <160/100 mmHg and total cholesterol of <8.0 mmol/l or 
<5.0 mmol/l in the case of previous myocardial infarction. From April 1998 
to June 1999, 864 subjects were included in the PREVEND IT and were 
randomized to 20mg fosinopril or matching placebo for the duration of four years 
(referred to as “active trial period”). At the end of this four year period, all 
subjects were taken off study medication and returned to the care of their general 
practitioners. Follow-up time was extended for an additional 6.0 years after 




of 10.0 years. To evaluate the FRS in our population, we excluded 
subjects in which variables of FRS were missing (N = 2, both missing values of 
HDL  cholesterol) or subjects with a history of CV disease (N = 29). Finally, a total 
of 833 subjects were eligible for the current analysis. An independent data 
and safety monitoring committee regularly monitored the progress 
of PREVEND IT during the entire follow-up period. The study was 
approved by the institutional medical ethics committee and conducted in 
accordance with the guidelines of the Declaration of Helsinki.
Informed consent was obtained from all subjects before randomization.
Endpoint collection and follow-up
The composite primary endpoint is the combined incidence of CV mortality and 
hospitalization for CV morbidity. CV morbidity was defined as hospitalization 
for documented non-fatal myocardial infarction or myocardial ischemia, heart 
failure, peripheral artery disease, and / or cerebrovascular accident. These 
endpoints are the same as for the FRS for general CV disease.14  Follow-up 
for all surviving subjects after the active trial was collected via personal 
communication and electronic hospital files. Data on mortality were 
retrieved from the municipal register. Cause of death was 
obtained through the Dutch Central Bureau of Statistics and was coded 
according to the 10th revision of the International Classification of 
Diseases. Follow-up on hospitalization for CV morbidity was derived from 
records held by PRISMANT, the Dutch national registry of hospital discharge 
diagnoses.15 In addition, personal communication was used to obtain data 
from subjects lost to follow-up. The date of admission was used as the 
date of the event. Details of each CV event were obtained from the treating 
physician. The independent endpoint committee of the active trial 
period reviewed all endpoints and the members had no knowledge of 
subject’s treatment assignments.
Measurements
At trial follow-up visits, various clinical and biochemical measurements were 
performed and two 24h urine collections were obtained. Systolic and diastolic 
blood pressures were calculated as the mean of the last two of ten consecutive 
measurements, using an automatic Dinamap XL model 9300 series device 
(Johnson & Johnson Medical Inc). Serum creatinine, plasma cholesterol and 
glucose were determined in one laboratory by Kodak Ektachem dry chemistry 
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(Eastman Kodak, Rochester, NY, USA), using an automated enzymatic method. 
The intra- and interassay variation coefficient of serum creatinine were 
respectively 0.9% and 1.1%. Serum triglycerides were measured enzymatically. 
A commercially available assay system was used to assess high-density 
lipoprotein (HDL) cholesterol (Abbott Inc., Abbott Park, IL, USA). Urinary 
albumin concentrations were determined by nephelometry with a threshold 
of 2.3 mg/l and intra-assay and interassay coefficients of variation of less than 
2.2% and 2.6%, respectively (Dade Behring Diagnostic). Ten-year risk for CV 
events according to the FRS was calculated as described by D’Agostino14 and 
divided into three risk categories: low (<10%), intermediate (10-20%) and high 
(>20%), as recommended by Wilson.16 UAE was categorized by low (<50 mg/24h) 
vs. high (≥50 mg/24h), according to the quintiles used in PREVEND IT.10, 13 
Statistical analysis
Baseline continuous data are reported as mean (standard deviation) for normal 
data. UAE and triglycerides showed a log-linear functional shape with the 
response variable and were transformed to a 2-log scale and reported as 
median (interquartile range). This means that risk estimates should be 
interpreted as the relative risk of values were doubled (e.g. 1 to 2 mg/l or 
10 to 20 mg/24h). Times to first occurrence of outcomes are presented as 
Kaplan-Meier estimates, and statistical differences between placebo and active 
treatment were analyzed by log-rank testing. To assess the additive value of 
UAE over the FRS, we evaluated the Integrated Discrimination Improvement 
(IDI) and Net Reclassification Improvement (NRI) indices for UAE (both as a 
continuous variable as well as dichotomized to high vs. low, using a cut-off 
of 50mg/24h) according to FRS. All reported probability values are two-tailed 
and P<0.05 was considered as the nominal level of statistical significance. All 
analyses were performed using StataIC (version 11.0 software for Windows).
Results
Baseline characteristics of subjects divided by low (<50 mg/24h) vs. high 
UAE (≥50 mg/24h) are summarized in Table 1. These characteristics 
show a middle-aged population with a low prevalence of conventional 
CV risk factors, exemplified e.g. by a low prevalence of diabetes mellitus 
(4.0%), and little use of CV drugs (3.5%). Subjects in the high UAE group were 
at baseline older and had higher levels of systolic and diastolic blood 




triglycerides and serum creatinine were slightly increased in the high 
UAE group. Baseline median FRS was 12.7% and was different 
between UAE groups, namely 11.9% (IQR 5.2-23.9) and 17.1% (IQR 7.8-30.7) 
for respectively the low UAE and the high UAE group (P=0.001). Mean follow-up 
was 10.0 years (range 9.8 to 10.3) from start of active trial until 1 January 2009.
At baseline, median UAE was 19 mg/24h (IQR 15-29) in the low UAE group 
and 77 mg/24h (IQR 59-115) for the high UAE group (P<0.001). The following 
changes, during the entire follow-up period are depicted in Figure 1. The 
low and high groups of UAE are divided by treatment group. In the low UAE 
group, four years of treatment with fosinopril during active trial resulted in a 
decrease in median UAE from 20 mg/24h to 15 mg/24h (P=0.003 compared to 
baseline). In the high UAE group, fosinopril treatment decreased UAE to 55 mg/24h 
(P=0.003 compared to baseline). Three months after cessation of fosinopril, 
median UAE increased in both groups and remained stable during further 
follow-up. UAE was unaffected by placebo during the entire follow-up period.
During the entire follow-up, the primary endpoint occurred in 119 subjects. 
The event rate in the high UAE group was significantly higher, compared to 
the low UAE group (22.0% vs. 12.3%, respectively, P=0.001). Treatment with 
fosinopril lowered the event rate in the high UAE group to the same height as 
Figure 1 Median urinary albumin excretion (mg/24h) by treatment and visit
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subjects with low UAE levels at start (15.6% vs. 12.3%, respectively, P=0.436).
The observed ten-year event rate for both the low UAE group as well as the high 
UAE group is plotted against the FRS-predicted risk, in Figure 2A and 2B. In 
subjects with UAE <50mg/24h, the observed event rate is identical to the 
FRS-predicted event rate. There was no effect of fosinopril on the observed 
event rate in the low UAE group. In contrast, the ten-year event rate of subjects 
in the group UAE ≥50mg/24h is significantly underestimated compared to the 
predicted ten-year FRS-predicted risk. The event rate almost doubled, 
from 17.2% (FRS-predicted) to 29.5 (observed). Treatment for four years 
with fosinopril during the active trial period significantly reduced observed 
CV risk and outcome to compared with placebo, and normalized 
the actual CV risk to the FRS-predicted CV risk level. 
The Integrated Discrimination Improvement (IDI) index for including 
UAE to the FRS was significant, P=0.033 (outcome variable: primary 
endpoint). The area under the curve for the FRS in our population is 76% for 
predicting CV events. Adding UAE to FRS improved the area under the curve 
by 0.54% (P=0.036; c-statistics). In the entire population, the NRI of UAE 
over the FRS was not significant (P=0.313). Given the increased event rate 
observed in subjects with UAE ≥50mg/24h, we repeated the NRI analysis in 
subjects in the high UAE group (N = 167). This resulted in a reclassification of 
4.6%, however not significant (P=0.313), see supplementary Table 1A and 1B.
Figure 2A and 2B Predicted Framingham Risk Score compared to Kaplan-Meier 
estimates of incidence of cardiovascular events in fosinopril and placebo group, 










Variables (N = 665) (N = 168) P-value 
Age (yrs) 50±12 54±12 <0.001 
Males (%) 65.0 64.9 0.984 
Caucasian (%) 96.2 95.8 0.575 
Body mass index (kg/m2) 26±4 27±5 0.009 
  Obesity (>30kg/m2) 13.9 17.3 0.263 
Smoking (%)  39.6 40.5 0.826 
Systolic blood pressure (mmHg) 128±17 135±19 <0.001 
Diastolic blood pressure (mmHg)  75±10 78±10 <0.001 
Heart rate  (bpm) 69±10 71±11 0.034 
Cholesterol (mmol/l)        
     Total  5.8±1.0 5.8±1.1 0.992 
     HDL  1.0±0.3 1.0±0.3 0.641 
     LDL  4.1±0.9 4.0±1.0 0.519 
Triglycerides (mmol/l)  1.3 (0.9-1.9) 1.5 (1.0-2.1) 0.001 
Glucose (mmol/l)  5.1±1.2 5.2±1.3 0.116 
eGFR (kg/min/1.73m2) 83±14 79±15 0.001 
Serum creatinine ( mol/l)  83 (75-92) 86 (76-96) 0.034 
UAE (mg/24h) 19.0 (14.0-28.0) 77.0 (59.5-124.5) <0.001 
Diabetes Mellitus (%)  2.4 3.6 0.400 
Prior event (%)  0.0 0.0 NA 
Cardiovascular drugs (%) 3.0 5.4 0.138 
  Aspirin  and antiplatelet agents 1.1 1.8 0.101 
  Beta-Blockers 0.6 0.6 0.993 
  Nitrates 0.0 0.0 NA 
  Diuretics 0.3 1.8 0.026 
  Calcium channel blockers 0.8 0.6 0.830 
  Digoxin  0.6 1.8 0.133 
       
Framingham Risk Score 11.9 (5.2-23.9) 17.1 (7.8-30.7) 0.001 
 
Table 1 Baseline characteristics of PREVEND IT subjects with high  vs. low UAE 
(N = 833)
UAE Urinary albumin excretion; HDL High-density lipoprotein; LDL low-density 
lipoprotein; eGFR estimated glomerular filtration rate; NA not available
160
UAE complements the framingham risk score
Discussion
Previously, the PREVEND IT trial reported on a high CV risk in subjects 
with elevated UAE (≥50mg/24h), with an event rate of almost 30% after ten 
years of follow-up.10 In this sub-analysis we compared the observed event 
rate in PREVEND IT with the populations’ FRS-estimated risk. Our results 
indicate that the FRS substantially underestimates CV risk of subjects 
with UAE ≥50mg/24h and that this increased risk is amenable to treatment 
with the ACE-inhibitor fosinopril, the use of which reduced the risk to the 
FRS-estimated risk. Adding UAE to the FRS, using a cut point of 50mg/24h, 
furthermore increased the area under the curve and IDI in risk estimation.
The FRS is the most well-known and most widely used models for CV risk 
stratification. Although the FRS does not suffice for specific risk groups, for 
example young or low-risk patients,17 its use for a general risk prediction for 
CV disease is undisputed. Still, multiple attempts have been made to improve 
CV risk stratification by adding variables to the FRS, like non-invasive vascular 
assessments,18 coronary artery calcium score,19 or brachial artery 
flow-mediated dilation,20 and several other variables. Limited studies have 
been done investigating the additional value of UAE on the FRS. 
The group of Cao showed in elderly subjects that the combination of UAE 
with the FRS improved risk stratification, over a follow-up period 
of 5.6 years.11  Other studies used albumin-creatinine ratio alone, or in 
  UAE <50mg/24h   UAE ≥50mg/24h 
 Placebo Fosinopril P 
 Placebo Fosinopril 
P 
Mortality (N = 343) (N = 322)   (N = 78) (N = 90) 
All causes 19 (5.5) 23 (7.1) 0.396   10 (12.8) 8 (8.9) 0.411 
CV causes 7 (2.0) 6 (1.9) 0.869  4 (5.1) 1 (1.1) 0.126 
        
Hospitalization for               
Non- fatal MI 21 (6.1) 22 (6.8) 0.710   9 (11.5) 9 (10.0) 0.748 
Heart failure 4 (1.2) 6 (1.9) 0.460  4 (5.1) 3 (3.3) 0.561 
PVD 5 (1.5) 5 (1.6) 0.920  3 (3.9) 1 (1.1) 0.246 
CVA 12 (3.5) 7 (2.2) 0.306  6 (7.7) 2 (2.2) 0.097 
Total CV morbidity 39 (11.4) 38 (11.8) 0.862  22 (28.2) 13 (14.4) 0.029 
                
Primary endpoint 42 (12.2) 40 (12.4) 0.945   23 (29.5) 14 (15.6) 0.030 
       
 
Table 2 Observed incidence of primary endpoint, divided by UAE groups
Values are N(%) UAE urinary albumin excretion; CV cardiovascular; MI myocardial infarction; 




combination with other biomarkers to improve FRS.21, 22 
In the current analysis, we compared the predicted ten-year CV risk to the 
observed event rate during follow-up. For subjects with an UAE <50mg/24h, 
the FRS proved to be very accurate. In contrast, subjects in the highest UAE 
quintile (≥50mg/24h) were substantially underestimated with regard to their CV 
risk. The addition of UAE ≥50mg/24h to the FRS increased the IDI and area 
under the curve significantly, implying additional value in predicting individual 
ten-year CV risk. This is strengthened by the observed high incidence of CV 
events in subjects in the highest quintile of UAE. In addition, the increased rate of 
observed CV events was neutralized in the group treated with fosinopril. 
Fosinopril-treated subjects also showed a significant decrease in UAE during the 
active trial period, while there was little effect of fosinopril treatment 
on blood pressure.13  We did however not find any additional value of UAE 
over the FRS using NRI, which can be explained by several factors. The IDI 
differs from the NRI in that the population is not cross-classified by fixed levels 
from the two prediction models. The conventional and widely used risk categories 
used in this analysis (≤10%; 11-20%; >20%) might not have been suitable 
for assessing additional value of UAE. Also, the baseline average FRS for 
subjects in PREVEND IT is 12.7%, which is already considerably 
increased. This is due to the relative high percentage of tobacco users and an 
average systolic blood pressure of 129mmHg at baseline in PREVEND IT. The 
lack of additional value of UAE might be caused by the already present high 
baseline risk for CV disease. Finally, the NRI was performed in the total 
population and the sub-group of subjects with UAE ≥50mg/24h, however 
irrespective of treatment group. This could have diluted the additional value of 
UAE, while subjects treated with fosinopril compared to placebo had less CV 
events during follow-up. Our study was unfortunately underpowered to assess the 
difference in added value of UAE over FRS for both treatment groups separately.
Limitations
The sample size of PREVEND IT does not allow making definite statements 
about the role of UAE in prediction CV risk.
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Conclusions
In subjects with elevated UAE (≥50mg/24h) the actual ten-year CV risk 
was significantly higher than predicted by FRS, and this excess risk was 
neutralized by fosinopril treatment. The FRS should be used carefully in 
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Framingham Risk Score  Model with Framingham Risk Score and UAE  
 
≤10% risk  
 
11-20% risk  
 
>20% risk  
 
Total no.  Participants with  CV event
 
≤10% risk  17  (94.4)  1 (5.6)  0 (0.0)  18  
11-20% risk  6 (18.8)  23 (71.9)  3 (9.3)  32 
>20% risk  0 (0.0)  4 (6.3)  60  (93.7)  64 
Total no.  23  28   63  114  
Participants with no CV event
 
       
≤10% risk  370  (95.6)  17  (4.4)  0 (0.0)  387  
11-20% risk  21  (12.3)  130  (76.5)  19  (11.2)  170  
>20% risk  0 (0.0)  27  (18.1)  122 (81.9)  149  
Total no.  391    174    141    706  
        
Framingham Risk Score  Model with Framingham Risk Score and UAE  
 
≤10% risk  
 
11-20% risk  
 
>20% risk  
 
Total no.  Participants with  CV event
 
≤10% risk  3 (75.0) 1 (25.0) 0 (0.0)  4 
11-20% risk  0 (0.0) 5 (83.3) 1 (16 .7) 6 
>20% risk  0 (0.0)  0 (0.0) 27 (100.0 ) 27 
Total no.  3  6  28  37 
Participants with no CV event
 
       
≤10% risk  52 (92.9) 4 (7.1) 0 (0.0)  56  
11-20% risk  1 (4.0) 22 (88.0) 2 (8.0) 25 
>20% risk  0 (0.0)  4 (8.2) 45 (91 .8) 49 
Total no.  53   30    47   130  
        
Supplementary eTable 1A Reclassification of participants without CV disease at 
baseline in the entire PREVEND IT population *
* Data presented as number (percent). The NRI was estimated at -0.036 (P = 0.313)
Supplementary eTable 1B Reclassification of participants without CV disease at 
baseline in the PREVEND IT population UAE≥50mg/24h*





Summary and future perspectives
In this thesis, the origin and manifestation of new onset heart failure 
are discussed with a special focus on clinical and pathophysiological 
differences between heart failure with reduced ejection faction 
(HFrEF) and heart failure with preserved ejection faction (HFpEF).
The first part of this thesis concerns the epidemiology of new onset heart 
failure, as well as clinical characteristics and biomarkers of new onset 
HFrEF and HFpEF. In chapter 1 and chapter 2, an update is provided on 
incidence and prevalence of heart failure. During the past decade, several large, 
community-based, prospective studies have presented important 
epidemiological data on new onset heart failure. The available evidence 
suggests an overall decrease in heart failure incidence and successful 
preventive strategies for the development of heart failure. However, it should 
be noted that changes in HFrEF incidence may account for most of this 
decrease, while the incidence of HFpEF may have increased. These 
epidemiologic trends underscore the necessity to differentiate between patients 
with HFpEF and HFrEF. Earlier studies suggested that HFrEF and 
HFpEF might be two different cardiovascular syndromes and would require a 
different approach. However, our review showed that very few cohorts obtained 
factual information on left ventricular ejection fraction (LVEF) to discern HFrEF 
from HFpEF. Distinct risk factors in community-based cohorts are therefore not 
properly defined and studies directly comparing new onset HFrEF vs. HFpEF 
are lacking. Accordingly, chapter 3 presents the incidence and epidemiology 
of new onset HFrEF and HFpEF in the large community-based Prevention of 
REnal and Vascular ENdstage Disease (PREVEND) cohort in The Netherlands. 
In total, 374 subjects were diagnosed with new onset heart failure during a 12-
year follow-up period. HFrEF and HFpEF were classified by an adjudication 
committee based on LVEF and various other parameters (derived from ESC 
guidelines) at the time of diagnosis. The observed incidence rate of new 
onset heart failure in the PREVEND population was in agreement with previous 
epidemiologic studies in community-based cohorts. The proportion of patients 
with new onset HFpEF, compared to new onset HFrEF, was initially relatively 
low (34% vs. 66%, respectively), but there was a catch-up effect later on in the 
study, suggesting higher incidence of HFpEF in elderly subjects. Also, clear 
evidence is provided for a differential risk profile for HFpEF compared to HFrEF. 
It appears that substantial clinical differences arise years before signs and 
symptoms due to either HFrEF or HFpEF become apparent. Apart from higher age 
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and female sex, increased urinary albumin excretion, atrial fibrillation and renal 
dysfunction emerged as novel risk indicators for HFpEF. In chapter 4, these 
clinical differences between HFrEF and HFpEF are further amplified by evaluating 
the prognostic value of multiple biomarkers for both subtypes of heart failure. 
An increased risk for heart failure was observed for several biomarkers, and 
in particular for HFrEF. In contrast, there was no clinically relevant association 
of biomarkers with new onset HFpEF. Additionally, the incremental value per 
biomarker increased when the general population was categorized into low 
and high-risk subjects. This simple stratification was based on the presence 
or absence of previous cardiovascular disease at baseline of PREVEND. This 
investigation also included a biomarker score, in which the risk for new onset 
heart failure increased more than seven-fold for the combination of an increase 
in NT-proBNP, hs-TnT and urinary albumin excretion. Finally, in chapter 5, the 
best combination of common clinical and biochemical parameters was evaluated 
to establish the first risk prediction model for early identification of subjects at 
risk for new onset HFrEF and HFpEF. The risk model for heart failure included 
21 commonly available variables and showed good internal validation and 
calibration. However, the predictive power for both heart failure syndromes was 
modest and therefore its clinical utility remains questionable. For HFpEF in 
particular, risk prediction will remain a significant challenge in daily clinical 
practice.
In the second part of this thesis, the aforementioned results are supported by 
several separate analyses, associating the prognostic value of single biomarkers 
with poor cardiovascular outcome. Urinary albumin excretion in particular 
has a powerful prognostic association with adverse cardiovascular outcome, 
as shown from data from the extended PREVEND Intervention Trial 
(PREVEND IT). The PREVEND IT was a randomized clinical trial with a 2x2 
design, where subjects were randomized to 20mg fosinopril or matching 
placebo, and to 40mg pravastatin or matching placebo. In chapter 6, its follow-up 
was extended to ten years and it was evident that elevated urinary albumin 
excretion was associated with a significant increase in cardiovascular 
mortality and morbidity, especially in subjects in the highest quintile of 
albuminuria (≥50mg/24h). Additionally, the beneficial effects of fosinopril in 
reducing cardiovascular risk persisted after cessation of treatment during 
prolonged ‘passive’ follow-up. In chapter 8, a sub-analysis of PREVEND IT, the 
Framingham Risk Score was shown to substantially underestimate the ten-year 
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predicted risk for cardiovascular disease in these same subjects in the highest 
quintile of albuminuria (≥50mg/24h). Finally, chapter 7 presents the results 
of the novel biomarker mid-regional pro-adrenomedullin. This multifunctional 
peptide is expressed primarily in endothelial cells, and is capable of promoting 
vasorelaxation, natriuresis, diuresis and cardiac output. This biomarker 
is associated with adverse cardiovascular outcome, especially in 
subjects below 70 years of age.
Discussion
Epidemiology
Heart failure is a major public health problem, with a prevalence of over 6.5 million 
in Europe and over 26 million worldwide.1, 2 It is estimated that one in five 
adults over the age of 40 will develop heart failure in their lifetime, and as such, 
heart failure has repeatedly been identified as an emerging epidemic.3, 4 The 
increase in the global prevalence of heart failure over the last few decades can be 
attributed to several factors: an aging population, an increase in the incidence 
of cardiovascular disease, improved treatment of heart disease in general 
(especially acute coronary syndromes), which all lead to a reduction in 
short-term mortality and heart failure development over time. Greater 
awareness of this heart failure epidemic and the fact that more reliable 
and sensitive diagnostic tools are available, e.g. natriuretic peptides 
and echocardiography, could also explain a disproportionate increase in the 
incidence and prevalence of heart failure. Despite the reported increase in 
prevalence, the majority of evidence indicates a stabilizing incidence 
of heart failure, and possibly even a decrease in some groups.5-7
The left ventricular ejection fraction (LVEF) enables classification of heart failure 
as preserved (HFpEF) or reduced (HFrEF).8, 9 Although different cut-off values 
for LVEF have been proposed, general consensus is that heart failure with 
LVEF above 50% is considered preserved. It is estimated that the LVEF is 
preserved in approximately half of all heart failure cases in the community.10-12 
Epidemiologic data on the incidence and prevalence of heart failure according 
to ejection fraction and its development over time are limited. The available 
evidence suggests the current prevalence of HFpEF is increasing, in contrast 
to HFrEF.13, 14 Another recent large study, including data from 275 hospitals 
in the USA, confirms these findings.15 Importantly, in this thesis we suggest 
that this rise in number of HFpEF patients remains an underestimation of 
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the true burden of HFpEF. Clinical under-recognition of HFpEF may play a 
role, because signs and symptoms tend to be less specific and concomitant 
co-morbidities more common.14, 16 Furthermore, studies on incidence and 
prevalence of heart failure comprised of hospitalized subjects, while few included 
outpatient data.17-19 Again, this is especially true for HFpEF, which a significant 
proportion of stable outpatients with unexplained dyspnea may suffer from.20 
Our attention is, or at least should be, shifting from HFrEF towards HFpEF. 
A significant development, as various studies published in recent years 
have shown that prognosis is equally poor for HFpEF and HFrEF.16, 21 At the 
beginning of the 20th century, survival estimates after diagnosis of heart failure 
were 50% and 10% at 5 and 10 years, respectively.22-24 Although there have 
been several studies reporting improved survival in the past decade, survival 
after heart failure diagnosis remains poor.6, 25-27 These trends are in agreement 
with temporal major changes in the treatment of heart failure, and thus suggest 
that heart failure treatment is effective in the community. However, much 
progress remains to be accomplished. As the proportion of HFpEF, for which there 
is no specific treatment, is increasing over time, its prevalence will likely increase, 
underscoring the urgent need for new therapeutic approaches to this entity.
Differential characteristics of HFrEF and HFpEF
It has been speculated that HFrEF and HFpEF either represent distinct 
forms of heart failure, or exist as part of one heart failure spectrum.9 Recent 
structural, functional and molecular biological arguments support the theory 
that they are two discrete disease processes.28-31 This thesis provides further 
evidence that new onset HFrEF and HFpEF are different syndromes and 
that each require a different approach. Most data on HFrEF and HFpEF are 
derived from prevalent heart failure studies, where several retrospective cohort 
studies have shown clinical differences between patients with prevalent HFpEF 
and HFrEF. At first presentation, patients with HFpEF are older and more often 
female and obese than those with HFrEF. Furthermore, they are less likely to 
have coronary heart disease and more likely to have hypertension and atrial 
fibrillation.12 On the other hand, patients with HFrEF are more likely to have a 
history of ischemic heart disease, defined as either prior myocardial infarction 
or ECG abnormalities.11, 12, 32 Other risk factors which have been associated 
with HFrEF are diabetes mellitus and a history of alcohol abuse.33, 34 Renal 
dysfunction is also a frequently occurring condition in both HFrEF and HFpEF, 
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the so-called cardiorenal syndrome.35 Our data suggest, however, that renal 
dysfunction is a more significant risk factor for new onset HFpEF than for new 
onset HFrEF, based on measuring cystatin C or urinary albumin excretion.36, 37 
We found similar differential clinical characteristics for HFrEF and HFpEF in 
PREVEND. Notably, distinct clusters of antecedent risk factors can be used to 
classify subjects at risk for new onset HFpEF vs. HFrEF. As such, our findings may 
have important implications for targeted heart failure prevention strategies. This 
is further strengthened by the observed mean time from baseline assessment 
to diagnosis of heart failure, which was 7.2 years. Additionally, time to diagnosis 
of HFpEF (8.3 years) was significantly longer than for HFrEF (6.6 years). The 
existence of the aforementioned different risk profiles for HFrEF and HFpEF, 
many years before symptoms of heart failure becomes manifest, probably 
reflects the long-term process of left ventricular remodeling preceding heart 
failure symptoms. Especially for asymptomatic individuals with hypertension, 
more aggressive antihypertensive treatment to prevent further left ventricular 
remodeling, leading to HFpEF, is recommended. Many specific risk factors 
for HFpEF are related to hypertensive end organ damage, such as atrial 
fibrillation, left ventricular hypertrophy and renal dysfunction – either 
functional damage, as reflected by cystatin C, or structural damage, as 
reflected by urinary albumin excretion.36 For HFrEF, a similar strategy has 
already proven effective, as post-myocardial infarction anti-remodeling 
therapy significantly reduces the development of heart failure. While heart 
failure is epidemiologically still considered a disease of the elderly, the process of 
left ventricular remodeling begins many years earlier. Whether earlier and more 
aggressive treatment of cardiovascular risk factors for HFrEF and HFpEF should 
be a key strategy for preventing future new onset heart failure remains unclear.
Biomarkers
The question remains whether biomarkers can aid in early risk identification 
for new onset heart failure, as described above. The presence or absence of 
specific biomarkers represent separate pathophysiological pathways involved 
in the development of heart failure, and include enzymes, biologic substances, 
and markers of cardiac stress or myocyte injury.38 Multiple biomarkers are 
currently available, reflecting several pathophysiological processes influencing 
the development of heart failure. Several established biomarkers exist in current 
heart failure diagnosis and management, however the only biomarkers 
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mentioned in current heart failure guidelines are NT-proBNP and hs-TnT.4 The 
association of many new, emerging biomarkers with cardiovascular disease 
has yet to be determined, for example adrenomedullin, galectin-3, and the 
neurohormonal biomarkers renin and aldosterone. In this thesis, the 
predictive value of biomarkers for new onset heart failure was found to be 
modest. In other words, with regard to clinical utility, the additional value per 
biomarker was low. This is consistent with previous reports on the long-term 
predictive value of biomarkers for cardiovascular disease, and specifically heart 
failure.39, 40 We postulate several possible explanations. The average time from 
baseline assessment (of biomarker) and diagnosis of heart failure is usually quite 
long. In PREVEND, this was over seven years.36 Perhaps the predictive value of 
biomarkers would increase if measured closer to the clinical stage, when heart 
failure becomes symptomatic. It also illustrates the diversity and complexity 
of heart failure. The pathophysiologic pathways induced by hypertension, 
activation of the adrenergic and renin-angiotensin systems, or inflammation are 
diverse, though all can potentially lead to left ventricular hypertrophy and HFpEF. 
Distinguishing between HFrEF and HFpEF based on LVEF is probably not specific 
enough to distinguish between biologic profiles underlying both syndromes.
Can we still use biomarkers to identify subjects at risk for heart failure? 
Though the predictive power of all single biomarkers may be moderate, the 
measurements provide vital clinical information on the pathogenesis of heart 
failure. We showed that a combined increase in the three strongest biomarkers 
in PREVEND (NT-proBNP, hs-TnT and urinary albumin excretion) resulted in a 
seven-fold increased risk for new onset heart failure, compared to subjects with 
low values of these three biomarkers. Future studies are required to evaluate
further options for cardiovascular biomarkers. For instance, different 
stratification strategies ought to be considered, to improve stratification of 
subjects at specific risk for heart failure. Additionally, the effect of time 
to event for every biomarker has not yet been evaluated properly. 
The effect of sex differences between biomarkers and their associations with 
outcome should also be accounted for in further studies.
Future perspectives
The primary objective of this thesis was to describe the epidemiology of new 
onset heart failure, with a special interest for clinical characteristics and 
biomarkers associated with new onset HFrEF and HFpEF. We expected 
174
Summary and future perspectives
our findings could lead to a better algorithm for more accurate identification 
of subjects at risk for new onset heart failure. In other words, we set out to 
assess an individual’s risk for new onset heart failure based on standard 
clinical and biochemical variables, similar to the Framingham Risk Score for 
assessing cardiovascular risk.41 We have shown that risk parameters with 
predictive value for new onset heart failure in a community-based cohort 
can be identified. We have also demonstrated that several specific clinical 
variables and biomarkers are significantly and specifically associated with 
either new onset HFrEF or HFpEF. Nonetheless, the actual prediction of 
heart failure proved fairly inaccurate and remains a considerable challenge, 
especially for new onset HFpEF. The low discrimination in our risk 
prediction model for HFpEF (and to a certain extent for HFrEF as well), reflects the 
diversity and complexity of the heart failure syndrome. Based on our results, we 
can conclude that a considerable timeframe exists between identification of a 
certain risk factor and the actual development of heart failure signs and symptoms. 
The development of heart failure can be described in two phases. The 
first phase of heart failure development consists of etiology-specific 
remodeling, in which compensatory mechanisms preserve the cardiac output, 
ensuring patients remain asymptomatic. During this period, it is speculated that 
distinct pathophysiologic pathways underlie the process of left ventricular 
remodeling and that biomarkers could accurately differentiate between these 
pathways. At a certain point in time, there is a transition to a decompensated 
state, with manifest, symptomatic cardiac failure. In this phase, patients are 
identified by symptoms and hospitalization for decompensated heart failure 
and biomarkers are have better prognostic value with regard to survival or 
rehospitalisation. In order to improve therapy, especially for subjects with 
HFpEF, identification of high-risk subjects in the compensated phase is crucial.
In summary, the present thesis investigated and discussed the epidemiological, 
clinical and biochemical differences underlying new onset heart failure 
separately for HFrEF and HFpEF. New pathophysiologic links were identified, 
providing new insights in the predictive value of clinical characteristics and 
multiple biomarkers. Additionally, we have confirmed that HFpEF is a complex 
syndrome, with increasing incidence and high mortality. Early identification of 
subjects at risk for heart failure, especially HFpEF, remains difficult based on the 
presently available clinically and biochemically oriented risk prediction model. 
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In dit proefschrift wordt het ontstaan en de manifestatie van hartfalen 
beschreven, met speciale aandacht voor klinische en pathofysiologische 
verschillen tussen hartfalen met verminderde ejectiefractie (Engels: 
HFrEF) en hartfalen met behouden ejectiefractie (Engels: HFpEF).
Het eerste deel van dit proefschrift omvat de epidemiologie van nieuw 
hartfalen, evenals de klinische karakteristieken en biomarkers voor nieuw 
HFrEF en HFpEF. In hoofdstuk 1 en hoofdstuk 2 wordt een actueel overzicht 
gegeven over de incidentie en prevalentie van hartfalen. Gedurende de 
afgelopen tien jaar is er belangrijke epidemiologische informatie gepresenteerd 
over nieuw ontstaan van hartfalen uit een aantal grote, prospectieve studies 
met mensen uit een algemene populatie. De huidige beschikbare informatie 
suggereert dat de incidentie van hartfalen over het geheel aan het dalen is. Dit 
is het gevolg van succesvolle preventieve aanpak tegen de ontwikkeling van 
hartfalen. Echter, het moet benadrukt worden dat deze daling vooral komt door 
de daling van HFrEF patiënten en dat de hoeveelheid patiënten met HFpEF 
juist toegenomen zou zijn. Dergelijke epidemiologische trends onderstrepen 
de noodzaak om patiënten met HFpEF te onderscheiden van HFrEF. Eerdere 
studies suggereerden dat HFrEF en HFpEF misschien wel twee verschillende 
cardiovasculaire syndromen zouden zijn, en dat beide een verschillende 
aanpak vereisen. In onze review wordt echter aangetoond dat er momenteel 
nog zeer weinig cohorten zijn die daadwerkelijk HFrEF van HFpEF kunnen 
onderscheiden, omdat er geen informatie is over de linker ventrikel ejectiefractie 
(LVEF). Verschillende risicofactoren voor beide syndromen uit de algemene 
populatie zijn daardoor nog niet goed gedefinieerd en studies die rechtstreeks 
onderscheid maken tussen nieuw ontstaan van HFrEF ten opzichte van 
HFpEF ontbreken. Zodoende wordt in hoofdstuk 3 de incidentie en 
epidemiologie van HFrEF en HFpEF beschreven in de Prevention of REnal and 
Vascular ENdstage Disease (PREVEND) studie uit Nederland. In totaal werden 
374 deelnemers gediagnosticeerd met hartfalen, gedurende de 12 jaar waarin 
ze werden gevolgd. De diagnose HFrEF of HFpEF werd toegewezen door een 
gespecialiseerde commissie en was gebaseerd op de LVEF en diverse andere 
parameters, volgens de richtlijnen van de European Society of Cardiology. 
De waargenomen incidentie van nieuw ontstaan hartfalen in de PREVEND 
populatie was in overeenstemming met voorgaande epidemiologische studies in 
algemene populaties. De proportie van patiënten met nieuw HFpEF, vergeleken 
met nieuw HFrEF, was aanvankelijk relatief laag (34% vs. 66%, respectievelijk), 
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maar dit trok bij naargelang de studie voortduurde. Dit suggereert hogere 
incidentie van HFpEF in oudere mensen. Daarnaast werd er duidelijk 
bewijs geleverd voor een verschillende risicoprofiel voor HFpEF, vergeleken met 
HFrEF. Het blijkt dat er aanzienlijke klinische verschillen ontstaan, jaren voordat 
symptomen, als gevolg van hartfalen, duidelijk worden. Afgezien van hogere 
leeftijd en vrouwelijk geslacht, kwamen een verhoogde urine-uitscheiding 
van albumine, boezemfibrilleren en nierfunctiestoornissen naar boven als 
nieuwe risico-indicatoren voor HFpEF. In hoofdstuk 4 worden deze klinische 
verschillen tussen HFrEF en HFpEF verder versterkt door het evalueren van 
de prognostische waarde van meerdere biomarkers voor beide subtypen van 
hartfalen. Een verhoogd risico op hartfalen werd aangetoond door verschillende 
biomarkers, en in het bijzonder voor HFrEF. Daarentegen was er geen 
klinisch relevante associatie van biomarkers met het ontstaan van HFpEF. De 
toegevoegde waarde per biomarker werd tevens vergroot wanneer algemene 
bevolking werd gecategoriseerd in laag- en hoog-risico patiënten. Deze 
eenvoudige stratificatie was gebaseerd op de aanwezigheid of afwezigheid van 
een cardiovasculaire ziekte bij aanvang van de PREVEND studie. Tenslotte, 
dit onderzoek omvatte ook de ontwikkeling van een biomarker score, waarbij 
het risico voor het ontstaan van hartfalen meer dan zevenvoudig toenam, 
met de combinatie van een verhoogd NT-proBNP, hs-TnT en urine 
excretie van albumine. In hoofdstuk 5, het laatste hoofdstuk uit deel I, 
is de beste combinatie van standaard klinische en biochemische parameters 
geëvalueerd, om het eerste voorspellingsmodel voor risico op HFrEF en 
HFpEF te creëren. Voor dit risicomodel voor hartfalen werden 21 regulier 
beschikbare variabelen gebruikt en toonde een goede interne validatie 
en kalibratie. Echter, de voorspellende kracht van het model 
voor beide hartfalen syndromen was bescheiden en daarom blijft 
het klinisch nut twijfelachtig. Het voorspellen van risico op HFpEF in het 
bijzonder, zal een belangrijke uitdaging in dagelijkse klinische 
praktijk blijven.
In het tweede deel van dit proefschrift worden de eerder genoemde resultaten 
ondersteund door meerdere onafhankelijke analyses, die de prognostische 
waarde van alleenstaande biomarkers associëren met slechte 
cardiovasculaire uitkomst. Urine excretie van albumine in het 
bijzonder heeft een krachtige prognostische associatie met cardiovasculaire 
uitkomst, zo blijkt uit gegevens van de verlengde PREVEND Intervention 
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Trial (PREVEND IT). De PREVEND IT was een gerandomiseerde klinische 
trial met een 2x2 ontwerp, waarbij patiënten werden gerandomiseerd 
naar 20mg fosinopril of placebo, en 40mg pravastatine, of met placebo. In 
hoofdstuk 6 is de duur van deze studie verlengd tot tien jaar en het was 
duidelijk dat verhoogde urine excretie van albumine geassocieerd was met 
een significante toename in cardiovasculaire mortaliteit en morbiditeit, vooral 
bij patiënten in het hoogste kwintiel van albuminurie (≥50mg/24h). Bovendien, 
het gunstige effect van fosinopril in het verminderen van het cardiovasculaire 
risico bleef bestaan na het staken van de behandeling, gedurende verdere 
‘passieve’ follow-up. In hoofdstuk 8, een subanalyse van PREVEND IT, werd 
bij dezelfde deelnemers (≥50mg/24h) aangetoond dat de Framingham Risk 
Score het tien-jaars risico op cardiovasculaire ziekte aanzienlijk onderschat. 
Tot slot, in hoofdstuk 7 worden de resultaten gepresenteerd van de nieuwe 
biomarker Adrenomedulline. Deze multifunctionele peptide komt voornamelijk 
tot expressie in endotheelcellen, en is betrokken bij vasorelaxatie, natriurese en 
het verhogen van het hartminuutvolume. Deze biomarker wordt geassocieerd 
met ongunstige cardiovasculaire afloop, met name bij personen onder de 70 jaar.
Discussie
Epidemiologie
Hartfalen is een belangrijk probleem voor de volksgezondheid, met een 
prevalentie van meer dan 6,5 miljoen in Europa en meer dan 26 miljoen 
wereldwijd. Er wordt geschat dat een op de vijf volwassenen ouder dan 
40 jaar hartfalen zal ontwikkelen in hun leven. Als zodanig is hartfalen al 
herhaaldelijk genoemd als een opkomende epidemie. De toename in de 
wereldwijde prevalentie van hartfalen in de afgelopen tientallen jaren kan worden 
toegeschreven aan verschillende factoren: vergrijzing, een toename van de 
incidentie van cardiovasculaire ziekte, verbeterde behandeling van 
hartaandoeningen in het algemeen (vooral het acuut coronair syndroom), 
die alle leiden tot een vermindering van de mortaliteit op korte termijn, en 
ontwikkeling van hartfalen op langere termijn. Een verhoogd bewustzijn van 
deze hartfalen epidemie, en het feit dat er meer betrouwbare en gevoelige 
diagnostische hulpmiddelen beschikbaar zijn (bijvoorbeeld natriuretische 
peptiden en echocardiografie), zou ook deze relatieve toename van de 
incidentie en prevalentie van hartfalen kunnen verklaren. Ondanks alles, 
uit de meest recente studies blijkt de incidentie van hartfalen te 
stabiliseren, en in sommige groepen patiënten zelfs af te nemen.
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De linker ventrikel ejectiefractie (LVEF) classificeert tussen hartfalen met 
behouden ejectiefractie (Engels: HFpEF) of verminderde ejectiefractie 
(Engels: HFrEF). Hoewel verschillende afkapwaarden voor de LVEF zijn 
voorgesteld, is de algemene consensus dat hartfalen met een LVEF boven de 
50% wordt beschouwd als behouden. Er wordt geschat dat de LVEF behouden 
blijft in ongeveer de helft van alle gevallen van hartfalen in de gemeenschap. 
Epidemiologische gegevens over de incidentie en prevalentie van hartfalen, 
ingedeeld naar ejectiefractie, en de ontwikkeling ervan in de tijd zijn beperkt. 
Het beschikbare bewijs suggereert dat de huidige prevalentie van HFpEF 
toeneemt, in tegenstelling tot HFrEF. Een andere grote studie, die gebruik 
maakt van gegevens van 275 ziekenhuizen in de Verenigde Staten, 
bevestigen deze bevindingen. Belangrijker nog, in dit proefschrift stellen we 
dat deze stijging van HFpEF patiënten zelfs een onderschatting is van de 
werkelijke HFpEF last. Het niet herkennen van HFpEF in de dagelijkse kliniek 
kan hierbij een rol spelen, omdat klinische signalen en symptomen van 
hartfalen de neiging hebben om minder specifiek te zijn, en daarnaast 
verscheidene comorbiditeiten vaker gelijktijdig voorkomen. Bovendien, 
studies aangaande de incidentie en prevalentie van hartfalen betroffen 
patiënten die waren opgenomen in ziekenhuizen, terwijl weinig 
studies patiënten vanuit de polikliniek gebruikten. Nogmaals, dit geldt 
met name voor HFpEF, waar een significant deel van stabiele patiënten 
met benauwdheidsklachten wellicht aan kan lijden.
Onze aandacht is, of zou tenminste moeten verschuiven van HFrEF naar HFpEF. 
Een belangrijke ontwikkeling, aangezien diverse studies gepubliceerd 
in de afgelopen jaren hebben aangetoond dat de prognose voor HFpEF 
even slecht is als voor HFrEF. Aan het begin van de 20e eeuw, de geschatte 
overleving na de diagnose van hartfalen was 50% en 10%, na 5 en 10 jaar, 
respectievelijk. Hoewel er het afgelopen decennium verscheidene studies 
een verbeterde overleving rapporteren, de overleving na hartfalen diagnose 
blijft nog steeds slecht. Deze trends zijn in overeenstemming met recente 
grote veranderingen in de behandeling van hartfalen, en suggereren 
daarmee dat de behandeling van hartfalen effectief is in de algemene 
populatie. Echter, er moet nog veel vooruitgang geboekt worden. 
Aangezien de groep HFpEF patiënten toe zal nemen gedurende de 
tijd, terwijl er nog een specifieke behandeling voor is, zal de prevalentie 
van HFpEF toenemen. Dit benadrukt de dringende behoefte aan nieuwe 
therapeutische aanpak van dit syndroom.
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Differentiële kenmerken van HFrEF en HFpEF
Er wordt gespeculeerd dat HFrEF en HFpEF verschillende vormen van 
hartfalen vertegenwoordigen, ofwel bestaan als onderdeel van een 
hartfalen spectrum. Huidige kennis omtrent structurele, functionele en 
moleculair biologische processen ondersteunen echter de theorie dat 
het twee discrete ziekteprocessen zijn. Dit proefschrift levert verder bewijs dat 
HFrEF en HFpEF verschillende syndromen zijn en dat elk een andere aanpak 
vereist. De meeste gegevens over HFrEF en HFpEF zijn vooralsnog afkomstig 
van studies met hartfalen patiënten, waarin retrospectief klinische verschillen 
tussen patiënten met HFpEF en HFrEF zijn aangetoond. Bij de eerste klinische 
presentatie, zijn patiënten met HFpEF ouder, vaker vrouw en hebben vaker 
overgewicht, dan patiënten met HFrEF. Bovendien hebben ze minder 
vaak onderliggend ischemische  hartziekte, terwijl hypertensie en 
boezemfibrilleren vaker voorkomen. Anderzijds, patiënten met HFrEF hebben 
vaker een ischemische hartziekte, gedefinieerd als een eerder hartinfarct 
of ischemische ECG afwijkingen. Andere risicofactoren die zijn 
geassocieerd met HFrEF zijn diabetes mellitus en een voorgeschiedenis 
van alcoholmisbruik. Nierfunctiestoornissen zijn een veel voorkomende 
aandoening in zowel patiënten met HFrEF als HFpEF, het zogenaamde 
cardiorenaal-syndroom. Onze gegevens suggereren echter dat 
nierfunctiestoornissen een grotere risicofactor voor het ontstaan van 
HFpEF zijn, dan voor het ontstaan van HFrEF, gebaseerd op het meten van 
cystatine C of albuminurie.
We vonden gelijkwaardige resultaten in PREVEND, namelijk evident differentiële 
klinische kenmerken voor HFrEF en HFpEF. Verschillende clusters van 
cardiovasculaire risicofactoren kunnen met name worden gebruikt om het 
individuele risico voor het ontstaan van HFrEF vs. HFpEF in te schatten. Als 
zodanig kunnen onze bevindingen belangrijke implicaties hebben voor gerichte 
hartfalen preventiestrategieën. Dit wordt verder versterkt door de waargenomen 
gemiddelde tijd van start van PREVEND tot de diagnose van hartfalen, welke 
7.2 jaar was. Bovendien, gemiddelde tijd tot diagnose van HFpEF (8.3 jaar) was 
significant hoger dan voor HFrEF (6.6 jaar). Het bestaan van de bovengenoemde 
verschillende risicoprofielen voor HFrEF en HFpEF, vele jaren voordat de 
symptomen van hartfalen op de voorgrond komen te staan, weerspiegelt 
meest waarschijnlijk het lange termijn proces van linker ventrikel remodeling, 
voorafgaande aan symptomen van hartfalen. Vooral voor asymptomatische 
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individuen met hypertensie, meer agressieve behandeling met anti-hypertensiva 
wordt aanbevolen, om verder linker ventrikel remodeling, leidend tot HFpEF, te 
voorkomen. Vele specifieke risicofactoren voor HFpEF zijn namelijk gerelateerd 
aan hypertensieve eindorgaanschade, zoals boezemfibrilleren, linker ventrikel 
hypertrofie en nierfunctiestoornissen - hetzij functionele schade, zoals bij 
cystatine C of structurele schade, zoals bij albuminurie. Voor HFrEF is 
een soortgelijke strategie al bewezen effectief  gebleken, aangezien 
therapie gericht tegen linker ventrikel remodeling in mensen na een hartinfarct, 
aanzienlijk de ontwikkeling van hartfalen vermindert. Terwijl hartfalen 
epidemiologisch nog steeds beschouwd wordt als een ziekte van de 
ouderen, begint het proces van de linker ventrikel remodeling al vele jaren 
eerder. Of vroegere en meer agressieve behandeling van cardiovasculaire 
risicofactoren voor HFrEF en HFpEF een belangrijke strategie zou 
kunnen zijn, voor het voorkomen van toekomstig hartfalen blijft onduidelijk.
Biomarkers
De vraag blijft of biomarkers kunnen helpen bij het vroegtijdig identificeren van 
verhoogd risico op het ontstaan van hartfalen, zoals hierboven beschreven. 
De aanwezigheid of afwezigheid van biomarkers representeert afzonderlijke 
pathofysiologische mechanismen, betrokken bij het ontwikkelen van 
hartfalen en omvat diverse enzymen, biologische stoffen en markers van cardiale 
myocyten-stress of -letsel. Vele biomarkers zijn momenteel beschikbaar, 
en geven informatie over verscheidene pathofysiologische processen die 
de ontwikkeling van hartfalen beïnvloeden. Een aantal biomarkers hebben 
momenteel een gevestigde plaats in de diagnostiek en behandeling van 
hartfalen, maar de enige biomarkers die genoemd worden in de meest recente 
richtlijnen voor hartfalen, zijn NT-proBNP en hs-TnT. De associatie van vele nieuwe 
opkomende biomarkers met cardiovasculaire ziekte moet nog worden 
bepaald, zoals bijvoorbeeld bij adrenomedullin, galectin-3, en de neurohormonale 
biomarkers renine en aldosteron. In dit proefschrift werd de voorspellende 
waarde van biomarkers voor nieuw ontstaan van hartfalen beschouwd als 
bescheiden. Met andere woorden, met betrekking tot klinische toepasbaarheid, 
de toegevoegde waarde per biomarker was laag. Dit is consistent met 
eerdere studies over de lange-termijns voorspellende waarde van biomarkers 
voor cardiovasculaire ziekte, en specifiek voor hartfalen. We postuleren enkele 
mogelijke verklaringen. De gemiddelde tijd van meting van biomarker (start van 
studie) en de diagnose van hartfalen is over het geheel vrij lang. In PREVEND, 
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dit was meer dan zeven jaar. Misschien zou de voorspellende waarde van 
biomarkers toenemen als de bepaling dichter bij het moment zou zitten, als 
hartfalen symptomatisch wordt. Het illustreert daarnaast ook de diversiteit en 
complexiteit van hartfalen. De pathofysiologische mechanismen die gang gezet 
worden door hoge bloeddruk, activering van het adrenerge en renine-angiotensine 
systeem, of inflammatie zijn divers, terwijl allen kunnen leiden tot linker ventrikel 
hypertrofie en HFpEF. Onderscheid tussen HFrEF en HFpEF, gebaseerd op 
LVEF, is waarschijnlijk niet specifiek genoeg om onderscheid te maken tussen 
de diverse biologische profielen die ten grondslag liggen aan beide syndromen.
Kunnen we nog steeds gebruik maken van biomarkers om mensen met een 
risico op hartfalen te identificeren? Hoewel de voorspellende 
kracht voor hartfalen van de meeste biomarkers matig is, de waardes 
geven belangrijke klinische informatie over de pathogenese van 
hartfalen. We hebben in dit proefschrift laten zien dat een gecombineerde 
verhoging van de drie sterkste geassocieerde biomarkers met hartfalen 
in PREVEND (NT-proBNP , hs-TnT en albuminurie) resulteerde in een 
zevenvoudig verhoogd risico voor het ontstaan van hartfalen, in vergelijking 
met deelnemers met lage waardes van deze drie biomarkers. Toekomstige 
studies zijn nodig om verdere mogelijkheden voor cardiovasculaire biomarkers 
te evalueren. Bijvoorbeeld, verschillende stratificatie strategieën moeten 
worden overwogen, om beter hoogrisico patiënten voor hartfalen te 
identificeren. Bovendien, het effect van tijd van bepaling tot eindpunt voor 
elke biomarker is nog niet voldoende geëvalueerd. Het effect 
van geslachtsverschillen tussen biomarkers en hun associaties met uitkomst 
moet ook worden beoordeeld in verdere studies.
Toekomstperspectief
De primaire doelstelling van dit proefschrift was om de epidemiologie van 
beginnend hartfalen te beschrijven, met speciale aandacht voor de klinische 
kenmerken en biomarkers voor het ontstaan van HFrEF en HFpEF . We hadden 
verwacht dat onze bevindingen zouden kunnen leiden tot een beter algoritme 
voor meer nauwkeurige identificatie van patiënten met hoog risico op het ontstaan 
van hartfalen. Met andere woorden, we streefden naar een individuele risico
inschatting voor het ontstaan van hartfalen op basis van standaard klinische en 
biochemische variabelen, vergelijkbaar met de Framingham Risk Score voor de 
beoordeling van cardiovasculair risico. We hebben risicofactoren aangetoond 
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met voorspellende waarde voor het ontstaan van hartfalen in een algemene 
populatie. We hebben ook aangetoond dat een aantal klinische variabelen en 
biomarkers aanzienlijk en specifiek geassocieerd zijn met ofwel het ontstaan 
HFrEF of HFpEF. Niettemin, het werkelijke voorspellen van hartfalen bleek 
vrij onnauwkeurig en blijft nog een grote uitdaging, vooral voor beginnend 
HFpEF. Het lage onderscheidend vermogen in ons risico 
voorspellingsmodel voor HFpEF (en tot op zekere hoogte ook voor 
HFrEF), weerspiegelt de diversiteit en complexiteit van het hartfalen 
syndroom. Op basis van onze resultaten kunnen we ook concluderen 
dat er een aanzienlijke tijdspanne bestaat tussen de identificatie 
van een bepaalde risicofactor en de feitelijke ontwikkeling van 
hartfalen symptomen. 
De ontwikkeling van hartfalen kan worden beschreven in twee fasen. De eerste 
fase van hartfalen ontwikkeling bestaat uit etiologie-specifieke remodeling, 
waarin compensatiemechanismen zorgen voor behoud van het 
hartminuutvolume, en waardoor patiënten klachtenvrij blijven. Er wordt 
gedacht dat er tijdens deze periode verschillende pathofysiologische 
mechanismen ten grondslag liggen aan het proces van linker ventrikel 
remodeling en dat biomarkers nauwkeurig onderscheid kunnen maken 
tussen deze mechanismen. Op een bepaald punt in de tijd, is er een overgang 
naar een gedecompenseerde status, met manifest symptomatisch hartfalen. 
In deze fase worden patiënten klinisch geïdentificeerd door symptomen en 
ziekenhuisopname voor decompensatio cordis, en biomarkers hebben dan een 
betere prognostische waarde ten aanzien van overleving of heropname. Om de 
behandeling en overleving te verbeteren, in het bijzonder voor patiënten met 
HFpEF, is identificatie van hoogrisico patiënten in de eerste, 
gecompenseerde fase cruciaal.
Samenvattend, dit proefschrift evalueerde de epidemiologische, klinische en 
biochemische verschillen die ten grondslag liggen aan het ontstaan 
van hartfalen, en afzonderlijk voor HFrEF en HFpEF. Nieuwe 
pathofysiologische mechanismen werden geïdentificeerd, wat nieuwe inzichten 
geeft in de voorspellende waarde van klinische karakteristieken 
en biomarkers. Daarnaast wordt andermaal bevestigd dat HFpEF 
een complex syndroom is, met toenemende incidentie en hoge mortaliteit. 
Vroege identificatie van patiënten met verhoogd risico op hartfalen, vooral 
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